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When things go wrong as they sometimes will –
When the road you’re trudging seems all up hill.
Don’t give up though the pace seems slow –
You may succeed with another blow.
Success is failure turned inside out –
The silver tint of the clouds of doubt
And you never can tell how close you are –
It may be near when it seems so far.
So stick to the fight when you’re hardest hit –
It’s when things seem worst that you must not quit.
       
 Author unknown
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1. Preface
Bloodstream infections (BSIs) are characterized by high morbidity and mortality all over the 
world. BSI can be categorized as either community acquired or hospital acquired and can be 
the result of a broad variety of microorganisms. Both bacteria and fungi can enter the, normal 
sterile, bloodstream. These conditions are called bacteremia and fungemia, respectively. 
The first case of bacteremia was already reported in 1897 by Libman [1]. Since then, culture 
methods for blood have evolved, with the development of guidelines for optimal handling 
of blood cultures [2]. Currently, blood cultures are still the gold standard, for detection of 
pathogens from blood, in the medical microbiology laboratories. The possibility to detect and 
identify the pathogen, and simultaneously determine the antimicrobial susceptibility pattern 
is very helpful to guide physicians to optimal patient-tailored antibiotic therapy. However, 
this traditional approach for detection of pathogens from blood is time-consuming (minimal 
24-72  hours), and prior antibiotic treatment of a patient can result in false-negative blood 
cultures. New developments to detect bloodstream infections (BSI) are needed as it has 
been shown by Kumar et al. [3] that initiation of inappropriate antibiotic therapy decreases 
the survival rate of patients fivefold. However, misuse of antibiotics increases the emergence 
of antibiotic resistance among bacteria, which in turn hampers further antibiotic treatment 
[4]. This means that other techniques, besides conventional culture approaches, need to 
be developed, and used, to improve the diagnostic process of detection of bloodstream 
infections to be able to initiate adequate therapy.
In the present chapter, an overview will be given of bloodstream infections, and the 
currently available diagnostic tools in the laboratories for molecular diagnostics and medical 
microbiology.
2. Bloodstream infections
BSI can be caused by a broad scala of microorganisms, including bacteria (bacteremia) and 
fungi (fungemia). It is defined as the presence of viable microorganisms in the bloodstream 
[5]. BSI is often a result of infection due to trauma, use of intravascular devices, invasive 
procedures (surgery), or a result of infection at another organ site (i.e. respiratory tract 
infections) [6]. The host response to (systemic) infection, such as BSI, can lead to Systemic 
Inflammatory Response Syndrome (SIRS). The term SIRS was introduced in 1992 at the 
American College of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM) 
Consensus Conference and was used to describe a systemic inflammatory process, despite 
of its cause. Four clinical symptoms can be recognised and are indicative of SIRS, as 
summarized in Table 1 [7].
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Table 1. Systemic Infl ammatory Response Syndrome (SIRS) and sepsis stages.
Stage Clinical symptoms Value
SIRS
(≥2 symptoms)
Temperature
Heart rate
Respiratory rate
White blood cell count
<36ºC or >38 ºC
>90 beats/minute
>20 breaths/minute or PaCO2 <32mmHg
>12,000 cells/mm3 or <than 4000 cells/mm3
Sepsis SIRS with proven infection
Severe sepsis Sepsis with organ dysfunction
hypoperfusion and/or hypotension
Septic shock Severe sepsis, hypoperfusion
and/or hypotension despite
adequate fl uid resuscitation
A patient is diagnosed with sepsis when ≥ 2 SIRS symptoms are present in combination with 
a proven infection. Sepsis has different severity stages and can develop to severe sepsis and 
septic shock (Table 1). Frequently, infection is strongly suspected but not microbiologically 
confi rmed [8]. In other words, blood cultures drawn from a suspected sepsis patient can be 
negative.
Sepsis ranks in the top 10 causes of death [9]. The prevalence of sepsis in intensive care 
units (ICU) remains increasing [10]. A Dutch study performed in 2004 by Van Gestel et 
al. [11] calculated that the annual number of admissions for severe sepsis in Dutch ICUs 
was 8643 +/- 929 cases/year, which is 0,054% of the total population, 0,61% of hospital 
admissions and 11% of ICU admissions. On average 750,000 patients develop sepsis in 
the United States annually [12]. The mortality rate ranges from 20 to 70% and is related to 
severity of underlying illness [13-16]. In Germany, approximately 79,000 new sepsis cases, 
and 75,000 severe sepsis cases are annually expected [17].
The accurate and timely detection of sepsis remains a challenge. The main problem is that 
the clinical signs of a patient with sepsis resemble that of a patient with SIRS caused by 
non-infectious causes, such as pancreatitis or burns [7]. Accurate and fast identifi cation of 
pathogens involved and biomarkers might be of additional value in the diagnosis of BSI in 
suspected sepsis patients.
2.1 Biomarkers
In general, a biomarker has been defi ned as the “quantifi able measurement(s) of biological 
homeostasis that defi ne(s) what is normal; therefore providing a frame of reference for 
predicting or detecting what is abnormal” [18]. It is highly unlikely that one single biomarker is 
able to predict BSI in sepsis patients.
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Several studies have been published which investigated the diagnostic value of several 
biomarkers, such as C-reactive protein (CRP) [19-21], procalcitonin (PCT) [19-22], neutrophil 
lymphocyte-count-ratio (NLCR) [23], and soluble urokinase plasminogen activator receptor 
(suPAR) [24-28].
CRP is an acute-phase protein released by the liver after the onset of inflammation or tissue 
damage. CRP is a frequently used marker to detect infection and inflammation. It is cheap, 
but not sufficiently specific for an accurate diagnosis of severe sepsis [19, 21]. Reasons for 
this might be that concentrations of CRP also increase during minor infections and therefore 
do not adequately predict the severity of the infection. Additionally, plasma levels remain 
elevated for several days, even when the infection is treated [29]. There has been a lot of 
debate about the usefulness of CRP in determining the prognosis of sepsis [30], and a more 
promising candidate might be PCT.
PCT is the prohormone of calcitonin, and is produced ubiquitously in response to endotoxin 
or to mediators released in response to bacterial infections (i.e. Interleukin 6). It strongly 
correlates with the extent and severity of bacterial infections [31]. Several meta-analyses 
studies have been published but results remain contradictory [32-34]. This is mainly the 
result of different patient inclusion criteria. However, in most studies PCT appears superior 
to CRP in differentiating and predicting severe sepsis patients from other patients [21, 35].
As the physiological immune response of circulating leucocytes to various stressful events is 
often characterized by an increase in neutrophil counts and a decline in lymphocyte counts, 
Zahorec et al. proposed to use the ratio of both as an additional infection marker in clinical 
ICU practice [36]. This so-called neutrophil-lymphocyte stress factor was found to correlate 
well with the severity of disease and outcome. De Jager et al. have investigated the ratio 
of neutrophil and lymphocyte counts, referred to as the NLCR, in predicting bacteremia in 
an emergency care unit [23]. They showed that this marker has a high value in predicting 
bacteremia, is simple, easily obtained and calculated, easy to integrate in daily practice and 
without extra costs. It would be very interesting to investigate if NLCR has more value in 
daily practice to predict BSI in sepsis patients as compared to i.e. CRP, which is determined 
standard in most hospitals in The Netherlands.
The urokinase-type plasminogen activator system consists of a proteinase (uPA), a 
receptor (uPAR) and inhibitors. suPAR is the soluble form of uPAR. In 1990, uPAR was 
cloned [37], and, in 1991 the soluble form was discovered [38]. The system plays a role in 
various immunological functions, including cell adhesion, migration, chemotaxis, proteolysis, 
immune activation, invasion, and signal transduction [39]. uPA and uPAR are predominantly 
expressed by tumor cells and blood cells, including neutrophils, monocytes, macrophages, 
and activated T-cells [40]. After cleavage from the cell surface, suPAR can be found in the 
blood and other body fluids in all individuals. Elevated suPAR levels, in septic intensive care 
unit patients, were already reported in 1995 by Mizukami et al. [41]. Koch et al. published one 
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of the fi rst studies in which the diagnostic and prognostic impact of suPAR was investigated 
in a large cohort of critically ill patients [28]. They found that suPAR serum concentrations, 
in sepsis and non-sepsis patients, are increased upon admission to the intensive care unit, 
probably refl ecting the state of the immune system. These levels remained stably elevated 
in the initial course of treatment. Low suPAR levels were reported to be a positive predictor 
of overall survival in critically ill patients, including sepsis patients [26, 28]. Especially in 
the emergency department, it is crucial to categorize individual patients according to their 
disease severity and determine treatment priority. In the heterogeneous patient population 
which presents at the emergency department, suPAR might be very valuable to determine 
who needs intensive monitoring [42]. More clinical studies are needed to determine suPAR 
cut-off levels for optimal clinical management. Moreover, the association of biomarkers 
needs to be further addressed in different patient populations such as the intensive care and 
the emergency care unit.
2.2 Etiologic agents of BSI and clinical load
BSI can be the result of a broad scala of pathogens. One of the largest multicenter studies 
found that hospital acquired (nosocomial) BSI is in 65% of the cases a result of Gram positive 
bacteria, in 25% Gram negative bacteria are found, and 10% of BSI cases are caused by fungi 
[43]. The most commonly isolated pathogens were coagulase-negative staphylococci (31%), 
Staphylococcus aureus (20%), and Enterococcus spp. (9%) [43]. Gram-negative bacteria 
that are frequently detected from blood cultures are Escherichia coli (27%), Pseudomonas 
aeruginosa (15%), and Klebsiella pneumoniae (7%) [44]. Nosocomial fungal infections are 
mostly the result of Candida spp., and are associated with high morbidity and mortality [45]. 
Recently, a large study was performed in The Netherlands investigating microorganisms 
causing BSI in patients with and without cancer [46]. Again, Gram-positive isolates were 
more prevalent than Gram-negative isolates. Amongst Gram-positive organisms, the 
pathogens making up the top 3 were similar as found in the US study [43]. In cancer patients, 
twice as many BSIs were caused by Enterococcus faecalis and E. faecium. Amongst Gram-
negative organisms, E. coli was the most common isolate in non-cancer patients. However, 
in cancer patients, twice as many BSIs were caused by P. aeruginosa and Enterobacter 
cloacae. Yeasts were grown twice as much from cancer patients as compared to cultures 
from non-cancer patients.
Different pathogens were cultured from blood cultures in different patient groups as shown 
from prevalence data obtained from different departments of a Dutch teaching hospital 
(unpublished data A.J.M. Loonen, G. Janssen, A.R. Jansz, and A.J.C. van den Brule, PAMM 
regional laboratories and Catharina Hospital, Eindhoven, The Netherlands). In Figure 1, the 
fi ve departments which order most blood cultures are displayed, together with the top 5 of 
most frequently recovered pathogens from positive blood cultures. This again demonstrates 
Loonen.indd   13 30-10-2013   8:14:42
14  |  Chapter 1
that BSI can be caused by a broad scala of pathogens and the causative pathogens differ 
in distinct patient populations. A diagnostic test should be able to detect the most frequently 
encountered pathogens.
Figure 1. Overview of pathogens recovered from blood cultures of five departments of the 
Catharina Hospital (Eindhoven, The Netherlands).
The most frequently recovered pathogens (top 5) per department are depicted. Only S. aureus and 
S. epidermidis are detected from cultures collected from every department. (Unpublished data A.J.M. 
Loonen, G. Janssen, A.R. Jansz, and A.J.C. van den Brule, 2008).
BSI refers to the condition in which pathogens have entered the bloodstream. Bacteremia is 
a BSI caused by bacteria. Bacteremia in adults is characterized by low numbers of circulating 
bacteria, often 1-100 colony forming unit (CFU) /millilitre (ml) [47, 48]. However, other studies 
indicate a number of circulating bacteria (E. coli and S. aureus) of less than 0.04 CFU/
ml [49]. BSI in young children are presumed to be characterized by higher bacterial loads 
(> 100 CFU ml) as compared to bacteremia in adults [48, 50]. Therefore, the volume of 
blood cultured is a critical factor in the detection of BSI [51-55]. The higher the blood volume 
cultured, the higher the detection rate of BSI.
It has been shown that inappropriate antibiotic therapy can result in higher mortality rates 
[3, 56], increased antibiotic resistance [57], and increased length of hospital stay [58]. 
Increased nosocomial BSI rates due to antibiotic resistant bacteria increase the total 
burden of disease [59, 60]. Therefore, a fast diagnosis and adequate management of BSI is 
necessary for successful patient outcome.
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3. Diagnostics of bloodstream infection
3.1 Blood cultures: the reference method
Blood cultures are regarded as the “gold standard” for the detection of viable bacterial and 
fungal organisms from blood. Blood is usually collected from a single venipuncture and at 
least 2 culture bottles (aerobe and anaerobe) are fi lled with approximately 8-10 ml blood. 
However, this volume cannot be drawn from infants and children. The volume for pediatric 
blood cultures should be based on body weight and the estimated total blood volume in each 
child. Recent recommendations suggest the collection of no more than 1% of the total blood 
volume for children [2, 61].
When microorganisms start to grow, CO2 is produced, and the bottom of each culture 
bottle contains a CO2 indicator, which can change colour upon exposure. The automated, 
continuous-monitoring culture system detects this alteration. When a positive blood culture 
bottle is detected it is used for subsequent Gram staining, subculture on agar plates, 
biochemical testing, and antibiotic susceptibility testing (AST). The management of BSI is 
based on important parameters; 1) the detection and identifi cation of (a) viable pathogen(s), 
and 2) the AST results. General principles and procedures for blood cultures from suspected 
sepsis patients are described in the Clinical and Laboratory Standards (CLSI) guidelines [2].
Despite the fact that improved media and automated culture systems, e.g., BacT/ALERT 3D 
(bioMérieux) and BACTEC (BD), have been developed and microorganisms are detected 
faster and more frequently [62], several factors are known which limit the clinical value of 
blood cultures.
The improved media in the culture bottles have indeed increased the diagnostic yields and 
decreased the time to detection [63, 64]. However, not every culture bottle is immediately 
inserted in the automated culture system, as not every medical microbiology laboratory is in 
progress for 24 hours / 7 days a week. Several studies have demonstrated that a 24h storage 
of blood culture bottles at room temperature negatively infl uenced the time to positivity [65-
67]. Furthermore, fast-growing strains (e.g. E. coli) and high bacterial loads inhibited bacterial 
detection due to exhausted CO2 production on which most culture systems are based. This 
indicates that delays from sample collection to insertion in the automated culture device 
affect the time to the detection of viable pathogens and might even lead to false-negative 
results.
Coagulase-negative staphylococci (CoNS) are normal habitants of human skin and mucous 
membranes. For decades they have been considered as culture contaminants (false-positive 
blood cultures). Since recent years, an important role of CoNS as pathogens has been 
recognized [68]. Several studies have provided guidelines on how to differentiate between 
contaminants and true pathogens [6, 69]. Usually, when only one of four taken blood 
culture bottles is positive for CoNS, this blood culture is considered as contaminant. The 
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microbiologist will also consider patient history to differentiate a true pathogen from possible 
contaminants. In case of CoNS it is important to know if a patient has indwelling medical 
devices, such as intravascular catheters, artificial heart valves, and orthopedic appliances 
[68]. Guidelines exist which describe approaches to limit blood culture contamination [2]. 
Thorough skin antisepsis, an adequate venipuncture method, and well-trained phlebotomist 
teams should reduce the chance of blood culture contamination [70-72].
Blood cultures are known to have a low sensitivity for slow-growing (e.g. Mycobacterium 
tuberculosis and most fungi) and fastidious microorganisms. Some examples of a highly 
fastidious microorganisms are Coxiella burnetii and Bartonella spp. which have been found 
in blood culture negative infective endocarditis [73, 74]. Furthermore, the sensitivity of blood 
cultures decreases significantly when antibiotic therapy has been started before blood 
samples are taken [75-77].
After the detection of microbial growth in a culture bottle, the pathogen(s) need(s) to be 
identified and the antibiotic susceptibility profile of the causative agent is needed. Subculturing 
from a positive blood culture takes at least 24 hours. For pathogen identification a wide 
variety of (semi-automated) biochemical tests are available. However, phenotypical tests 
(i.e. API tests) are slow and can display low specificity [78]. Clearly, Gram staining and fast 
biochemical tests (i.e. catalase test) can provide an initial diagnosis about the etiologic agent. 
However, detailed pathogen identification and AST take up several days and cause a delay 
in time-to-results.
3.2 Identification of pathogens from positive blood cultures
Recently, new techniques have become available for the rapid identification of pathogens 
from positive blood cultures. Most techniques are only suitable for identification of the 
causative pathogen and do not allow determination of antibiotic resistance. The antimicrobial 
susceptibility status of most locally prevalent bacterial and fungal species is largely predictable 
from past experience, and this information guides physicians to start empirical antibiotic 
treatment for patients with sepsis caused by these pathogens. Thus, rapid identification of 
pathogens commonly causing BSI is important and could allow species specific therapy to 
be started earlier.
The next paragraphs will highlight the latest technologies employed to aid in the identification 
of BSI pathogens. These techniques are based on the detection of proteins (matrix-assisted 
laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS)), or DNA 
(fluorescence in situ hybridization (FISH) and (real-time) PCR). By using these techniques, 
results can be available within a few hours, from growth positive cultures, reducing turnaround 
time. Furthermore, fast identification of the disease causing pathogen allows more rapid 
initiation of adequate antibiotic therapy.
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3.2.1 Protein based diagnostics
MALDI-TOF MS
Matrix-assisted laser desorption ionization time-of-fl ight mass spectrometry (MALDI-TOF 
MS) is increasingly used for high-throughput identifi cation of bacteria and yeast from agar 
plates [79]. Each individual microorganism contains an unique protein profi le (fi ngerprint) 
that allows identifi cation of microorganisms to the species level. Figure 2 illustrates the 
principle of MALDI-TOF MS. In 1975, Anhalt et al. were the fi rst to describe the use of mass 
spectrometry for bacterial identifi cation [80]. Several studies have been published that show 
that MALDI-TOF MS can be employed for identifi cation of a wide variety of pathogens, 
including Gram-positive and Gram-negative bacteria [81-84], non-fermenting bacteria [85], 
anaerobes [86, 87], and yeasts [88].
Figure 2. Overview of the general principle of MALDI-TOF MS.
A colony is picked from an agar plate, spotted on a steel target plate, and overlayed with matrix. The 
laser hits the samples and charged ions of various sizes are generated on the sample slide. Ions with 
a smaller mass to charge value (lighter ions) move faster through the fl ight tube until they reach the 
detector. A peak pattern is generated and this pattern is in most cases specifi c per bacterial species. 
This fi gure was redrawn from sigmaaldrich.com.
The main advantage of the use of MALDI-TOF is that results can be available within minutes 
and in most cases no sample preparation is needed. For fungal identifi cation sample pre-
treatment with formic acid might be necessary. One limitation of the method is that for a 
successful protein profi le at least >107 CFU/ml need to be present in the sample. Christner 
et al. have shown that when only 106 CFU/ml are present in a sample this peak pattern 
resembles that of a negative culture [89]. This indicates that a pre-culture step remains crucial 
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for optimal results. In addition, MALDI-TOF MS has been shown to encounter difficulties 
when identifying viridans streptococci [79, 90, 91] and mixed infections [90, 91].
Aside from bacterial identification, the first reports are available in which successful 
identification of antibiotic resistance, e.g. methicillin resistance in S. aureus, is described 
[92, 93]. Schaumann et al. described a first effort towards the discrimination of beta-
lactamase-producing clinical isolates of Enterobacteriaceae and P. aeruginosa by MALDI-
TOF MS [94]. The role of MALDI-TOF MS in the determination of antibiotic resistance is not 
yet reliable for routine microbiological diagnostics. It is expected that implementation of this 
technique, in diagnostics of BSI, will result in an increased number of patients on adequate 
antimicrobial treatment within 24 hours of onset of disease [95].
3.2.2 DNA based diagnostics
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) is a technique in which fluorochrome-labelled 
oligonucleotide probes are used to target rRNA molecules of different microorganisms. 
Subsequently, these probes are visualised by microscopy (Figure 3). FISH can be used on 
colonies as well as positive blood cultures.
FISH assays were developed for the detection of S. aureus and CoNS [96, 97], Enterococcus 
spp. [98, 99], Streptococcus spp. [98], P. aeruginosa [100], E. coli [100], Brucella spp. 
[101], and fungi [102]. Peters et al. developed a FISH protocol which allows identification of 
bacteria and yeast from positive blood cultures within 1 hour [103]. Although this technique 
seems promising, it is hampered by the permeabilization of the cell wall during preparation, 
hybridisation conditions, and the available probe collection. Due to the limited probe 
collection, species-specific identification for all BSI causing pathogens is not feasible.
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Figure 3. Overview of the FISH workfl ow.
When a positive blood culture bottle is recovered from the blood culture system a Gram strain is 
performed. Based on the Gram stain a suitable FISH probe-set can be chosen. First, the sample is 
fi xed on a glass slide and permeabilized. Next, fl uorescent-labelled probes are added (hybridization) 
and these can be visualised by using a microscope. This fi gure was redrawn from wrhsrc.oregonstate.
edu.
PCR based technologies
Conventional PCR
The polymerase chain reaction (PCR) is one of the most important nucleic acid amplifi cation 
techniques, in the laboratory, available today and can be used for pathogen identifi cation 
from both colonies as well as blood cultures. It was already developed 25 years ago, by Mullis 
and Faloona [104]. PCR is an enzyme-driven process, and makes it possible to turn a few 
DNA or RNA molecules into large quantities. First, DNA is denatured, and in the presence 
of nucleotides, buffer and primers, DNA can be copied by using a heat-stable polymerase 
(Figure 4). Primers are short DNA oligomers that are complementary to the ends of a target 
sequence.
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Figure 4. General principle of the polymerase chain reaction (PCR).
DNA is heated to 95ºC to denature the DNA strands. Subsequently, the temperature is lowered 
(usually to 60 ºC, this depends on the primer sequences) to allow the primers to bind to the 
complementary sequences in the target (left). At 72ºC, Taq polymerase extends the complementary 
strands from the primers (middle) by using nucleotides. The DNA target has been doubled (right), 
and the second cycle can start. This results in an exponential increase of target DNA molecules. This 
figure was redrawn from molecular.roche.com.
In the conventional PCR procedure amplification and detection are separated. To check 
whether the PCR generated the anticipated DNA fragment, agarose gelelectrophoresis is 
employed for size separation of the PCR fragments. Before size separation, DNA has to be 
stained (ethidiumbromide or Midori Green). When exposed to ultraviolet light, these dyes will 
fluoresce and DNA will be visible [105].
Microarray
Recently, a new platform was launched, Prove-It Sepsis (Mobidiag, Helsinki, Finland). The 
assay constitutes of a broad-range PCR with a microarray-based platform that is designed to 
identify 60 bacterial pathogens, 13 fungal pathogens, and mecA (methicillin resistance) from 
positive blood cultures [106]. After growth positivity, results can be available within 3.5 hours. 
Tissari et al. evaluated the clinical performance of Prove-It Sepsis and found a sensitivity and 
specificity of 94.7% and 98.8%, respectively [106].
Sequencing
DNA sequencing (Sanger) is a technology that can be employed to determine unknown 
amplified DNA fragments [107]. The Sanger sequencing method is well known and the 
procedure is similar to conventional PCR. The main difference is that, in addition to the other 
compounds, modified nucleotides (dideoxy-nucleotides) are used which terminate DNA strand 
elongation. The modified nucleotides are fluorescently labelled for detection in automated 
sequencing machines [108]. Currently, newer sequencing technologies are emerging. The 
use of next generation sequencing for BSI diagnostics needs to be demonstrated in future 
studies.
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Real-time PCR
In real-time PCR, nucleic acid amplifi cation and detection are performed simultaneously 
within the same vial. This approach reduces contamination risks signifi cantly. This technique 
is easy to perform, fast, and characterized by high sensitivity and specifi city making it a 
suitable alternative to use in the clinical microbiology setting [109]. In the real-time PCR 
approach, conventional PCR can be combined with fl uorescent probe detection of the 
amplifi ed target DNA. The probe is an oligonucleotide with a fl uorescent label (i.e. FAM or 
VIC) that consists of a reporter dye that is quenched in proximity of a quencher (i.e. BHQ or 
TAMRA). As Taq polymerase extends the new DNA strand, it cleaves the probe releasing the 
reporter from the quencher. The resulting fl uorescence is measured in each PCR cycle and 
plotted against the cycle number [110]. Another way to visualize DNA in a real-time setting is 
by using SYBR Green. SYBR Green binds all double–stranded DNA, making it unspecifi c, 
and detection is monitored by measuring the increase in fl uorescence throughout the PCR 
cycles. By using melting curve analysis, it is possible to differentiate between targets.
After its fi rst development, PCR was considered a promising approach for diagnosis of 
infectious diseases [111, 112]. PCR turned out to be a major development in the area of 
molecular diagnostics. Various studies have been published describing real-time PCR based 
assays for the identifi cation of pathogens from clinical samples. These are based either 
on broad-range (e.g. 16S or 18S rDNA), pathogen-specifi c or multiplex detection [113-116]. 
When using universal amplifi cation, DNA sequencing analysis can provide identifi cation 
within 4 hours after the initial positive PCR result. This approach is useful when unexpected 
pathogens are recovered by conventional methods or confi rmation of results is necessary. 
In previous studies, both conventional as well as real-time PCR assays were developed for 
the detection of CoNS, S. aureus, and/or methicillin resistant S. aureus (MRSA) [117-122], 
S. pneumoniae [123, 124], E. faecalis [125], Neisseria meningitides [124], Aspergillus spp. 
[126], and Candida spp. [127]. The use of pathogen specifi c assays proves challenging as 
the wide variety of causative pathogens would lead to a complex combination of assays 
[128]. Pathogen-specifi c assays might be clinically valuable when combined with the clinical 
presentation of a patient or Gram staining, as it is then known which microorganism is most 
likely present in the sample. Broad-range or multiplex assays enable detection of a broad 
scala of pathogens, this makes these assays more suitable for BSI diagnostics [129, 130].
Overall, the described technologies allow pathogen identifi cation results to be available within 
several hours after growth positive blood cultures are detected by the automated culture 
system. When sequencing is necessary, time to results increase signifi cantly. More rapid 
pathogen detection and identifi cation can be achieved when whole blood is used, because 
the time consuming pre-culture steps can then be eliminated.
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3.3  PCR based detection and identification of pathogens directly from 
whole blood
Direct detection from blood, and thus eliminating the time consuming culturing step, will 
result in faster pathogen detection and identification. Molecular assays can overcome the 
main limitations associated with the conventional blood culture based approach such as 
decreased sensitivity for fastidious or slow-growing pathogens, and prior antibiotic treated 
patients. Pathogen detection and identification can be available within a few hours, but first 
the crucial step of sample preparation will be discussed in this non-comprehensive overview.
3.3.1 Sample preparation
A crucial step in the whole process of pathogen detection using DNA based assays is 
sample preparation [131]. Cultured specimens contain high bacterial or fungal loads, but 
compounds present in the culture media can interfere in the downstream PCR reaction (e.g. 
charcoal, sodium polyanethol sulfonate (SPS, anticoagulant)) [132]. Due to the presence of 
high pathogen loads, the nucleic acid extraction procedure is less important. By applying a 
few washing steps (water), subsequent dilution, and heating of the sample, PCR results can 
already be obtained. When PCR is performed on positive culture material a reduction in time-
to-result can be achieved [133].
The first attempts to directly detect bacteria in whole blood date from 1993 [134, 135]. 
The numbers of clinical samples were small, but the sensitivities were 80% and 92% as 
compared to blood culture. As Gram-positive bacteria contain another cell-wall composition 
as compared to Gram-negative bacteria or fungi it is difficult to apply one nucleic acid 
isolation procedure for all these different pathogens [136].
Several challenges need to be dealt with when pathogens need to be detected directly 
from whole blood of suspected BSI patients. First, the low pathogen load in whole blood 
results in low amounts of pathogen DNA versus human DNA [137]. Second, whole blood 
contains inhibitory compounds which can interfere in the PCR (i.e. hemoglobin) [138]. Third, 
commercial PCR and DNA isolation reagents can be contaminated with bacterial of fungal 
DNA, leading to false-positive results [139, 140].
A frequently used nucleic acid isolation procedure in the molecular diagnostic laboratory is 
the NucliSENS EasyMAG (Biomérieux, Marcy l’Etoile, France). It is an automated system for 
total nucleic acid extraction from a variety of sample types and volumes. Whole blood can be 
used (200 µl) which is first lysed. Then, magnetic silica particles (beads) are added to which 
total nucleic acids can bind. Denatured proteins and other compounds are washed away and 
finally bound DNA and RNA are removed from the beads by using a buffer with a low-salt 
concentration.
To circumvent the difficulties encountered when working with whole blood (high human DNA 
levels), pathogen enrichment might be a solution. Recently, commercial pathogen DNA 
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isolation methods became available; SeptiFAST (Roche Diagnostics, Mannheim, Germany), 
Looxter (SIRS-Lab, Jena, Germany) and MolYsis (Molzym GmbH, Bremen, Germany). Looxter 
allows total genomic DNA isolation from 5 ml whole blood, followed by the specifi c binding of 
prokaryotic DNA to a column. Specifi c bacterial DNA isolation is based upon the presence 
of non-methylated CpG dinucleotides in the bacterial but not in the human DNA [141, 142]. 
Most eukaryotic DNA is removed by washing the column. Thus, Looxter concentrates the 
prokaryotic DNA and eliminates a high amount of background DNA. The MolYsis method 
can process 1 to 5 ml whole blood. This method enables selective lysis of human cells, 
followed by the enzymatic degradation of human DNA and DNA of compromised pathogens. 
Subsequently, bacteria are enriched by centrifugation and lysed. Finally, pathogen DNA is 
isolated. SeptiFAST does not allow specifi c isolation of only pathogen DNA. It isolates total 
nucleic acids from the whole blood sample and might therefore be comparable with the 
EasyMAG. The only difference is that the EasyMAG can process only 200 µl, while SeptiFAST 
enables processing of 1.5 ml whole blood. It has been shown by Handschur et al. that human 
DNA can interfere in a 16S rDNA real-time PCR, and when human DNA is removed from 
the sample these unspecifi c signal are eliminated [137]. Other studies have shown that when 
combining a human DNA removal protocol (MolYsis or Looxter) with EasyMAG sensitive 
results can be obtained as well [143, 144]. A detection limit of 10-100 CFU/ml in whole blood 
was obtained. This pathogen enrichment strategy can be applied to other clinical specimens 
as well (i.e. biopsy, pleural fl uid, and cerebrospinal fl uid) [136]. MolYsis and Looxter allow 
removal of at least 90% of the human DNA [141]. The perfect method which works optimal for 
all pathogens and every clinical specimen still needs to be developed.
Besides the commercially available DNA isolation methods, new pathogen enrichment 
strategies are being established. Smith et al, have developed a solution-based hybridisation 
method for the enrichment of pathogen DNA from samples that contain human DNA [145]. 
This technique utilises off-the-shelf reagents and home-made probes which can be made 
using whole-genome DNA from any organism of interest. This is an example of an approach 
which might result in optimal enrichment of every pathogen. There seems to be a continuous 
development of techniques which further optimise sample preparation.
3.3.2 Multiplex PCR assays for detecting pathogen DNA
To date, several commercially available assays have been developed, which allow 
detection of the most frequently encountered and clinically relevant pathogens causing BSI 
(Table 2). SeptiFAST (Roche Diagnostics, Mannheim, Germany) ensures detection of up to 
25 pathogens and mecA (methicillin resistance) from whole blood by using real-time PCR 
coupled to melting curve analysis. Results can be available in less than 6 hours. Most studies 
have demonstrated the benefi ts of using SeptiFAST in addition to blood culture [129, 146, 
147], especially in antibiotic pre-treated patients.
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SepsiTest (Molzym GmbH, Bremen, Germany) is a real-time PCR test in which 16S rDNA and 
18S rDNA are being amplified by using broad-range primers and SYBR Green. Subsequent 
sequencing analysis needs to be performed to identify the microorganism in the sample. 
By using SepsiTest, more than 345 bacteria and fungi can be detected from whole blood 
samples within 8 hours. In a study performed by Kuhn et al., SepsiTest was used to diagnose 
infectious endocarditis and proved to be twice as sensitive as compared to culture methods 
[148]. Wellinghausen et al. have shown that the concordance of SepsiTest with blood culture 
is 86% [149].
The VYOO method (SIRS-Lab GmbH, Jena, Germany) simultaneously detects 34 bacterial
and 6 fungal species as well as 5 of the most frequent resistance markers from whole blood 
within 8 hours. First, a multiplex PCR is performed followed by microarray analysis. Fitting et 
al. found a concordance in bacterial identification between microbiology and the VYOO test 
of 46.2% [150]. Based on the results obtained in their first patient cohort, they decided not to 
continue the study.
Seegene’s MagicPlex Sepsis Test (Seoul, Korea), allows detection of up to 90 pathogens 
and 3 resistance markers (methicillin and vancomycin A and B) from whole blood. First an 
amplicon bank needs to be created by conventional PCR and subsequent signal amplification 
serves as primary detection system. Next, 27 pathogens can be identified to the species level: 
21 bacterial species and 6 fungal species. The results can be available within 6 hours, including 
pathogen DNA isolation. Serra et al. clinically evaluated the MagicPlex Sepsis Test to detect 
candida DNA in pediatric patients [151]. They considered the test as an effective diagnostic 
tool for diagnosing invasive candidiasis along with conventional cultures. No studies have 
been published in which the MagicPlex Sepsis Test has been evaluated in adult BSI patients.
Table 2. Overview of pathogen detection and identification tests for whole blood.
Test (company) Pathogen DNA 
enrichment
# of pathogens 
detected
# of resistance 
markers
Time to results
SeptiFAST
(Roche Diagnostics)
No 25 1 (mecA) 6 hours
SepsiTest (Molzym) Yes, MolYsis 345 0 8 hours
VYOO (SIRS-Lab) Yes, Looxter 40 5 (mecA, vanA, 
vanB, blaSHV, 
blaCTX-M)
8 hours
MagicPlex Sepsis 
Test (Seegene)
Yes, MolYsis 90 (27 to species 
level)
3 (mecA, vanA, 
vanB)
6 hours
MecA: methicillin resistance, vanA and vanB: vancomycin resistance, blaSHV and blaCTX-M: 
β-lactamases.
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The clinical interpretation of a positive PCR signal with a negative culture result is still 
unclear. The PCR results might be correct and be the result of the higher sensitivity of the 
PCR for slow-growing microorganisms, or pathogens that do not grow due to presence of 
antibiotics. However, the PCR signal might be false-positive and due to detection of dead 
microorganisms or contamination. Due to the lack of an appropriate “gold standard” to 
compare to, the (discordant) results of new diagnostics methods need to be related to the 
clinical context of the patient. In such studies, patient outcome and possible modifi cation 
in treatment regime of a patient, based on results from new diagnostic tests, need to be 
monitored.
3.3.3. Detection of active BSI
As bacteremia is defi ned as the presence of viable bacteria in the bloodstream, it might 
be important to assess the viability of the bacteria in blood samples. Classical methods 
for the detection of BSI are based on culturing which intrinsically confi rm the viability of 
the microorganisms. However, culturing methods could be hampered by the fact that many 
pathogens can, when exposed to stress (i.e. starvation), enter either a dormancy state or die 
[152]. In this viable but non-culturable state, the pathogens are not able to form colonies on 
solid media but can become infective again when exposed to a good environment.
The presence of pathogen DNA in a clinical sample does not immediately provide information 
about the viability status of that pathogen as it can originate from both living and dead 
microorganisms [153-156]. The clinical signifi cance of pathogen DNA detection is therefore 
not clear.
It has been shown, by others, that DNA detection in time (measured for several days), after 
initiation of antibiotic therapy, can be used to provide information about the rate of bacterial 
clearance [157, 158]. The cycle threshold (Ct) values in the real-time PCR increase, indicating 
a lower amount of pathogen DNA present in the sample. Furthermore, it has been shown 
by Peters et al. that DNA load (related to the amount of pathogens) in blood can be used as 
a marker of severity of infection in patients with community acquired pneumonia [159]. This 
indicates that the amount of pathogen DNA present in a patient needs to be monitored in 
time to provide clinical useful information (e.g. initiation of appropriate therapy). Currently, 
most (commercially) available molecular sepsis tests are only used to detect (absence or 
presence) and identify pathogens from whole blood at a single moment in time. There are 
ways to ensure detection of DNA solely from living microorganisms. The dye propidium 
monoazide (PMA) is membrane-impermeable and can only selectively penetrate pathogens 
with compromised membranes, which can be considered dead. Subsequently, PMA binds to 
the DNA thereby inhibiting PCR amplifi cation [160].
Other molecules, such as messenger RNA (mRNA) or ribosomal RNA (rRNA), might also be 
more suitable to determine pathogen viability status as compared to pathogen DNA detection 
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[161, 162]. It has been shown that DNA can be detected after viable organisms have been 
eradicated [163]. It is clear that the clinical value of pathogen DNA detection from whole 
blood needs further investigation.
Outline of the thesis
It is highly unlikely that culture techniques can still be improved to significantly decrease time-
to- results. Therefore, the research presented in this thesis focussed on improving turnaround 
times by using new technologies for detection and identification of microorganisms (directly) 
from clinical specimens of BSI patients. The techniques used for this study, needed to be 
fast, robust, sensitive and specific.
A first step forward, to decrease time-to-result, can be achieved by using faster identification 
technologies on growth positive blood cultures. Moreover, eliminating culture steps will lead 
to the most optimal turnaround time. This means that using molecular assays directly on 
whole blood might be promising. When using molecular diagnostics, sample preparation is 
crucial and needs careful investigation, as it is known that no single pathogen nucleic acid 
isolation procedure is optimal for the different causative pathogens of BSI. Furthermore, 
large whole blood volumes need to be used to have optimal detection rates as compared 
to blood cultures. Whole blood contains lots of human cells, and as a consequence human 
DNA, and often only few microorganisms. Pathogen enrichment technologies for whole 
blood might be the solution for this problem.
Various biomarkers might have predictive value for BSI in patients with (suspected) sepsis. 
Nonetheless, the single biomarker which can predict BSI in different patient populations 
remains to be found. Furthermore, it would be interesting to use biomarkers as patient pre-
selection tools for the new and still expensive molecular assays. When BSI can be predicted, 
molecular assays can provide results within hours as compared to culture methods, which 
take several days. Although molecular assays are promising, their performance needs 
thorough investigation. The main objective of this research was to improve laboratory 
diagnostics of BSI.
In the first part of this thesis the main focus was to decrease time-to-results by using faster 
pathogen identification technologies on (positive) blood cultures. First, sensitive and specific 
real-time PCR assays, based on the tuf gene, were developed enabling accurate and fast 
detection of pathogens from different clinical specimens indicative for Gram-positive cocci, 
as these microorganisms are most frequently encountered in de medical microbiology 
laboratory (Chapter 2).
Second, we evaluated a number of bacterial DNA extraction methods for blood culture 
material to obtain optimal results. Then, we attempted to accelerate the direct identification 
of S. aureus and CoNS from blood culture bottles by reducing culture times, isolate bacterial 
DNA with the best method, and using real-time PCR analysis (Chapter 3).
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As the clinical relevance of CoNS infections is not clear, we performed a comparative study 
using phenotypic, genotypic and proteomics methods to fi nd the best identifi cation method 
for CoNS spp. available today (Chapter 4). Next, the best method found, MALDI-TOF MS, 
was used to identify more than 300 CoNS strains obtained from bacteremia patients of 2 
academic centres (Rotterdam and Maastricht). The bacterial identifi cation was linked to clinical 
parameters to investigate the clinical relevancy of this bacterial identifi cation (Chapter 5).
After that, we evaluated processing methods and the effect of reduced culture times for faster 
direct identifi cation of pathogens from blood cultures by using MALDI-TOF MS (Chapter 6). 
In this way, pathogens are identifi ed faster and this might improve patient care.
In the second part of the thesis, we focussed on direct pathogen detection and identifi cation 
from whole blood. Polaris, a novel non-enzymatic method for enrichment of pathogen DNA 
from large volumes of whole blood was developed and evaluated in comparison with available 
methods (i.e. MolYsis and EasyMAG). This was done for commonly detected microorganisms 
from blood of sepsis patients (Chapter 7).
In Chapter 8, several biomarkers were investigated for their ability to predict BSI in patients 
showing two or more SIRS symptoms. These patients originated from the emergency 
department. Subsequently, molecular assays were investigated in comparison to blood 
culture to determine the additional value of these assays.
RNA was investigated as a viability marker, as compared to DNA, for S. aureus after antibiotic 
treatment in both culture broth as well as whole blood (Chapter 9).
In Chapter 10, a summary is provided about the preceding fi ndings and future perspectives 
are given.
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Abstract
Bloodstream infections (BSI) are often nosocomial infections that are frequently caused by 
Gram-positive cocci and are associated with high morbidity and mortality rates. Although 
culture techniques remain the gold standard for pathogen identification they are hampered 
by the lengthy time-to-result. To accelerate the diagnostic procedure, two multiplex real-time 
PCRs were developed to detect these pathogens.
The PCRs were evaluated using 100 bacterial strains to determine the specificity. Additionally, 
317 blood cultures and 30 whole blood samples were analysed, to study the potential clinical 
value of this multiplex assay. Five bacterial DNA isolation methods were compared to 
determine the optimal sensitivity of this assay on remnant whole blood samples.
The analytical sensitivity of this real-time PCR is 0.4 CFU for Staphylococcus aureus and 
4 CFU for Enterococcus faecalis. Both the S. aureus and the Enterococcus spp. probes 
indicated to be 100% sensitive and specific. The PCRs showed 100% sensitivity and 
specificity on positive blood culture bottles containing Gram-positive cocci. The optimal DNA 
detection limit from 1 ml whole blood was 10 CFU/ml, obtained with the MolYsis Complete kit. 
This method was therefore used on 1 ml EDTA blood of 30 patients suspected of having BSI, 
to show proof-of-principle. Of the whole blood samples analysed, identical results between 
culture and PCR were found in 81.8% (18/22) of the cases. All CoNS and S. aureus samples 
were confirmed with PCR.
In conclusion, sensitive and specific real-time PCR assays were developed enabling accurate 
and fast detection of pathogens from clinical samples indicative for Gram-positive cocci. The 
pilot study on remaining EDTA blood of suspected sepsis patients supports further evaluation 
in a larger patient group.
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Introduction
Bloodstream infection (BSI) is a serious medical condition. Gram-positive microorganisms, 
especially Staphylococcus aureus, coagulase-negative staphylococci (CoNS), and 
Enterococcus species, account for the majority of episodes of bacteremia in critically ill 
patients in the intensive care unit (ICU) [1, 2]. CoNS are increasingly recognized as causative 
agents for both community-acquired and nosocomial bloodstream infections worldwide, 
mainly due to increased usage of medical devices [3]. A rapid and reliable method to detect 
these pathogens is therefore of clinical importance. Early detection and subsequent adequate 
treatment of bloodstream infections is critical for patient outcomes [4].
Blood cultures are still considered as the gold standard for pathogen detection from blood. 
However, this technique is slow, taking 24-72 hours, and can result in false-negative results 
(30%) even when the patient shows clear signs of systemic infection [5]. This is frequently 
thought to be the result of previous administration of antibiotics [1].
Nucleic acid based techniques offer a rapid and sensitive option for detecting pathogens 
directly from clinical specimens [6-11]. However, blood consists of many cells containing 
genomic DNA. This highly abundant genomic DNA might decrease the sensitivity of a 
PCR specifi cally detecting bacterial DNA. An optimal sample processing method should 
diminish human DNA, concentrate pathogen DNA and wash out inhibitory factors present in 
clinical samples. Several studies have investigated both automated and manual methods for 
isolation of bacterial DNA from several clinical specimens [12-16]. Sample preparation is of 
crucial importance when a sensitive test result needs to be obtained.
This study aims to develop a fast and sensitive PCR to detect S. aureus, CoNS, and 
Enterococcus spp, based on the tuf gene, which has been described as a reliable target for 
detection of staphylococci [17, 18]. Furthermore, this assay will be clinically evaluated using 
blood culture materials and whole blood specimens of sepsis suspected patients, using a 
combined sensitive pathogen DNA isolation method and in-house PCR.
Materials and Methods
Bacterial strains
Bacterial strains (n=100), commonly encountered in our laboratory were selected (Table 1). 
The bacteria tested were mainly clinical isolates (n=95), although a few reference strains 
(ATCC 33591 MRSA, ATCC 25923 MSSA, ATCC 12228 S. epidermidis, RIVM 122 S. hominis, 
and ATCC 29212 E. faecalis) were used (derived from the American Type Culture Collection 
and the National Institute for Health and Environment (RIVM, Bilthoven, The Netherlands)). 
All clinical isolates were identifi ed by standard culture and biochemical methods used in our 
certifi ed diagnostic laboratory (PAMM laboratories, Veldhoven, The Netherlands).
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Clinical samples
Three hundred and seventeen positive blood cultures were used, which consisted of BacT/
ALERT Standard Aerobe (SA) and Standard Anaerobe (SN) bottles (bioMérieux, Marcy 
L’Etoile, France). Bottles were handled according to manufacturer’s instructions. After being 
flagged positive by the BacT/ALERT 3D system (bioMérieux), Gram staining was performed. 
Positive blood cultures containing either Gram-positive cocci or Gram-negatives were 
included in the study. All positive blood cultures were further evaluated by routine culture 
and biochemical methods. The negative culture bottles had been incubated for 1 week and 
remained negative before inclusion in this study.
Whole blood was obtained from patients admitted to the Intensive Care Unit (ICU) of the 
Catharina Hospital, Eindhoven, The Netherlands. Patients were included in the study when 
showing ≥ 2 signs of systemic inflammatory response syndrome (SIRS) and were suspected 
of having a bloodstream infection [19]. Duration of hospital stay was not taken into account. 
Patients (n=30) were selected by the intensive care physician. For routine diagnostic purposes 
both blood cultures (n=22) for pathogen detection and EDTA whole blood were collected. 
After routine diagnostics, 1 ml remnant whole blood of these patients was obtained after 
blood culture was drawn. Whole blood was used for pathogen DNA isolation. Laboratory 
and clinical data were anonimised for analyses and no informant consent was obtained. This 
7 0
Strains n Staphylococcus probe S.aureus Probe Enterococcus Probe
S.aureus 22 22 22 0
CoNS: S.epidermidis (4), S.haemolyticus
(2), S.hominis (1), S.schleiferi (1),
S.lugdunensis (2), S.arlettae (1), S.sciuri
(1), S.auricularis (1), S.capitis (1),
S.simulans (1), S.saprofyticus (1),
S.cohnii (1), S.warneri (1) 
18 18 0 0
Non-staphylococcus: E.coli (3),
C.albicans (1), Hemolytical Strep A (1),
Hemolytical Strep B (3), S. marcescens
(1), M.morgani (1), P. aeruginosa (1),
K.plantico (1), Enterobacter spp (1),
Yeast (2), Difteroides (1), P.vulgaris (2),
S.sonnei (1), Y. enterocolitica (2), K. 
pneumoniae (3), B. cereus (2), S. mutans
(1), S. pneumoniae (2), E. cloacae (2),
Lactobacillus spp (1), L. acidophilus (1),
S. flexneri type 6 (1), S. enteritidis (1), M. 
catarrhalis (2), S. typhimurium (1), S. 
paratyphi (1), S. bovis (1), S. pyogenes
(2), L. monocytogenes (2),
Campylobacter spp (2), Bacteroides spp
(3), H. influenzae (2), V. cholerae (2)
53 L. monocytogenes 0
7E.Faecalis (4) and E.faecium (3) 
0
7
 
Table 1. Bacterial strains used for specificity of the tuf real-time PCR assay.
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is in agreement with the code for proper use of human tissue as formulated by the Dutch 
Federation of Medical Scientifi c Societies.
DNA isolation
DNA from bacterial strains was obtained by 10 min boiling of 1 McF bacterial suspensions in 
Tris-HCL 20 mM pH 8.3. Blood culture DNA was prepared by diluting positive blood culture 
material 1:100 in Tris-HCl 20 mM pH 8.3. This was centrifuged for 5 min at maximum speed 
and the pellet was subsequently dissolved in 100 µl aquadest. When the DNA sample of 
blood culture material showed to be red/brownish of colour, it was additionally diluted 10 fold 
before real-time PCR analysis.
EDTA whole blood sample preparation
For spiking experiments, randomly taken EDTA blood (remaining after diagnostics) of the 
same blood type (i.e. O+), was pooled and subsequently spiked with a 2 McF MRSA (ATCC 
33591), to obtain a ten-fold dilution series. Bacterial DNA was isolated with 5 different methods: 
EasyMAG generic protocol, EasyMAG specifi c A off-board lysis protocol, EasyMAG specifi c 
B off-board lysis protocol (bioMérieux, Marcy L’Etoile, France), MolYsis Complete kit (1 and 
5 ml) according to manufacturer’s instructions (Molzym GmbH, Bremen, Germany), and 
the MolYsis Basic kit (Molzym GmbH, Bremen, Germany) followed by the EasyMAG spec 
B protocol. Input for each isolation method was 200 µl, except for the Molzym Complete kit 
isolations for which the recommended volumes of 1 ml and 5 ml were used. Samples isolated 
with one of the EasyMAG protocols were eluted in 70 µl elution buffer provided; all other 
samples were eluted in 100 µl elution buffer provided with the isolation system. From each 
sample of the dilution series, 100 µl was plated on bloodagar to determine CFU/ml. DNA 
samples were analysed with the tuf LightCycler assay described below. Each isolation was 
at least performed in three independent experiments. Of the EDTA blood samples derived 
from sepsis suspected patients 1 ml was processed with the best performing protocol (see 
Results section).
Tuf real-time PCR assay
Two multiplex real-time PCRs were developed to detect S. aureus, CoNS, and Enterococcus 
spp., as schematically shown in Figure 1. PCR 1 detects and differentiates both Staphylococcus 
spp. and S. aureus specifi cally, and PCR 2 detects both Enterococcus spp. and Phocine 
herpesvirus (PhHV, gB polymerase), which is used as an internal amplifi cation control and to 
check for inhibitory factors.
Primers and probes are described in Table 2. All Staphylococcus spp. and S. aureus primers 
and probe positions are based on S. aureus tuf gene sequence (GenBank accession no 
AF298796). Enterococcus probe position is based on E. faecium and E. faecalis tuf gene 
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Figure 1. Schematic overview of tuf real-time PCR duplex assays.
Two real-time PCR duplex tests are performed on each sample. By using duplex 1 (left), two 
fragments of the tuf gene are amplified detecting both Staphylococcus spp. (339bp) and S. aureus 
(115bp) specifically. Duplex 2 is used to detect Enterococcus spp, based on the tuf gene, and PhHV 
(gB polymerase) which is added to each eluate as amplification and inhibition control.  The figure is 
not presented on correct scale.
Table 2. Primers and probes used for tuf real-time PCR assays.
Primers and Probes Sequence 5’-3’ Position Reference
Staphylococcus FW ccaatgccacaaactcgtga 32-51 [25]
Staphylococcus RV cacgaccagtgattgagaatacg 371-349 [25]
Staphylococcus probe VIC-ccattcatgatgccagttg-BHQ1 326-344 [25]
S. aureus FW tcctggttcaattacaccacatactg 583-608 [25]
S. aureus RV ggaaatagaattgtggacgatagtttga 698-671 [25]
S. aureus probe FAM-tgataatacrtawacttctgc-BHQ1 637-617 This study
Enterococcus probe FAM-gctgcagttgacgaata-BHQ1 281-297 This study
PhHV-1 FW gggcgaatcacagattgaatc [20]
PhHV-1 RV gcggttccaaacgtaccaa [20]
PhHV-1 probe VIC-tttttatgtgtccgccaccatctggatc-BHQ1 [20]
sequences (GenBank accession no AF124222 and no AF124221). Oligonucleotide primers 
were obtained from Eurogentec (Liège, Belgium). XS probes were obtained from Biolegio 
(Nijmegen, The Netherlands). PhHV-1 primers and VIC labeled probe [20] were obtained 
from Applied Biosystems (Nieuwerkerk aan den IJssel, The Netherlands). In silico analysis 
(BLAST) of the probes revealed cross-reactivity of the Staphylococcus spp. probe with 
Enterococcus spp, and the Enterococcus spp. probe detects besides E. faecalis and 
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E. faecium 9 other Enterococcus spp. (E. saccharolyticus, E. mundtii, E. hirae, E. urans, 
E. dispar, E. columbae, E. cecorum, E. casselifl avus, E. qallinarum).
PCR mixtures consisted of 5x LightCycler TaqMan Master mixture (Roche Diagnostics, 
Almere, The Netherlands), 0.9 µM concentration of each primer, 0.2 µM concentration of 
each probe, and aquadest in a volume of 15 µl to which 5 µl DNA sample was added, leading 
to a fi nal reaction volume of 20 µl in each capillary. Primers and probe targeting PhHV had 
a concentration of 0.1 µM each. All samples were amplifi ed on the LightCycler v2.0 (Roche 
Diagnostics) according to the following cycling parameters: an initial incubation step for 
10 min at 95ºC, subsequently 45 cycli of 15 sec 95 ºC followed by 1 min 60ºC. Results were 
analyzed using LightCycler Software version 4.05 (Roche Diagnostics).
Results
Analytical specifi city of tuf real-time PCR
Specifi city of the assay was determined using a representative panel of bacteria (Table 
1). The S. aureus and Enterococcus spp. probe showed correct results in the tuf real-time 
PCR assay with all tested bacterial strains. The Staphylococcus spp. probe showed cross-
hybridisation with E. faecalis, E. faecium, and L. monocytogenes, although in silico analysis 
indicated at least 1 to 3 mismatches with the primers.
Analytical sensitivity of tuf real-time PCR
The analytical sensitivity of the tuf real-time PCR was determined using 10-fold serial 
dilutions in Tris-HCl buffer in combination with MolYsis Complete DNA isolation (Molzym), 
and was shown to be 0.4 CFU per PCR reaction for S. aureus and 4 CFU per PCR for 
E. faecalis. Additionally, the sensitivity of the tuf PCR was analysed on serial dilutions of S. 
aureus spiked EDTA whole blood samples. From whole blood bacterial DNA was isolated 
according to 5 different methods as described in Materials and Methods (Table 3). All 
isolations were performed in 3 independent experiments. The automated extractor EasyMAG 
did not result in sensitive detection from whole blood material. The generic protocol resulted 
in a detection limit of 105 CFU/ml, however in one run 104 CFU/ml was detected.  The most 
sensitive detection limit using the EasyMAG was 103 CFU/ml; this was reached by using 
the off-board lysis combined with the specifi c B protocol. Bacterial DNA isolation with the 
MolYsis Complete kit (Molzym) resulted in the most sensitive detection of 10 CFU/ml for 
S. aureus from 1 ml EDTA blood. This equals a sensitivity of 0.5 CFU/PCR. Occasionally, 
1 CFU/ml could be detected when bacterial DNA was isolated from 5 ml spiked EDTA blood 
with the MolYsis Complete kit (1 out of 3 isolations). Inhibiting factors were not present since 
the internal control, i.e. PhHV gave comparable signals (Cp±0.5) for all samples in one run.
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Table 3. Evaluation of 5 different DNA isolation protocols on EDTA whole blood spiked with 10-fold 
dilution series of Staphylococcus aureus.
DNA isolation protocol
Detection limit in colony forming units/ ml
105 104 1.000 100 10 1
EasyMAG generic + ± - - - -
EasyMAG specific A + + - - - -
EasyMAG specific B + + + - - -
MolYsis Basic + EasyMAG specific B + + + + - -
MolYsis Complete 1 ml + + + + + -
MolYsis Complete 5 ml + + + + + ±
+ detected; - not detected; ± detected in 1 of 3 experiments (in tuf real-time PCR)
Clinical evaluation
Blood cultures
The tuf assay was clinically evaluated on 317 blood cultures which were either culture 
negative or showed presence of Gram-positive cocci or Gram-negative bacteria (Table 4). 
Conventional culture showed that 79 bottles contained S. aureus, 78 bottles CoNS, 5 bottles 
showed Micrococcus spp., 22 bottles Enterococcus spp. (E. faecalis or E. faecium), 97 bottles 
indicated Gram negatives to be present, 30 bottles were culture negative and 6 bottles 
contained double infections. All 79 blood cultures containing S. aureus were correctly 
identified by this PCR assay. CoNS containing bottles correctly only showed a positive signal 
with the Staphylococcus spp. probe. Bottles containing Micrococcus spp. were all negative 
with this assay, and the Enterococcus spp. were all positive with the Enterococcus spp. 
probe. As described before, Enterococcus spp. also showed a false positive signal with the 
Staphylococcus spp. probe. All double infections found (n=6) during this study were correctly 
identified by PCR. In addition to the microorganisms detected by culture, the tuf assay detected 
CoNS in 13/97 Gram-negative bottles (13.4%), and in 5/30 culture negative bottles (16.6%). 
In 5/13 Gram-negative bottles, which showed the unexpected presence of CoNS by PCR, a 
high load was detected as Cp values of less than 36 were found. In the culture negative bottles 
the CoNS detected by PCR showed a Cp value higher than 40, and this was also found for 
8/13 Gram-negative bottles that indicated presence of CoNS (Cp>39). The PhHV signals were 
comparable for all samples, as well as the negative (water) control, tested in one run (Cp±0.5).
EDTA blood samples
In addition to blood cultures, whole blood samples from a total of 30 patients with suspected 
bloodstream infection were evaluated in a small proof-of-principle pilot study. The MolYsis 
Complete kit was used to isolate bacterial DNA from 1 ml residual EDTA blood after 
completion of all other routine diagnostics. Available blood cultures data of these patients 
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were compared to tuf real-time PCR data. Of 22/30 patients it was possible to compare PCR 
data to blood cultures results (Table 5). From 8/30 patients no blood cultures were drawn. 
In 18 out of the 22 samples (81.8%) of which blood culture and PCR data were available, 
identical results were found. Fourteen culture negative samples were also negative in PCR, 
whereas S. aureus (sample 5 and 26) and CoNS (sample 1) positivity was confi rmed in 
PCR. In 4/22 (18.2%) of the blood samples different results were obtained using either blood 
culture technique or PCR (Table 5). Cp values of positive samples were found in the range 
of 32-40. PhHV signals were comparable for all samples in one run (CP±0.5), indicating that 
none of the samples contained inhibiting factors.
Discussion
In this study, we developed and evaluated the potential clinical value of a real-time PCR 
assay for detection of commonly encountered Gram-positive cocci from clinical samples.
The analytical sensitivity of this assay has shown to be 0.4 CFU/PCR for S. aureus, 
and 4 CFU/PCR for E. faecalis. Some clinical specimens (i.e. blood) contain many cells 
containing genomic DNA. This highly abundant genomic DNA might decrease the sensitivity 
of a PCR specifi cally detecting bacterial DNA [21]. An optimal sample processing method 
should diminish human DNA, concentrate pathogen DNA, and wash out inhibitory factors 
present in clinical specimens. As specimen preparation is of crucial importance when a 
sensitive test result needs to be obtained, the analytical sensitivity of the developed real-time 
PCR was investigated from S. aureus spiked EDTA whole blood. By using MolYsis complete 
Table 4. Comparison of blood culture results with tuf real-time PCR.
tuf real-time PCR
Blood culture results
S. aureus 
probe
Staphylococcus 
probe
Enterococcus 
probe
S. aureus 79 79 79 -
CoNS 78 - 78 -
Micrococcus spp. 5 - - -
Enterococcus spp. 22 - 22 22
Enterococcus spp. + S. aureus 3 3 3 3
Gram negative culture 97 - 13 (8/13 Cp>39; 
5/13 Cp<36)
-
Gram negative + CoNS 1 - 1 (Cp<24) -
Gram negative + Enterococcus spp. 2 - 2 (Cp<29) 2 (Cp<29)
Negative blood culture 30 - 5 (Cp>40) -
Total 317
CoNS: coagulase-negative Staphylococci; - indicates negative test result
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Table 5. Comparison of blood culture results with tuf real-time PCR from blood of suspected 
sepsis patients.
Number Blood culture result TTP (days) PCR result
1 Staphylococcus epidermidis 1 CoNS
2 Not done CoNS
3 Negative Negative
4 Negative Negative
5 Staphylococcus aureus 6 S. aureus
6 Negative Negative
7 Enterococcus faecium <1 CoNS
8 Negative Negative
9 Negative Negative
10 Negative Negative
11 Negative Negative
12 Negative Negative
13 Not done Negative
14 Negative Negative
15 Klebsiella pneumoniae 1 CoNS
16 Not done Negative
17 Not done Negative
18 Not done Negative
19 Bacillus fragilis 1 Negative
20 Negative Negative
21 Negative Negative
22 Negative CoNS
23 Not done Negative
24 Negative Negative
25 Not done Negative
26 Staphylococcus aureus <1 S. aureus
27 Negative Negative
28 Negative Negative
29 Negative CoNS
30 Not done CoNS
CoNS: coagulase-negative staphylococci; TTP: time to positivity
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(Molzym) a detection limit of 0.5 CFU/PCR was obtained, which is similar as the detection 
limit obtained from spiked Tris-buffer.
The S. aureus and Enterococcus spp. probe are shown to be 100% specifi c. The cross-
hybridisation observed of the Staphylococcus spp. probe with L. monocytogenes is a limitation 
of this assay. However, as this assay is proposed to be used in combination with Gram 
staining, the observed aspecifi c PCR detection of Listeria is considered less important due to 
the fact that this pathogen shows a different Gram stain. Additionally, Listeria is a food-borne 
pathogen and is not commonly described to cause bloodstream infections as staphylococci 
and enterococci do [3, 22]. A potential limitation of this assay, as previously discussed by 
Sakai et al. [10], is that diseases resulting from mixed infections of both S. aureus and CoNS 
will not be correctly identifi ed by this assay. If both probes show a positive signal, one would 
automatically conclude the presence of S. aureus bacteria and not the presence of CoNS. 
This also holds true for mixed infections of CoNS with Enterococcus spp.
Several clinical applications of the tuf gene based PCR assay were investigated in which 
the detection of S. aureus, CoNS, and enterococci are of importance; 1) blood cultures 
containing Gram-positive cocci, and 2) whole blood from patients of the ICU.
Firstly, the multiplex PCRs described were evaluated using 317 blood culture bottles of the 
BacT/ALERT system. All positive cultures containing Gram-positive cocci were detected with 
100% sensitivity and specifi city. In addition, all double infections were correctly identifi ed 
with this assay. CoNS were detected in blood culture negative bottles (16.6%) as well as in 
positive bottles containing Gram negatives (13.4%). Both Kocuglu et al. [23] and Shigei et al. 
[24] describe a 3-6% false negative rate in culture negative blood culture bottles. These false 
negative bottles mostly result, when subcultured, in Gram positives (83.3%) [23]. However, 
no DNA detection was used to investigate false negative rates in those studies, indicating 
that more false negatives might have been detected when PCR based methods were used 
due to the fact that this is a more sensitive method. When taking into account the Cp levels 
obtained in the present study, CoNS contamination might be indicated in cases where the Cp 
value is higher than 39 and true false negatives in culture when the Cp value is lower than 
39. This needs to be further investigated in more detail using a larger sample group to draw 
defi nitive conclusions. Although the PCR described is potentially of use for determination of 
S. aureus, CoNS, and Enterococcus spp. from positive blood cultures, the new technology 
matrix assisted laser desorption ionisation-time of fl ight mass spectrometry (MALDI-TOF 
MS) is an even faster alternative for pathogen identifi cation from positive cultures. This 
relatively new technique has shown its value in the microbiology laboratory for identifi cation 
of bacterial strains from positive blood cultures. However, not every diagnostic laboratory 
can afford a MALDI-TOF MS system. Due to the high sensitivity of this tuf based PCR assay 
it can be applied directly on positive blood culture bottles, but, also on blood cultures with 
reduced incubation times [25]. MALDI-TOF MS can thus only be applied on positive blood 
cultures, because >107 CFU needs to be used for this technique [26].
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In addition to blood cultures, the application of the assay for whole blood samples was 
studied. When using the MolYsis Complete kit on EDTA whole blood samples of patients 
suspected of having a bloodstream infection, a similar result between blood culture results 
and PCR data was found in 81.8% of the samples. For one patient it took 6 days for the culture 
bottle to become positive for S. aureus, whereas PCR results were available within 4 hours 
(including pathogen DNA isolation). It cannot be excluded that CoNS are causative agents 
of disease as this group of microorganisms is increasingly detected in nosocomial infections 
[27-29]. Bacterial loads in these samples can be low and antibiotics could be administered 
to patients before blood cultures were taken resulting in negative culture results and positive 
PCR signals. Although strict regulations and precautions are part of standard procedures 
in our hospital, contamination from skin during blood sample taking cannot be excluded. 
Double infections can also explain differences between culture and PCR data. We are able 
to detect double infections in a sensitive way in reconstruction experiments (data not shown) 
and in blood cultures. However, in this whole blood pilot study only single infections were 
detected by PCR as well as in blood cultures. A positive blood culture for K. pneumoniae 
could not be confirmed by this PCR (Table 1); however PCR showed the presence of CoNS, 
which might indicate a double infection in this patient. Commercially available sepsis tests 
for whole blood, for example SepsiTest (Molzym), SeptiFAST (Roche) and MagicPlex Sepsis 
Test (Seegene), are currently under investigation in several laboratories. Preliminary results 
obtained with these assays [30-33] showed that real-time multiplex PCR has potential value 
in addition to blood culture. This is in agreement with the outcome in this small pilot study. 
However, molecular testing still needs further optimization and detection of more clinical 
relevant pathogens besides S. aureus, CoNS, and Enterococcus spp. needs to be added in 
blood based diagnostics. Furthermore, a more extended clinical evaluation, using a larger 
group of patients, is of the essence.
In summary, sensitive and specific tuf gene based real-time multiplex PCR assays were 
developed for S. aureus, CoNS, and Enterococcus spp., which enabled fast and accurate 
detection from positive blood cultures. In a small pilot study using whole blood samples 
of ICU patients suspected of having bloodstream infection, the developed PCR assays 
combined with a sensitive bacterial DNA isolation method have shown potential use in 
detecting frequently encountered Gram-positive cocci. These results justify further clinical 
evaluation of this PCR assay in a larger group of patients.
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Abstract
To accelerate differentiation between Staphylococcus aureus and coagulase-negative 
staphylococci (CoNS), this study aimed to compare six different DNA extraction methods from 
two commonly used blood culture materials, i.e. BACTEC and BacT/ALERT. Furthermore, we 
analysed the effect of reduced blood culture incubation for detection of staphylococci directly 
from blood culture material.
A real-time polymerase chain reaction (PCR) duplex assay was used to compare the six 
different DNA isolation protocols on two different blood culture systems. Negative blood 
culture material was spiked with methicillin-resistant S. aureus (MRSA). Bacterial DNA was 
isolated with automated extractor EasyMAG (three protocols), automated extractor MagNA 
Pure LC (LC Microbiology Kit MGrade), a manual kit MolYsis Plus and a combination of MolYsis 
Plus and the EasyMAG. The most optimal isolation method was used to evaluate reduced 
bacterial incubation times.
Bacterial DNA isolation with the MolYsis Plus kit in combination with the specific B protocol 
on the EasyMAG resulted in the most sensitive detection of S. aureus, with a detection limit 
of 10 CFU/ml, in BacT/ALERT material, whereas using BACTEC resulted in a detection limit 
of 100 CFU/ml.
An initial S. aureus or CoNS load of 1 CFU/ml blood can be detected after 5 h of incubation in 
BacT/ALERT 3D by combining the sensitive isolation method and the tuf LightCycler assay.
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Introduction
Staphylococcus aureus is a pathogen which can cause both hospital- and community 
associated infectious diseases, ranging from minor skin infections to endocarditis, 
bacteremia, sepsis and septic shock [1]. Sepsis can result in high morbidity and mortality. 
In the United States, bloodstream infections develop in approximately 250.000 people 
annually [2]. In The Netherlands, the incidence of patients admitted to the intensive care unit 
(ICU) with severe sepsis is in the range of around 8643 ± 929 per year [3]. Currently, blood 
culture is the gold standard for identifi cation of pathogens from suspected bacterial sepsis 
patients. Unfortunately, blood culture is time-consuming, taking at least 24-72 hours for the 
fi nal determination of the bacteria causing the disease. Staphylococci are the most common 
Gram-positive organisms in blood cultures. Differentiating S. aureus from coagulase-
negative staphylococci (CoNS) is important, because sepsis with S. aureus is common 
and virulent with mortality rates in the range of 20-30% [4]. CoNS are often considered 
as being contaminants in blood cultures due to the fact that these species are members of 
the normal skin fl ora and mucous membranes, and can contaminate the sample when it is 
taken. However, it is known that CoNS infections are increasingly recognized as clinically 
relevant infections and confi rmation on the presence of these species in blood culture is, 
therefore, important (reviewed in [5-8]).  Several molecular methods for rapid and accurate 
detection of bacteria from positive blood culture material have been described, including 
(commercial) real-time PCR based diagnostic tests [9-11], fl uorescence in situ hybridization 
[12, 13], MALDI-TOF MS [14], and also DNA micro-arrays [15, 16]. However, all of these 
techniques are used on positive blood culture material.
Reduction in the time to obtaining results can be achieved by applying molecular methods 
either directly on whole blood or on blood culture material with reduced incubation times. 
Ideally, usage of whole blood is preferred but the techniques that are now available are often 
not sensitive enough, clinically, as has been shown by others investigating a commercial 
real-time PCR test currently available [17-19]. Blood culture materials are known to contain 
inhibiting factors which can reduce detection in a sensitive real-time PCR [20-23]. It is, 
therefore, important to include a good isolation method in the molecular diagnostic strategy, 
which is able to effi ciently remove inhibiting factors and one which still allows sensitive DNA 
detection by PCR.
In this study we compared six different, both manual and automated, bacterial DNA isolation 
methods for two commonly used blood culture systems, i.e. BACTEC (Becton Dickinson) 
and BacT/ALERT (bioMérieux), to be able to fi nd the most sensitive bacterial DNA isolation 
method. Additionally, we investigated the occurrence of inhibition in PCR amplifi cation 
after DNA isolation. A sensitive real-time PCR assay was designed to be able to detect 
staphylococci and to differentiate S. aureus from CoNS [Loonen et al., manuscript submitted]. 
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Subsequently, this real-time PCR was used in combination with the optimal DNA isolation 
method to investigate the level of time reduction to identify staphylococci from blood culture 
material. The results were compared with conventional blood culture techniques used in 
diagnostic laboratories.
Materials and Methods
Culture methods
Negatively cultured blood culture bottles, derived from routine diagnostics of both BACTEC 
(Becton Dickinson, The Netherlands) and BacT/ALERT (bioMérieux, The Netherlands) 
systems, were used in this study for spiking experiments (bottles have been cultured for 
1 week and remained negative). Additionally, healthy volunteers donated 10 ml blood as 
the input for the BacT/ALERT bottles. The bottles were incubated and handled according to 
manufacturer’s protocol.
DNA isolation methods
Methicillin-resistant S. aureus (MRSA) ATCC 33592 was cultured overnight on blood agar. 
Fresh plates were used to make a  2-McF solution which was subsequently serially diluted 
(1:10) in negative blood culture material from both systems (BACTEC and BacT/ALERT). One 
hundred µl was plated on blood agar plates to check the number of CFU per sample. Three 
different isolation protocols on the NucliSens EasyMAG (bioMérieux) were tested (generic, 
specific A and specific B protocol: the main difference between protocols is the number of 
washing steps, with least steps in the generic protocol and most washing steps in the specific 
B protocol), one isolation kit (LC Microbiology Kit MGrade) on the MagNA Pure LC (Roche 
Diagnostics), the MolYsis Plus kit (Molzym GmbH, Bremen, Germany) was used according 
to Molzym’s  instructions and in combination with the EasyMAG. When MolYsis was used 
in combination with the EasyMAG, manufacturer’s instructions (Molzym) were followed until 
the Buglysis step and, subsequently, bacterial DNA was extracted according to the specific 
B protocol on the EasyMAG. Input volume in each isolation was 200µl, only for the MagNA 
Pure LC 100µl was used, and samples were always eluted in 100µl elution buffer provided 
with each isolation method. Each extraction was performed at least 2-3 times in independent 
experiments. Phocine herpes virus type 1 (PhHV-1) was added to each sample eluate as 
an amplification and inhibition control. Samples were analysed with the LightCycler assay 
described below.
LightCycler assay
A duplex real-time PCR, detecting the tuf gene of both staphylococci and S. aureus 
specifically, is used as described in detail elsewhere [Loonen et al., submitted]. In brief, the 
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positions of the primers and probes were derived from the S. aureus tuf gene sequence 
(GenBank accession no. AF298796). The sequences of the primers and probes were as 
follows: Staphylococcus spp. forward primer ccaatgccacaaactcgtga (position 32-51), 
Staphylococcus spp. reverse primer cacgaccagtgattgagaatacg (position 371-349), S. 
aureus forward primer tcctggttcaattacaccacatactg (position 583-608), S. aureus reverse 
primer ggaaatagaattgtggacgatagtttga (position 698-671), Staphylococcus spp. probe VIC-
ccattcatgatgccagttg-BHQ1 (position 326-344), S. aureus probe FAM- tgataatacgtatacttctgc-
BHQ1 (position 637-617). Oligonucleotide primers were obtained from Eurogentec (Liège, 
Belgium), Staphylococcus XS probe and the S. aureus XS probe were obtained from 
Biolegio (Nijmegen, The Netherlands). PhHV-1 primers and VIC-labeled probe [24] were 
obtained from Applied Biosystems (Nieuwerkerk aan den IJssel, The Netherlands). PCR 
mixtures consisted of 5x LightCycler TaqMan Master mixture (Roche Diagnostics), 0.9 µM 
concentration of each primer, 0.2 µM concentration of each probe, and aquadest in a volume 
of 15 µl to which 5 µl DNA sample was added, leading to a fi nal reaction volume of 20 µl in 
each capillary. Primers and probe targeting PhHV had a concentration of 0.1 µM each and 
were used in a separate single real-time PCR. All samples were amplifi ed on the LightCycler 
v2.0 (Roche Diagnostics) according to the following cycling parameters: an initial incubation 
step for 10 min at 95ºC for enzyme activation and DNA denaturation, then, 45 cycles of 15 s 
95ºC followed by 1 min 60ºC. The results were analysed with LightCycler Software version 
4.05 (Roche Diagnostics).
Results
Evaluation of different bacterial DNA extraction methods
In Table 1, the results are presented of the comparison of six different bacterial DNA 
extraction methods on S. aureus spiked blood culture material. The MagNA Pure LC (Roche 
Diagnostics) resulted in a detection limit of 104 CFU/ml for both culture systems. On the 
EasyMAG, three protocols were evaluated to isolate bacterial DNA from spiked clinical 
material, generic, specifi c A and specifi c B. We tested all three protocols and usage of the 
specifi c B protocol resulted in the best detection limit of 102 CFU/ml of S. aureus in BacT/
ALERT material. Although MolYsis Plus did not result in a low detection limit, we tested this 
manual kit in combination with the specifi c B protocol on the EasyMAG. By combining both 
methods, all human DNA was removed and bacteria were lysed by the MolYsis Plus kit, and, 
subsequently, the EasyMAG was used for optimal washing and elution of bacterial DNA. It 
was possible to reduce hands-on time and avoid possible contamination due to skipping 
of manual handlings. This combination of methods resulted in the most sensitive detection 
limit, i.e.10 CFU/ml, in BacT/ALERT material. The time to obtaining results for this combined 
method followed by real-time PCR is approximately 4-5 h, but it strongly depends on the 
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number of samples. No inhibition was observed in the real-time PCR, and all samples and 
controls showed similar Cp values in one run (Cp±0.5). All experiments were performed at 
least 2-3 times.
Reduced blood culture times
To investigate the effect of reduced blood culture incubation for pathogen detection by PCR, 
a combination between the sensitive tuf LightCycler assay and the sensitive isolation method, 
the MolYsis Plus Kit in combination with the specific B protocol on the EasyMAG, was 
analysed on S. aureus (ATCC 33592)-spiked BacT/ALERT blood culture bottles containing 
fresh blood of healthy volunteers. First, it was investigated how many CFU of S. aureus per 
ml needed to be present to be able to detect a signal with the LightCycler assay, therefore, 
1.000, 100 and 10 CFU were spiked in different bottles, both SA (Standard Aerobic) and SN 
(Standard Anaerobic) BacT/ALERT bottles. BACTEC bottles were not investigated due to 
poorer results obtained with all isolation methods analysed. The results of this experiment 
are depicted in Figure 1 and indicate that 1.000 CFU of S. aureus (100 CFU/ml blood) 
could be detected by PCR immediately after spiking, indicating that no incubation step was 
required. The bottles containing 100 CFU of S. aureus (10 CFU/ml blood) resulted in positive 
real-time PCR signals after 1 h of incubation in the BacT/ALERT 3D. The 10-CFU bottles (1 
CFU/ml blood) needed a maximum of 5 h of incubation in the BacT/ALERT3D to be able to 
detect the S. aureus bacteria present using a subsequent PCR. The experiment with 10 CFU 
S. aureus per bottle was repeated eight times with both aerobe and anaerobe bottles and 
showed reproducible results. Standard deviations (SD) of the Cp values were calculated for 
the 10 CFU/bottle experiments (aureus probe). The 3-h time point (2/8 positive) showed an 
SD of 3.44, the 4-h time point (5/8 positive) indicated an SD of 1.09, and the 5-h time point 
(8/8 positive) resulted in an SD of 1.09. Clinical strains of S. aureus and S. epidermidis were 
also spiked in BacT/ALERT blood culture bottles (aerobe (SA) and anaerobe (SN)) containing 
Table 1. Evaluation of six different DNA isolation protocols on blood culture material spiked with ten-
fold dilution series of Staphylococcus aureus
                                                                                      Detection limit in CFU/ml
DNA isolation protocol 105 104 103 102 10 1
EasyMAG generic +* +* + - - -
EasyMAG specific A +* +* +* - - -
EasyMAG specific B +* +* +* + - -
MagNA Pure LC +* +* - - - -
MolYsis Plus +* +* - - - -
MolYsis Plus + EasyMAG specific B +* +* +* +* + -
*BACTEC; + BacT/ALERT; - not detected
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the blood of healthy volunteers. The results of these experiments were similar as the results 
presented for the S. aureus ATCC 33592 strain. With conventional detection methods, the 
results of the bottles containing 10 CFU of S. aureus were available after at least 28 h.
Discussion
In this study, six different bacterial DNA extraction protocols were evaluated, by using a 
sensitive and specifi c tuf gene based real-time PCR detection assay, which enabled the 
differentiation between S. aureus and CoNS. From this study, it can be concluded that the 
A
                                                                              Timepoints (hours)
Bacterial load CFU/bottle 0 1 2 3 4 5
1.000 1/1 1/1 1/1 1/1 1/1 1/1
100 0/1 1/1 1/1 1/1 1/1 1/1
10 0/8 0/8 0/8 2/8 5/8 8/8
B
Figure 1. Staphylococcus aureus detection in relation to reduced bacterial culture times.
A, Overview of the detection of S. aureus in relation to reduced culture times. BacT/ALERT blood 
culture bottles with blood of healthy volunteers were spiked with S. aureus and samples were taken 
every hour. The experiments with 1.000 and 100 bacteria per bottle were performed once. The 
1.000 bacteria/bottle did not need a pre-culture step, a tuf real-time PCR signal could be detected 
immediately after spiking (0 hr). The 100 bacteria/bottle needed a pre-culture step of 1 hour in the 
BacT/ALERT 3D to obtain a positive signal in the real-time PCR. The experiment with 10 bacteria/
bottle (10 ml blood) was repeated eight times. Real-time PCR signal could be detected after a pre-
culture step of 3-5 hours. All bottles, 8 of 8, were positive after 5 h of pre-culture. Standard deviations 
(SD) for 10 CFU/bottle were calculated as follows: 3 hr SD 3.44, 4 hr SD 1.09, and 5 hr SD 1.09.  B, 
LightCycler tuf real-time PCR result in the 530nm fl uorescence channel (S. aureus probe).
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MolYsis Plus kit (Molzym) in combination with the specific B protocol on the EasyMAG 
(bioMérieux) resulted in the most optimal isolation of bacterial DNA from BacT/ALERT blood 
culture material. A detection limit of 10 CFU/ml was obtained in the tuf LightCycler assay for 
BacT/ALERT material. By using the tuf LightCycler assay, 1 CFU/ml of S. aureus or CoNS 
could be detected from BacT/ALERT blood culture material when an incubation step of a 
maximum of 5 h was applied. By using this reduced incubation time, it was possible to identify 
S. aureus versus CoNS within one working day.
Six different bacterial DNA extraction methods were compared on two commonly used blood 
culture systems (BACTEC and BacT/ALERT). The specific B protocol on the EasyMAG 
contains the most washing steps compared to the generic and specific A protocol, possibly 
explaining the better results obtained with this isolation protocol. The bacterial DNA isolation 
performed with the MolYsis Plus kit resulted in a low detection limit for both culture systems. 
Gebert et al., published a study in 2008 in which they show that the MolYsis Plus kit performs 
well in their hands [25]. They used 500 µl input material and were able to conclude that PCR 
analysis in combination with MolYsis Plus DNA isolation resulted in accelerated detection of 
pathogens in blood culture samples. Inhibiting factors were not found to be present in the 
samples in the study of Gebert et al. [25]. In our study, no PCR inhibition was observed (all 
samples and controls showed similar Cp±0,5 values in one run). The detection limit in the 
LightCycler assay, after MolYsis Plus isolation, was low, i.e. 104 CFU/ml. The MolYsis Plus kit 
eliminates human background DNA from the samples and enrichment of bacterial DNA takes 
place. Complete isolation with the MolYsis Plus kit takes 3 h, of which 2 h is hands-on time. 
By using the EasyMAG specific B protocol after completion of the MolYsis Plus Buglysis step, 
the total isolation time is not significantly reduced. However, hands-on time and the chance 
for contamination are drastically reduced, due to the fact that column handling is skipped. A 
comparison between both culture systems resulted in a difference in bacterial DNA isolation 
efficiency. The use of BacT/ALERT blood culture material lead, in most isolation methods, 
to better results compared to BACTEC material. We experienced difficulties in the bacterial 
DNA isolations due to the beads present in BACTEC bottles, but we cannot conclude that 
the beads lead to the weaker performance of BACTEC material compared to BacT/ALERT 
material. However, due to this finding, all experiments were continued with BacT/ALERT 
material.
By applying a 5-h incubation step for blood culture bottles containing approximately 10 
CFU of S. aureus or CoNS, it was possible to detect these bacteria by the tuf LightCycler 
assay. These results could be produced within one working day when starting early in the 
morning. Compared to conventional culture techniques for staphylococci, the results were 
available at least 19 h faster. Gebert et al. [25], also showed in their paper that, by combining 
a sensitive real-time PCR and a sensitive isolation method, culture times can be reduced. 
They showed a 5.0-8.7 h time gain in spiking experiments and an average time gain of 10.7 
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h was obtained when the method was applied on blood culture bottles of septic patients. The 
maximum time gain can be reached when starting either immediately in the morning or when 
the microbiology laboratory has 24-h service. Laboratories with a 24-h setup will always 
benefi t from this method.
The experiments described in this paper all focus on accelerated detection of staphylococci, 
especially on detection of S. aureus. Staphylococci were chosen as a model system because 
Gram-positive bacteria are frequently detected in blood culture bottles, making it a relevant 
group of microorganisms for such a study [26-28]. Infections are, however, caused by a variety 
of pathogens. Staphylococci are fast-growing bacteria and, in this study, a proof-of-principle 
is shown. The accelerated detection, of other pathogens causing bloodstream infections (i.e. 
Escherichia coli), directly from blood culture material in combination with reduced culture 
time and with this sensitive isolation method should be investigated in future experiments. 
It is of clinical importance in the future to focus especially on fastidious pathogens or fungi, 
since those pathogens are diffi cult to culture and, for these pathogens, time to result can 
then, hopefully, be drastically reduced. A similar approach as presented in this study can be 
applied to investigate reduced incubation times for other pathogens.
It is known from literature that staphylococci are the most frequently causative agent of 
medical-device-related and surgical-site infections [7]. Therefore, it is interesting to apply 
the tuf LightCycler duplex assay in these patient groups using whole blood samples. The 
preliminary results showed that the MolYsis Complete kit (Molzym) has already proven to be 
successful in our hands (data not shown), as well as in the hands of others [29].
In conclusion, by combining the MolYsis Plus kit and the specifi c B protocol on the EasyMAG, 
10 CFU/ml could be detected from S. aureus spiked BacT/ALERT blood culture material. By 
applying this isolation method followed by the sensitive tuf LightCycler duplex assay, using 
5-h-incubated spiked blood culture material, 1 CFU S. aureus or CoNS per 1 ml blood could 
be detected. Future studies are needed in order to address the clinical application of this 
approach.
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Abstract
Five methods were compared to determine the most accurate method for identification of 
coagulase-negative staphylococci (CoNS) (n=142 strains). Matrix-assisted laser desorption 
ionization time-of-flight mass spectrometry (MALDI-TOF MS) showed the best results for 
rapid and accurate CoNS differentiation (99.3% of strains correctly identified). An alternative 
to this approach could be VITEK 2 combined with partial tuf gene sequencing (100% of strains 
correctly identified when both methods are performed simultaneously).
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Coagulase-negative staphylococci (CoNS) have emerged as signifi cant pathogens and 
are mainly found in hospitalized immunocompromised patients, often with indwelling or 
implanted medical devices [1-5]. Most infections are hospital acquired, and CoNS infections 
can result in several diseases, including bloodstream infection, endocarditis, mediastinitis, 
meningitis, urinary tract infections (Staphylococcus saprophyticus), and medical-device-
related infections [1, 2, 6-9]. Accurate identifi cation of CoNS is important when CoNS are 
isolated from multiple blood cultures of 1 patient.  Many CoNS are described to be resistant 
to multiple antibiotics [7, 10-12]. Matrix-assisted laser desorption ionization time-of-fl ight 
mass spectrometry (MALDI-TOF MS) is a relatively new technique that allows examination 
of protein profi les from bacteria, and this technique has been shown to work in a fast and 
accurate manner [13-16].
In the present comparative study, fi ve methods for differentiation of CoNS were compared, i.e., 
VITEK 2 (Gram Positive card REF 21342, bioMérieux), the ID 32 Staph strip (bioMérieux), partial 
16S rRNA gene sequencing (MicroSeq, Applied Biosystems), partial tuf gene sequencing (in-
house), and MALDI-TOF MS (Bruker Daltonics) on the same set of CoNS strains in order to 
fi nd the most suitable method available today for identifi cation of staphylococci.
A total of 142 CoNS strains were included in this study. Isolates were derived from clinical 
cultures (n=117), and 25 reference strains from the American Type Culture Collection (ATCC) 
and the National Institute for Health and Environment (RIVM, Bilthoven, The Netherlands) 
were included. The clinical isolates were selected from positive blood cultures (two or more 
positive cultures from 1 patient), urinary tract infections (S. saprophyticus), or deep-seated 
infections.  The CoNS species name that was found with ≥3 of the 5 used methods was 
chosen as the true CoNS species name (referred to here as the true ID). When only 2 
methods resulted in a similar true IDs (4/142 cases [2.8%]), tuf sequencing was selected 
as most reliable method, as the result for 16S rRNA gene sequencing was noninformative 
(Staphylococcus spp.).
CoNS strains were cultured overnight at 35°C on blood plates (made in-house). The 
phenotypical methods VITEK 2 (bioMérieux, Marcy L’Etoile, France) and ID 32 Staph 
(bioMérieux, Marcy L’Etoile, France) were both performed as described by the manufacturer.
DNA for sequencing was isolated from 2 McFarland bacterial suspensions by heating them 
(for 10 min at 95°C). The 16S rRNA primers from the MicroSeq kit were used, and these 
primers amplify approximately the fi rst 500 bp of the gene (Applied Biosystems, Foster 
City, CA). The tuf forward primer (tuf_32_FW) was described previously [17], and the tuf 
reverse primer (tuf_512_RV:  5’-AGCTTCAGCGTAGTCTAATAATTTACG-’3) was designed 
for this study. Positions of the tuf primers were derived from the Staphylococcus aureus 
tuf gene sequence (GenBank accession no. AF298796), and these primers amplify a 480-
bp fragment. The tuf primers were obtained from Eurogentec (Liège, Belgium). PCR was 
performed according to standard procedures. Sequencing was performed using the Big Dye 
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XTerminator sequencing mix 3.1 (Applied Biosystems, Foster City, CA) and ran on an ABI 
310 Prism genetic analyzer (Applied Biosystems, Foster City, CA). The 16S DNA sequences 
were analysed by using MicroSeqID Analysis software (Applied Biosystems, Foster City, 
CA). The tuf DNA sequences were analysed by using the Basic Local Assignment Search 
Tool (BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi).
For MALDI-TOF MS (Bruker Daltonics) analysis, 1 colony of each CoNS strain was spotted 
with a sterile wooden stick, in duplicate, on the polished steel target plate. Samples that 
could not be identified directly by MALDI-TOF MS were retested after pre-treatment (n=5 
clinical CoNS strains [1 strain each of Staphylococcus hominis, S. epidermidis, S. cohnii, S. 
schleiferi, and S. saprophyticus]) as described by van Veen et al., [13]. However, in this study 
formic acid (70%) and acetonitrile were added according to pellet size at a 1:1 ratio. The 
BioTyper database version V3 1.1.0_3476-3740 was used as reference.
The results (Table 1) of the phenotypic identification methods used in this study indicate that 
the VITEK 2 performs best, with a correct-identification rate of 92.3%, compared to 85.9% for 
ID 32 Staph. The acceptance criteria for all results are described in the footnote of Table 1.
With the use of 16S rRNA and tuf sequencing, 70.4% and 93% of the CoNS strains, 
respectively, were correctly identified. When the first hit with the MicroSeqID database was 
selected as true finding (disregarding analysis rules), then 137 out of 142 strains were correctly 
identified (96.5%). Application of the CLSI guidelines [18], which are stricter than those used 
in this study, will lead to even more results that are noninformative (Staphylococcus spp.) and 
thus incorrect identifications with 16S sequencing in this study. Whole-16S-gene sequencing 
will improve the Staphylococcus spp. differentiation ability of this specific gene but will also 
increase the number of required sequence reactions and consequently slightly increase 
costs and, in some cases, time-to results. Becker et al., [19] showed with the use of the 
quality-controlled Ribosomal Sequence Database (RIDOM), identification of staphylococci 
improved from 83.6% to 98.2% compared to the results obtained with the NCBI database. 
With the use of the RIDOM database, the results obtained in this study might positively change 
as well. However, tuf gene sequencing resulted in more informative data (species name) 
and was also in concordance with MALDI-TOF MS results. Although all Staphylococcus 
warneri strains (n=10) resulted in incorrect identification with tuf gene sequencing, due to 
high homology to Staphylococcus pasteuri, extensive analysis of S. pasteuri and S. warneri 
strains might solve the current problems. Therefore, the tuf gene seems more suitable for 
identification of staphylococci, as described by others [20, 21].
The MALDI-TOF MS data obtained in this evaluation indicate the superiority in identification 
of CoNS, as 99.3% of the strains were correctly identified with this method. Strains were 
spotted in duplicate and resulted in the same identification (strain name). The database 
(V3 1.1.0_3476-3740) used for this study contained the following numbers of reference 
spectra per tested CoNS species: Staphylococcus capitis (6), S. caprae (1), S. cohnii (5), 
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No. of strains identified by indicated method
ID 32 Staph Vitek2 16S sequencing tuf sequencing MALDI-TOF MS
True organism No. of strains Correctly   Incorrectly Correctly Incorrectly Correctly  Incorrectly Correctly Incorrectly Correctly   Incorrectly
S.capitis 13 12 1 12 1 11 2 13 13
S.caprae 1 1 1 1 1 1
S.cohnii 1 1 1 1 1 1
S.epidermidis 29 24 5 26 3 24 5 29 29
S.haemolyticus 18 18 16 2 13 5 18 18
S.hominis 22 19 3 21 1 17 5 22 21 1
S.lentus 1 1 1 1 1 1
S.lugdunensis 11 11 11 9 2 11 11
S.pasteuri 1 1 1 1 1 1
S.pettenkoferi 2 2 2 2 2 2
S.saprophyticus 12 12 12 8 4 12 12
S.schleiferi 10 4 6 10 4 6 10 10
S.sciuri 5 5 5 5 5 5
S.simulans 6 6 5 1 6 6 6
S.warneri 10 9 1 10 7 3 10 10
Total (%) 142 (100) 122 (85.9) 20 (14.1) 131 (92.3) 11 (7.7) 100 (70.4) 42 (29.6) 132 (93) 10 (7) 141 (99.3) 1 (0.7)
Table 1. Summary of the performance of methods for differentiation of CoNS*
*The acceptance criteria for the results were as follows: for ID 32 Staph, a score of ≥70%; for VITEK 2 
a score of ≥70% (in-house validation); for tuf sequencing, a species name provided by BLAST showing 
³99% sequence match (identity) and a mismatch of at least 1 nucleotide with the second hit; for 16S 
sequencing, a fi rst hit showing ³99% sequence match (identity) and a second hit having a mismatch 
of at least 1 nucleotide (MicroSeq software); for MALDI-TOF MS,  a score of ≥1.7, however, <2 were 
considered reliable to the species level if the fi rst and second database matches resulted in the same 
strain name; ideally,  ≥2 reference spectra need to be available in the database, and scores ≥2 were 
considered reliable to the species level.
S. epidermidis (9), S. haemolyticus (8), S. hominis (6), S. lentus (2), S. lugdunensis (5), S. 
pasteuri (2), S. pettenkoferi (4), S. saprophyticus (8), S. schleiferi (6), S. sciuri (4), S. simulans 
(5), and S. warneri (4). For S. caprae, only 1 reference spectrum is available, and duplicate 
measurement indicated S. caprae (hit 1: score, 1.853).  The second hit for this CoNS species 
indicated S. epidermidis twice (<1.5). For the proposed result acceptance criteria for MALDI-
TOF MS to be used, the number of reference spectra per CoNS strain ideally needs to be 
≥2. However, as hit 2 provided an unreliable score for S. epidermidis, we considered the S. 
caprea result as a correct identifi cation. On average, there was a 4.82% difference in score 
value between hit 1 and 2. The combination of MALDI-TOF MS with tuf gene sequencing 
resulted in a correct-identifi cation rate of 100%.
The 25 reference strains used in this study showed that different misidentifi cations occurred 
with the investigated methods. With the 16S sequencing protocol 9/25 reference strains 
could not be identifi ed to the species level (36%). For the VITEK 2, ID32 Staph, and tuf 
sequencing 2/25 reference strains were misidentifi ed (8%). MALDI-TOF MS resulted in 
correct identifi cation of all reference strains. MALDI-TOF MS has been investigated by others 
in relation to Staphylococcus species identifi cation directly from agar plates [15, 16, 22, 23], 
and the correct-identifi cation rates range from 74.2%-99.3%. The data obtained in this study 
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are comparable with data reported by Spanu et al., [23] and Dubois et al. [16], in which a 
sensitivity of 99.3% was found. In this study, only one S. hominis strain could not be identified 
with MALDI-TOF MS (Table 1), for unknown reasons.
Sequencing of the partial 16S gene resulted in most clinical relevant misidentifications, as 
both S. lugdunensis and S. saprophyticus were not correctly identified.
In conclusion, this is one of the most extensive comparative studies for CoNS identification. 
The results obtained in this study demonstrate the good performance of MALDI-TOF MS for 
identification of CoNS, a correct identification rate of 99.3% was achieved with this method. 
tuf gene sequencing is the most suitable substitute for MALDI-TOF MS. When cheap, fast 
and accurate identification of CoNS is needed, the usage of MALDI-TOF MS is the method 
of choice, and when necessary, the tuf gene can be sequenced. As an alternative method, 
due to the fact that not every diagnostic microbiology laboratory has access to a MALDI-TOF 
MS system, VITEK 2 combined with tuf sequencing is suggested as an accurate approach 
for CoNS differentiation.
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Abstract
The incidence of coagulase-negative staphylococci (CoNS) is rising, however, CoNS are 
also the most common blood culture contaminants. MALDI-TOF MS offers a cheap and 
reliable method for identification to species level of CoNS. In this study, we investigated the 
clinical relevance of various CoNS species isolated from positive blood cultures in a two 
center retrospective cohort study.
In two Dutch hospitals, CoNS blood culture isolates were collected and identified to species 
level using MALDI-TOF MS. Whether an isolate represented a bloodstream infection or 
contamination was established by CDC-criteria and by medical microbiologists or infectious 
diseases specialists.
265 strains were collected from 245 patients. Staphylococcus epidermidis was the most 
common species found (n=182, 68.7%) and the majority of these strains represented 
contamination (83.5% (CDC criteria) and 59.3% (clinical microbiologists/infectious diseases 
specialists)) . It was also the most common cause of CoNS bloodstream infections (66.7% 
(CDC criteria) and 75.5% (clinical microbiologists/infectious diseases specialists)). In 
comparison to the other CoNS species, Staphylococcus haemolyticus was significantly 
more frequently considered to cause a bloodstream infection (40.0% (CDC criteria) and 
70.0% (clinical microbiologists/infectious diseases specialists)). Some species, such as 
Staphylococcus warneri, were found to be always contaminants when using the CDC criteria. 
Clinicians were less likely to regard a strain as contaminant compared to the diagnosis 
according to the CDC-criteria.
In conclusion, determining whether or not a positive blood culture with CoNS represents a 
bloodstream infection needs standard use of criteria such as those of the CDC. This study 
shows that the various CoNS species vary considerably in pathogenicity. Speciation of CoNS 
by MALDI-TOF MS can therefore be helpful in establishing whether a patient is suffering from 
an actual CoNS bloodstream infection.
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Introduction
Coagulase-negative staphylococci (CoNS) have long been considered to be blood culture 
contaminants in the majority of patients. However, nowadays, CoNS is considered to be 
a true pathogen in special patient groups or conditions [1, 2]. Several species can cause 
infections without the presence of foreign body material, such as S. lugdunensis and S. 
schleiferi causing bloodstream infections or endocarditis, and S. saprophyticus causing 
urinary tract infections [3]. However, most CoNS bacteremias are associated with prosthetic 
device and intravenous catheter infections [4].
Whether a CoNS from a grown blood culture represents true bacteremia or a contaminant 
is usually based on the number of grown blood culture vials and clinical data, for which 
strict CDC-criteria are available (www.cdc.gov/nhsnpdfs/pscmanual/4psc_clabscurrent.
pdf). However, in clinical practice, treatment for CoNS bacteremia is also frequently started 
or maintained in patients not meeting these criteria [5]. Until now, it has been unclear 
whether identifi cation of subspecies of CoNS may be helpful in the discrimination between 
contamination and infection.
Phenotypic methods (VITEK 2, API system) for identifi cation of CoNS to species level are 
unreliable [6, 7]. PCR followed by sequencing is more reliable but also time-consuming and 
expensive. Furthermore, the gene most commonly used for identifi cation of bacteria, the 
16S rRNA-gene, is not specifi c enough for differentiation of different species of CoNS [6]. 
Therefore, up until now, most laboratories used coagulase production and DNAse production 
to discern CoNS from S. aureus and do not further determine the species of the CoNS strain, 
except in selected cases.
The recent introduction of MALDI-TOF MS systems, however, offers a cheap, rapid and 
reliable method for identifi cation of staphylococci [6, 8, 9]. Therefore, identifi cation to the 
species level of Staphylococcus strains can more easily be performed in routine patient care.
It is necessary to evaluate the value of this further identifi cation in the diagnosis of infection 
versus contamination. Therefore, we investigated the clinical relevance of various CoNS 
species isolated from positive blood cultures in a two center retrospective cohort study and 
compared the outcome to identifi cation of the Staphylococcal species.
Materials and Methods
Ethics statement
All data and strains in this study were collected retrospectively and anonimised before 
analysis. No consent from the patients was required and the ethics committee did not have 
to be approached. This is in agreement with the code for proper use of human tissue as 
formulated by the Dutch Federation of Medical Scientifi c Societies.
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Sample collection
Strains were collected in two hospitals: the Erasmus MC, Medical Centre in Rotterdam, The 
Netherlands, a 1200-bed university hospital, and the Maastricht University Medical Centre, 
Maastricht, The Netherlands, a 750-bed university hospital.
In Rotterdam, blood culture CoNS strains were collected retrospectively between January 
and June 2011. In Maastricht, blood culture samples were collected between October 2009 
and May 2011. Only one blood culture was included per patient. If this blood culture yielded 2 
strains of CoNS, both strains were included in the study. Exclusion criteria were: insufficient 
clinical data, age <18 years, and blood cultures with mixed cultures containing non-CoNS 
strains.
Blood cultures
In both centres, blood cultures bottles were cultured and automatically monitored for microbial 
growth in the BACTEC™ 9240 instrument (BD Diagnostic Systems, Sparks, MD, USA). If 
growth was detected, blood culture broth was subcultured on Columbia sheep blood agar.
From this subculture, Staphylococcus species were tested for clumping factor and DNAse 
production. If both tests were negative, the strain was identified as coagulase-negative 
Staphylococcus. In case of discrepancy between both tests, a tube coagulase test was 
performed as a gold standard.
In both centres, coagulase-negative staphylococci were not routinely identified to species 
level.
Antibiotic susceptibility testing was performed by automated systems: VITEK 2 system 
(bioMérieux, Marcy L’Etoile, France) in Rotterdam and BD Phoenix system (BD Diagnostic 
Systems, Sparks, MD, USA) in Maastricht. All strains were stored at -80oC.
MALDI-TOF MS
Strains stored at -80oC were subcultured twice on Columbia sheep blood agar, after which 
MALDI-TOF MS analysis was performed in duplicate, as was described elsewhere [6]. 
Scores <1.7 were considered to be unreliable, scores between 1.7 and 2 were considered 
to be reliable to the genus level; however, if database match number 1 and 2 resulted in 
the same strain name, it was considered correct to the species level, and scores ≥2 were 
considered to be reliable to the species level. Samples that could not be identified directly by 
MALDI-TOF MS were retested after pretreatment with formic acid and acetonitrile [6].
CDC-criteria for laboratory-confirmed bloodstream infection
A patient with a positive blood culture with CoNS was considered to have a bloodstream 
infection if the following criteria were met: fever (>38°C) or chills or hypotension, and: 
positive laboratory results are not related to an infection at another site, and CoNS cultured 
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from two or more blood cultures drawn on separate occasions (www.cdc.gov/nhsnpdfs/
pscmanual/4psc_clabscurrent.pdf).
Data collection
The following clinical data were collected from the patients’ electronic medical record: number 
of blood cultures drawn within 24 hours of drawing of the positive blood culture, number of 
positive blood cultures, antibiotic susceptibility of all blood cultures growing CoNS, positive 
cultures from other body sites, presence or absence of fever (>38oC) within 24 hours of blood 
culture drawing, presence or absence of hypotension (systolic blood pressure <90 mmHg), 
other potential foci of fever, results of consultations of clinical microbiologists and infectious 
diseases specialists regarding the positive blood culture.
Statistical analysis
For comparison of the percentage of strains causing infections between the various species, 
Chi-square tests were used. Differences between groups with a p-value <0.05 were 
considered to be statistically signifi cant.
Results
Identifi cation of CoNS strains
In total, 304 strains were collected, 172 in a six months period in Rotterdam and 132 in a 
fi fteen months period in Maastricht. These strains were cultured from 279 blood cultures. 
Four patients were excluded because their strains failed to grow after storage at -80˚C. Of 29 
patients, insuffi cient clinical data were available. One blood culture was excluded because it 
grew >1 genus (CoNS and Escherichia coli). This resulted in 265 strains (152 from Rotterdam 
and 113 from Maastricht) belonging to 245 patients being included in the study for analysis 
(Figure 1).
From 18 cultures, more than one species of CoNS was cultured, based on colony morphology 
and/or antibiotic resistance pattern: 17 grew 2 species and 1 grew 4 species.
The most commonly isolated species was S. epidermidis, followed by S. hominis, S. 
capitis and S. haemolyticus. S. hominis was almost twice as common in Maastricht than 
in Rotterdam, however, this did not reach statistical signifi cance. Overall, no signifi cant 
differences (p =0.60) were observed between the two hospitals in species distribution. No S. 
lugdunensis or S. schleiferi were found. (Table 1)
Six strains were identifi ed by MALDI-TOF MS as not being Staphylococcus species: two 
were Rothia mucilaginosa, four were Micrococcus luteus. One strain could not reliably be 
identifi ed to species level in four attempts.
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Positive blood cultures with 
CoNS: 
279 patients  
(304 strains)
Rotterdam:  
155 patients 
(172 strains) 
Maastricht:  
124 patients 
(132 strains) 
Strain available: 
151 patients  
(164 strains) 
Excluded cultures: 
Culture with >1 genus: 1 patient 
Strain(s) not available: 3 patients  
Strain available: 
123 patients  
(130 strains) 
Excluded cultures: 
Strain(s) not available: 1 patient  
 Included in analysis: 
139 patients 
(152 strains) 
Excluded patients:  
Insucient clinical data: 
12 patients 
Included in analysis: 
106 patients 
(113 strains)
Excluded patients: 
Insucient clinical data:  
17 patients 
Diagnosis of infection with CoNS
According to the CDC-criteria, 17.0% of all positive blood cultures with CoNS represented 
bloodstream infections. According to the consultations of clinical microbiologists and 
infectious diseases specialists, 37.0% of the CoNS strains caused bloodstream infections. 
(Table 2), which was significantly higher than the number of CoNS infections according to 
CDC-criteria (p <0.001). There was no significant difference (p =0.549 for the CDC-criteria, 
p =0.473 for the clinicians’ consultations) between the two hospitals in these numbers.
55 isolates were thought to be causative agents of a bloodstream infections by clinicians, 
whereas they were regarded to be blood culture contaminants by CDC-criteria (Table 2).
Figure 1. Flowchart showing included patients and strains.
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Of 100 patients, only one set of blood cultures was drawn, these patients therefore could 
never meet CDC-criteria. Twenty-two of them were considered to have a bloodstream 
infection by clinical microbiologists and infectious diseases specialists. Sixty-seven patients 
only had one positive blood culture set (of at least two sets drawn). Of these, 4 patients were 
regarded by clinicians, to have a CoNS infection.
Of the 82 patients not having either hypotension or fever at the time of blood culture drawing, 
19 were considered by clinicians to suffer from CoNS bloodstream infection.
In total, 36 patients grew a CoNS from a culture from another body site or removed foreign 
body material. These strains were not available for MALDI-TOF MS analysis and could 
therefore not be identifi ed to species level. Of these 36 patients, 12 patients met CDC-
Table 2. Number of true bloodstream infections, according to CDC-criteria and clinical 
microbiologist/infectious diseases specialist. 
Total Rotterdam Maastricht
Infection according to CDC-criteria 45 (17.0%) 24 (15.8%) 21 (18.6%)
Infection according to clinical microbiologist/
infectious diseases specialist 
98 (37.0%) 59 (38.8%) 39 (34.5%)
Infection according to clinical microbiologist/
infectious diseases specialist but not according 
to CDC-criteria
55 (20.8%) 35 (23.0%) 20 (17.7%)
Infection according to CDC-criteria but not 
according to clinical microbiologist/infectious 
diseases specialist 
2 (0.8%) 0 (0.0%) 2 (1.8%)
Table 1. Results of MALDI-TOF MS.
Total number of strains Number of strains in 
Rotterdam
Number of strains in 
Maastricht
S. epidermidis 182 (68.7%) 112 (73.7%) 70 (61.9%)
S. hominis 38 (14.3%) 16 (10.5%) 22 (19.5%)
S. haemolyticus 10 (3.8%) 5 (3.3%) 5 (4.4%)
S. capitis 17 (6.4%) 9 (5.9%) 8 (7.1%)
S. pettenkoferi 2 (0.8%) 1 (0.7%) 1 (0.9%)
S. caprae 1 (0.4%) 1 (0.7%) 0 (0.0%)
S. saprophyticus 1 (0.4%) 1 (0.7%) 0 (0.0%)
Rothia mucilaginosa 2 (0.8%) 1 (0.7%) 1 (0.9%)
Micrococcus luteus 4 (1.5%) 1 (0.7%) 3 (2.7%)
S. intermedius 1 (0.4%) 1 (0.7%) 0 (0.0%)
S. cohnii 2 (0.8%) 1 (0.7%) 1 (0.9%)
S. warneri 4 (1.5%) 2 (1.3%) 2 (1.8%)
No ID 1 (0.4%) 1 (0.7%) 0 (0.0%)
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criteria, whereas 32 were regarded to suffer from a CoNS bloodstream infection by clinical 
microbiologists and infectious diseases specialists.
Two positive blood cultures meeting the CDC-criteria for bloodstream infection were regarded 
to be a contaminant by clinical microbiologists/infectious diseases specialists.
Value of identification of CoNS in diagnosing infection
The species most often isolated in true bloodstream infections was S. epidermidis, 
representing 66.7% of all bloodstream infections by CDC-criteria, and 75.5% of infections 
according to clinical microbiologists or infectious diseases specialists. This was followed by 
S. hominis and S. haemolyticus. The vast majority (83.5%) of isolated S. epidermidis strains 
represented blood culture contamination as defined by CDC-criteria, thereby, also being the 
species most commonly isolated from contaminated blood cultures. S. saprophyticus and R. 
mucilaginosa were always associated with infections (Table 3A and B).
S. haemolyticus represented only 3.8% of all isolates. However, of all S. haemolyticus isolates, 
40.0% represented infection by CDC-criteria, and even 70.0% by the clinicians’ criteria, 
which was significantly more often than other species (p =0.012). Thereby, it represented 
8.9% of all bloodstream infections by CDC-criteria (Table 3A and B).
Of all species isolated more than once, S. pettenkoferi, S. cohnii, S. warneri and M. luteus 
were never associated with infection by CDC-criteria.
Discussion
In this study, we examined the added value of identification of CoNS from positive blood 
cultures to species level and showed that identification to species level can be helpful in 
determining whether an isolate is likely to be a true pathogen or a contaminant. S. haemolyticus 
was significantly more often associated with bloodstream infections than other CoNS species: 
40.0% according to CDC-criteria and even 70.0% according to clinicians. Several species were 
always found to be contaminants: S. pettenkoferi, S. caprae, S. intermedius, and S. cohnii.
Six strains were identified as not being staphylococci, but Rothia spp. or Micrococcus spp. 
However, it can be difficult to discern these strains from staphylococci by using only colony 
morphology, Gram-staining and catalase tests. MALDI-TOF MS can therefore be very helpful 
in their identification, especially since all Micrococcus strains represented contaminants and 
both Rothia strains were shown to be clinically relevant.
The two medical centres in this study represent two completely separate patient populations, 
since they both have different adherence populations. We found that the distribution of 
species was similar in both hospitals, as well as the ratio true pathogens/contaminants, both 
by CDC-criteria and as judged by clinical microbiologists and infectious diseases specialists.
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Table 3A Species distribution between contaminants and true bloodstream infection, A) by CDC-
criteria and B) clinical microbiologist/infectious diseases specialist.
CDC-criteria: 
contamination or 
infection, per species
No. of strains No. of 
infections
% of species 
representing 
infection
% of total 
number of 
infections
S. epidermidis 182 30 16.5% 66.7%
S. hominis 38 6 15.8% 13.3%
S. haemolyticus 10 4 40.0% 8.9%
S. capitis 17 2 11.8% 4.4%
S. pettenkoferi 2 0 0.0% 0.0%
S. caprae 1 0 0.0% 0.0%
S. saprophyticus 1 1 100.0% 2.2%
Rothia mucilaginosa 2 2 100.0% 4.4%
Micrococcus luteus 4 0 0.0% 0.0%
S. intermedius 1 0 0.0% 0.0%
S. cohnii 2 0 0.0% 0.0%
S. warneri 4 0 0.0% 0.0%
No ID 1 0 0.0% 0.0%
Total 265 45 17.0%  
Table 3B
Clinical microbiologist/
infectious diseases 
specialist:
contamination or infection, 
per species
No. of strains No. of 
infections
% of species 
representing 
infection
% of total 
number of 
infections
S. epidermidis 182 74 40.7% 75.5%
S. hominis 38 7 18.4% 7.1%
S. haemolyticus 10 7 70.0% 7.1%
S. capitis 17 6 35.3% 6.1%
S. pettenkoferi 2 0 0.0% 0.0%
S. caprae 1 0 0.0% 0.0%
S. saprophyticus 1 1 100.0% 1.0%
Rothia mucilaginosa 2 2 100.0% 2.0%
Micrococcus luteus 4 0 0.0% 0.0%
S .intermedius 1 0 0.0% 0.0%
S. cohnii 2 0 0.0% 0.0%
S. warneri 4 1 25.0% 1.0%
No ID 1 0 0.0% 0.0%
Total 265 98 37.0%  
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In this study, two definitions were used for true bacteremia: CDC-criteria and the clinical 
microbiologists’ or infectious diseases specialists’ judgement. The species distribution 
between pathogens and contaminants was very similar with both criteria. However, clinical 
microbiologists and infectious diseases specialists were less likely to regard a strain as 
contaminant than the CDC-criteria.
Clinicians may be reluctant to not treat a potential pathogen in case of doubt, especially 
when a patient is severely ill, even when a patient has a confirmed infection at another site 
with another microorganism that could explain the patients’ symptoms. This may result in an 
overestimation of the total number of actual CoNS bloodstream infections, and thus lead to 
excess use of antibiotics.
However, we have also shown that in clinical practise many patients will not meet CDC-
criteria when having a CoNS bloodstream infection. In 41% of patients in this study, no more 
than one blood culture set was drawn. These patients can never meet CDC-criteria, since 
they require positive blood cultures from more than one set. Also, bloodstream infections 
with CoNS are often much less severe than with other microorganisms, these patients 
therefore may not have high fever or hypotension, as well as patients using medication that 
suppress fever or hypotension. Furthermore, clinicians can use additional patient data in 
his/her decision making process that are not included in the CDC-criteria, for example a 
risk factor for acquiring CoNS infection such as indwelling devices. Indeed, in 36 patients 
in this study, in addition to growing a CoNS from a blood culture, the same CoNS species 
was cultured from another body site or removed foreign body material, which was deemed 
clinically relevant in 32 patients. Most of these infections would have been missed when 
using CDC-criteria only. In these cases, MALDI-TOF MS could be used for comparing the 
blood culture strain with strains cultured from other materials in order to aid in the diagnosis 
of CoNS bloodstream infection. Unfortunately, the strains cultured from other body sites were 
not available for analysis in this study.
Thus, clinicians may overestimate the number of actual CoNS bloodstream infections, but 
CDC-criteria are also likely to underestimate the number of infections. Additional criteria for 
diagnosing CoNS bloodstream infections therefore seem necessary. As we have shown, 
further speciation of CoNS by MALDI-TOF MS could be a useful addition to these criteria.
This study suggests that the various CoNS species may vary considerably in pathogenicity. 
S. schleiferi and S. lugdunensis possess virulence factors, such as extracellular slime which 
allows them to colonize tissues and evade phagocytosis, enzymes that allow them to invade 
tissues, and they can bind to a broad variety of molecules [3]. This makes it important to 
recognise them. Since they express clumping factor or DNAse, it can be difficult to discern 
them from S. aureus. For this, MALDI-TOF MS provides a useful tool. However, in this study 
of 265 CoNS strains from 245 blood cultures we did not find any of these species, indicating 
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that they are rare and using MALDI-TOF MS for fi nding these species alone would therefore 
not be very useful.
S. saprophyticus is a well-known pathogen in urinary tract infections, but generally these are 
uncomplicated infections, without bloodstream infection [10]. When found in blood cultures it 
is most often a contaminant and unrelated to an urinary tract infection [11]. In this study, we 
found one S. saprophyticus strain. Indeed this patient had undergone surgery to the prostate. 
According to both the clinical microbiologist and CDC-criteria, this patient suffered from a 
CoNS bloodstream infection. The history of the patient and the CoNS species make it very 
likely that the focus of this bloodstream infection was the urinary tract.
In this study, the CoNS species most commonly found in bloodstream infections was S. 
epidermidis. However, S. epidermidis was also the most common blood culture contaminant. 
This was also shown for S. hominis and S. capitis. However, S. haemolyticus was shown to 
be signifi cantly less likely to be a contaminant than the other species.
For S. haemolyticus, in comparison to S. aureus, S. lugdunensis, S. schleiferi, S. saprophyticus 
and S. epidermidis, much less information on virulence factors is known. S. haemolyticus is 
capable of biofi lm formation, which allows it to adhere to foreign material and evade the immune 
system and antibiotics [12]. Their genome allows for frequent genetic rearrangements, which 
could contribute to the acquisition of antibiotic resistance genes [13]. Indeed, they show a 
very high resistance rate for various antibiotics, including heteroresistance to glycopeptides 
[14-16]. This may result in selection in patients using antibiotics. Also, this makes them very 
diffi cult to treat, another reason to recognise them rapidly.
In most other studies, S. epidermidis, S. hominis and S. haemolyticus were also more likely 
to cause infection than other species [2], although species distribution may vary between 
countries. For example, in an Indian study by Chaudhury and Kumar [17], S. haemolyticus 
was the strain most commonly found in blood cultures, however, this study involved only 14 
CoNS blood culture isolates in total. Also, in a Japanese study by Kawamura et al. [18] on 
1230 clinical CoNS isolates, S. caprae was the third most commonly isolated species, after 
S. epidermidis and S. haemolyticus. Unfortunately, they did not mention how many strains 
were isolated from blood cultures and whether they represented an actual infection.
The methods by which CoNS species were identifi ed in all of those studies were not useful 
in clinical practise, such as sequencing, or the method used to identify them was not very 
reliable (for example VITEK or API system). MALDI-TOF MS provides a cheap, rapid and 
reliable alternative for these methods, making it more convenient to use for identifi cation to 
the species level in the clinical decision making process.
In patients with multiple positive blood culture bottles, it is shown using typing methods that 
the different bottles contain different strains, thus representing skin fl ora rather than true 
infection [19]. These typing methods are helpful in determining whether a patient has a true 
CoNS infection and prevent overtreatment, but for use in clinical practise they are too time 
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and money consuming. In the future however, MALDI-TOF MS might also offer a cheap and 
fast alternative for these typing methods, so typing may be used in clinical practise, allowing 
for a more accurate decision making process.
In conclusion, CoNS represent a large group of species, which vary considerably in 
pathogenicity and determining whether or not a positive blood culture represents a 
bloodstream infection remains difficult. We have shown in this study that speciation of 
CoNS could be helpful in establishing whether a patient is suffering from an actual CoNS 
bloodstream infection. The actual value of identification of CoNS by MALDI-TOF MS in 
clinical practise remains to be shown in a prospective trial.
Loonen.indd   82 30-10-2013   8:15:14
Speciation of CoNS from positive blood cultures using MALDI-TOF MS: clinical relevance  |  83
5
References
 1. Kloos, W.E. and T.L. Bannerman, Update on clinical signifi cance of coagulase-negative 
staphylococci. Clin Microbiol Rev, 1994. 7(1): p. 117-40.
 2. Piette, A. and G. Verschraegen, Role of coagulase-negative staphylococci in human disease. 
Vet Microbiol, 2009. 134(1-2): p. 45-54.
 3. von Eiff, C., G. Peters, and C. Heilmann, Pathogenesis of infections due to coagulase-
negative staphylococci. Lancet Infect Dis, 2002. 2(11): p. 677-85.
 4. Huebner, J. and D.A. Goldmann, Coagulase-negative staphylococci: role as pathogens. Annu 
Rev Med, 1999. 50: p. 223-36.
 5. Souvenir, D., et al., Blood cultures positive for coagulase-negative staphylococci: antisepsis, 
pseudobacteremia, and therapy of patients. J Clin Microbiol, 1998. 36(7): p. 1923-6.
 6. Loonen, A.J., et al., Comparative study using phenotypic, genotypic, and proteomics methods 
for identifi cation of coagulase-negative staphylococci. J Clin Microbiol, 2012. 50(4): p. 1437-9.
 7. Kim, M., et al., Comparison of the MicroScan, VITEK 2, and Crystal GP with 16S rRNA 
sequencing and MicroSeq 500 v2.0 analysis for coagulase-negative Staphylococci. BMC 
Microbiol, 2008. 8: p. 233.
 8. Spanu, T., et al., Evaluation of matrix-assisted laser desorption ionization-time-of-fl ight mass 
spectrometry in comparison to rpoB gene sequencing for species identifi cation of bloodstream 
infection staphylococcal isolates. Clin Microbiol Infect, 2011. 17(1): p. 44-9.
 9. Dubois, D., et al., Identifi cation of a variety of Staphylococcus species by matrix-assisted laser 
desorption ionization-time of fl ight mass spectrometry. J Clin Microbiol, 2010. 48(3): p. 941-5.
 10. Ronald, A., The etiology of urinary tract infection: traditional and emerging pathogens. Am J 
Med, 2002. 113 Suppl 1A: p. 14S-19S.
 11. Choi, S.H., et al., Clinical signifi cance of Staphylococcus saprophyticus identifi ed on blood 
culture in a tertiary care hospital. Diagn Microbiol Infect Dis, 2006. 56(3): p. 337-9.
 12. Fredheim, E.G., et al., Biofi lm formation by Staphylococcus haemolyticus. J Clin Microbiol, 
2009. 47(4): p. 1172-80.
 13. Takeuchi, F., et al., Whole-genome sequencing of staphylococcus haemolyticus uncovers 
the extreme plasticity of its genome and the evolution of human-colonizing staphylococcal 
species. J Bacteriol, 2005. 187(21): p. 7292-308.
 14. Chiew, Y.F., et al., Detection of vancomycin heteroresistant Staphylococcus haemolyticus 
and vancomycin intermediate resistant Staphylococcus epidermidis by means of vancomycin 
screening agar. Pathology, 2007. 39(3): p. 375-7.
 15. Froggatt, J.W., et al., Antimicrobial resistance in nosocomial isolates of Staphylococcus 
haemolyticus. Antimicrob Agents Chemother, 1989. 33(4): p. 460-6.
 16. Barros, E.M., et al., Staphylococcus haemolyticus as an important hospital pathogen and 
carrier of methicillin resistance genes. J Clin Microbiol, 2012. 50(1): p. 166-8.
 17. Chaudhury, A. and A.G. Kumar, In vitro activity of antimicrobial agents against oxacillin 
resistant staphylococci with special reference to Staphylococcus haemolyticus. Indian J Med 
Microbiol, 2007. 25(1): p. 50-2.
 18. Kawamura, Y., et al., Distribution of Staphylococcus species among human clinical specimens 
and emended description of Staphylococcus caprae. J Clin Microbiol, 1998. 36(7): p. 2038-42.
 19. Garcia, P., et al., Coagulase-negative staphylococci: clinical, microbiological and molecular 
features to predict true bacteraemia. J Med Microbiol, 2004. 53(Pt 1): p. 67-72.
Loonen.indd   83 30-10-2013   8:15:15
Loonen.indd   84 30-10-2013   8:15:15
Chapter 6
An evaluation of three processing methods and the effect 
of reduced culture times for faster direct identifi cation of 
pathogens from BacT/ALERT blood cultures by MALDI-TOF MS
Anne J.M. Loonen1-4, Arjan R. Jansz1, Jitske Stalpers1, Petra 
F.G. Wolffs3, and Adriaan J.C. van den Brule1,2,4
1 PAMM Laboratories, Department of Medical Microbiology, Veldhoven/Eindhoven, The Netherlands
2 Fontys University of Applied Science, Department of Medical Molecular Diagnostics, Eindhoven, The Netherlands
3 Maastricht University Medical Centre, CAPHRI, Department of Medical Microbiology, Maastricht, The Netherlands
4 Jeroen Bosch Hospital, Laboratory for Molecular Diagnostics, Departments of Medical Microbiology and 
Pathology, ’s-Hertogenbosch, The Netherlands
Eur J Clin Microbiol Infect Dis 2012, Jul;31(7):1575-83
Loonen.indd   85 30-10-2013   8:15:16
86  |  Chapter 6
Abstract
Matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF 
MS) is a fast and reliable method for the identification of bacteria from agar media. Direct 
identification from positive blood cultures should decrease the time to obtaining the result.
In this study, three different processing methods for the rapid direct identification of bacteria 
from positive blood culture bottles were compared. In total, 101 positive aerobe BacT/ALERT 
bottles were included in this study. Aliquots from all bottles were used for three bacterial 
processing methods, i.e. the commercially available Bruker’s MALDI Sepsityper kit, the 
commercially available Molzym’s MolYsis Basic 5 kit and a centrifugation/washing method. 
In addition, the best method was used to evaluate the possibility of MALDI application after 
a reduced incubation time of 7 h of Staphylococcus aureus- and Escherichia coli -spiked 
(1.000, 100 and 10 colony-forming units [CFU]) aerobe BacT/ALERT blood cultures.
Sixty-six (65%), 51 (50.5%) and 79 (78%) bottles were identified correctly at the species 
level when the centrifugation/washing method, MolYsis Basic 5 and Sepsityper were used, 
respectively. Incorrect identification was obtained in 35 (35%), 50 (49.5%) and 22 (22%) 
bottles, respectively. Gram-positive cocci were correctly identified in 33/52 (64%) of the 
cases. However, Gram-negative rods showed a correct identification in 45/47 (96%) of all 
bottles when the Sepsityper kit was used. Seven hours of pre-incubation of S. aureus- and 
E. coli -spiked aerobe BacT/ALERT blood cultures never resulted in reliable identification 
with MALDI-TOF MS.
Sepsityper is superior for the direct identification of microorganisms from aerobe BacT/
ALERT bottles. Gram-negative pathogens show better results compared to Gram-positive 
bacteria. Reduced incubation followed by MALDI-TOF MS did not result in faster reliable 
identification.
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Introduction
Fast and accurate diagnostic methods are necessary in order to be able to initiate correct 
treatment for bloodstream infections. Adequate and fast antibiotic treatment reduces 
the mortality rates in these patients [1, 2]. Cultivation techniques take at least a day, and 
although the subsequent Gram staining can be performed in several minutes, the result 
from this staining technique alone does often not provide suffi cient information to administer 
appropriate antibiotic therapy. Therefore, additional tests have to be performed so as 
to identify the pathogen that causes the disease, leading to an increased time to initiate 
appropriate therapy.
Improved techniques have been developed to reduce the time-to-result, i.e. VITEK 2, FISH 
(fl uorescent in situ hybridisation) and (commercial) real-time polymerase chain reaction 
(PCR)- based methods [3-6]. However, most of these techniques are limited by high costs 
and the fact that not every species can be detected in one assay. This makes it diffi cult to 
implement the technique in routine diagnostics.
Recently, a new method became available in several clinical microbiology laboratories, 
i.e. matrix-assisted laser desorption ionisation time-of-fl ight mass spectrometry (MALDI-
TOF MS). This technique can be used for pathogen identifi cation from agar media [7-9]. 
However, several reports are currently available which describe the possibility of direct 
identifi cation from positive blood cultures [10-15]. Most reports describe the use of BACTEC 
bottles, but a few studies [16, 17] used BacT/ALERT bottles. This makes the BacT/ALERT 
system underrepresented in the literature, while it is a frequently used culture system in many 
laboratories. Pathogens from blood cultures need to be separated from the liquid culture 
media prior to detection by MALDI-TOF MS. Several similar protocols have been published 
consisting either of the removal of erythrocytes by centrifugation [11, 12] or serum separation 
tubes [10, 14], followed by subsequently inactivating the bacteria by using ethanol, protein 
precipitation and extraction by formic acid and acetonitrile.
Recently, new processing methods have become available. Sepsityper (Bruker Daltonics) 
allows the easy and fast identifi cation of bacteria from positive blood cultures by using 
MALDI-TOF MS. Another commercially available method, MolYsis (Molzym), is capable of 
removing human background (cells and DNA) from blood (culture) samples by selective lysis 
and, additionally, ensures pathogen enrichment. This method has been shown to be suitable 
for molecular diagnostics [4, 18]. However, it is still unknown as to whether this enrichment 
method is also feasible for direct pathogen identifi cation from positive blood cultures by 
MALDI-TOF MS.
In addition, it was demonstrated that accelerated detection of staphylococci from spiked 
blood cultures was possible after only 5 h of pre-incubation when, subsequently, MolYsis 
enrichment was combined with real-time PCR [4].
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In the present study, we compared three easy-to-perform protocols, i.e. commercially 
available MolYsis Basic 5 and Sepsityper, and a non-commercial centrifugation/washing 
method as described by Ferreira et al. [11], for the direct identification of bacteria from positive 
aerobe BacT/ALERT blood cultures with MALDI-TOF MS. The results were compared to 
conventional diagnostics and MALDI-TOF MS directly from blood agar. To evaluate the 
possibility of reduced time-to-identification from blood cultures when using MALDI-TOF 
MS analysis, the best processing method was also investigated in relation to the reduced 
incubation times (7 h) of Staphylococcus aureus- and Escherichia coli-spiked BacT/ALERT 
blood cultures.
Materials and Methods
Clinical samples
Blood samples (8-10 ml) from patients were collected in standard aerobe (SA) and anaerobe 
(SN) BacT/ALERT blood culture bottles (bioMérieux, Marcy L’Etoile, France) without charcoal, 
and handled according to the manufacturer’s instructions. A total of 101 positive aerobe blood 
cultures (equal distribution of Gram-negative rods and Gram-positive cocci) were collected 
for this study (see Table 1 for details).
When patient samples were detected as positive by the BacT/ALERT 3D system (bioMérieux, 
Marcy L’Etoile, France), Gram staining was performed and, based on the Gram result, 
additional subculture and biochemical tests were performed (conventional diagnostics as 
schematically shown in Figure 3a). When Gram-negative rods were detected by Gram 
staining, several agar media were inoculated for subculture. One additional blood plate was 
inoculated for a spot-subculture (concentrated spot with blood culture material in the centre 
of the plate), which was used for the MALDI-TOF MS analysis. Resistance was determined 
by the use of VITEK 2 (bioMérieux). When Gram-positive cocci were detected in the blood 
culture sample, several agar media were inoculated for subculture. Standard biochemical 
tests were performed (based on the Gram result), because MALDI-TOF MS was still being 
validated in the laboratory for Gram-positive cultures, to obtain identification of the pathogen 
(coagulase, TLM plate, BAGG test, tellurite plate, rapid strep test, VITEK 2 [CoNS species]). 
As Streptococcus pneumoniae can die in the culture bottle (self-lysing ability), an LytA real-
time PCR [19] was performed when no subculture on blood agar was detected. Resistance 
determination occurred by the use of the disk diffusion method.
One colony of the subculture on blood agar was used for MALDI-TOF MS.
The Internal Review Board of the hospital ethically approves the anonymous use of remaining 
patient material.
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Strains for spiking experiments
The blood of healthy human volunteers (10 ml) was collected in SA BacT/ALERT culture 
bottles. For spiking experiments, S. aureus (ATCC 25923) and E. coli (ATCC 25922) were 
used.
Processing methods for MALDI-TOF MS
From each positive culture bottle, three aliquots were taken; for clarification, see Figure 1. 
For the Sepsityper method (Bruker Daltonics GmbH, Bremen, Germany) the recommended 
quantity of 1ml was used. The protocol was performed as recommended by the manufacturer. 
For the MolYsis Basic method (Molzym GmbH, Bremen, Germany), 1 ml was used and the 
provided protocol was followed until the first washing step. For the third method, 4 ml of 
positive culture material was used. The centrifugation/washing method was performed as 
described by Ferreira et al. [11]. All methods resulted in a pellet, which was subsequently 
dissolved in 300 µl of water, to which 900 µl of ethanol absolute was added. The mixture was 
centrifuged at 14,000 rpm for 2 min, and the supernatant was discarded. The centrifugation 
step was repeated so as to remove all residual supernatant. The pellet size was estimated in 
µl and, to this pellet, in a 1:1 ratio, 70% formic acid was added and mixed thoroughly. Next, 
the same amount of acetonitrile was added (1:1 ratio with formic acid) and mixed well before 
centrifugation at 14,000 rpm for 2 min. One µl of the supernatant was applied on a spot of 
the polished steel target plate and air-dried at room temperature. The dried spot was overlaid 
with 1 µl of HCCA matrix (Bruker Daltonics GmbH, Bremen, Germany) solution (saturated 
alpha-cyano-4-hydroxycinnamic acid in 50% acetonitrile and 2.5% trifluoroacetic acid) and 
allowed to air-dry at room temperature.
MALDI-TOF MS analysis
Samples were placed in the MALDI-TOF MS spectrometer (BioTyper, Bruker Daltonics 
GmbH, Bremen, Germany). The spectrometer was calibrated with Bruker bacterial test 
standard (Bruker Daltonics GmbH, Bremen, Germany). For pathogen identification, 240 
shots in 40-shot steps from different positions of the target spot (automatic) were recorded to 
obtain a spectrum per strain and spectra were imported in the MALDI BioTyper 2.0 software 
(Bruker Daltonics GmbH, Bremen, Germany) and analysed by standard pattern matching; 
the BioTyper database version V3 1.1.0_3476-3740 was used as a reference. No intervention 
took place in the process from measurement to identification. For each strain, the highest 
score obtained by pattern matching to the database was used for the identification. Scores 
<1.7 were considered to be unreliable, scores ≥1.7 x <2 were considered to be reliable to the 
genus level; however, if database match number 1 and 2 resulted in the same strain name, 
it was considered correct to the species level, and scores ≥2 were considered to be reliable 
to the species level. When “no reliable identification” or “no peaks found” was obtained 
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Statistical analysis
For analysis of the results, the McNemar test was used. The total amount of correct 
identifi cations (scores ≥1.7 with hit 1 and 2 being similar, and scores >2) and incorrect 
identifi cations were compared for all of the methods investigated. A binomial distribution was 
used.
Results
One hundred and one aerobe blood cultures detected as positive by the BacT/ALERT 3D 
system were processed by conventional methods, tested by MALDI-TOF MS from blood agar 
(direct smear method) and tested directly from positive blood cultures by using three different 
bacterial isolation methods (Figure 1). Only aerobe BacT/ALERT bottles were used because, 
in pilot experiments (preliminary data were obtained with small sample numbers), anaerobe 
BacT/ALERT bottles frequently resulted in unreliable data. Fifty- two cultures showed the 
presence of Gram-positive bacteria after Gram staining, 47 cultures showed the presence 
of Gram-negative bacteria  and two 2 cultures indicated, after conventional diagnostics, the 
presence of multiple bacterial species (Table 1). The direct smear method (blood agar) is the 
standard diagnostic method for Gram-negative bacteria and resulted in reliable identifi cation. 
For the Gram-positive cultures, both conventional diagnostics and the direct smear method 
Figure 1. Overview of bacterial identifi cation from positive aerobe BacT/ALERT cultures by 
using MALDI-TOF MS.
Three aliquots were taken from each positive blood culture bottle to analyse the different processing 
methods. All methods were performed as described in the Materials and Methods section. All results 
were compared to conventional diagnostics and/or MALDI-TOF MS directly from blood agar.
as a result, the manual selection of areas on the spot of the polished steel target plate 
was performed to possibly obtain reliable results. All data were compared to conventional 
diagnostics and MALDI-TOF MS results obtained from a colony grown on blood agar.
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were performed (due to the ongoing process validation of MALDI-TOF MS diagnostics).  Four 
of 52 blood agar plates did not result in growth. Of these four, three were characterised 
as S. pneumoniae by PCR and one was plated for a second time and was identified as 
Enterococcus faecium by conventional diagnostics. S. sanguis was detected as S. australis 
by MALDI-TOF MS from blood agar.  Blood culture samples that resulted in “unreliable data” 
or “no peaks found” were retested immediately from the same spot by the manual selection of 
areas on the polished steel target plate. This procedure never resulted in acceptable results 
(≥ 1.7) for further analysis.
Of the methods used for direct identification from positive blood cultures, Sepsityper showed 
(Table 1 and Figure 2) a correct identification in 79/101 cultures (≥1.7) equal to 78%, in 
contrast to MolYsis and the centrifugation/washing method, where only 50.5% and 65% were 
correctly identified, respectively. However, when Gram-negative cultures were separated 
from Gram-positive cultures and mixed cultures, it can be seen that cultures containing Gram-
negatives show more correct identifications with all of the methods used. When Sepsityper 
was used, 96% (45/47) of all Gram-negative cultures showed correct identification (≥1.7), 
on the contrary to cultures containing Gram-positives, where only 64% of the results (33/52) 
were correct. For the centrifugation method, 92% (43/47) and for the MolYsis method, 62% 
(29/47) of the Gram negatives were identified correctly (≥1.7). With both the centrifugation 
and the MolYsis methods, 42% (22/52) of the Gram-positive cultures were correctly identified.
Staphylococci were most frequently detected in the cultures containing Gram-positive 
bacteria, i.e. they represented 65% of these bottles (34/52). The direct smear method always 
resulted in reliable identification by MALDI-TOF MS. When identification directly from the 
positive blood culture was performed, Sepsityper resulted in the most correct identifications, 
as 12/14 S. aureus, 8/12 S. epidermidis, 1/1 S. haemolyticus, 0/1 S. warneri and 5/6 
Staphylococcus spp. showed identical results compared to the results obtained from the 
blood agar plate. In this study, streptococci showed to be the second most detected group of 
bacteria from culture bottles, with 12/52 (23%) cases. S. pneumoniae was recovered most 
frequently, in 9/12 cases. In three cases, no growth was detected on blood agar and, therefore, 
the direct smear method could not be performed. In five cases, S. pneumoniae was identified 
correctly from blood agar (≥1.7); however, directly from positive cultures successful detection 
of this pathogen proved to be difficult, as correct identification only occurred once with both 
the centrifugation/washing method and the Sepsityper method (≥1.7 x <2). Enterococci 
were recovered from 6/52 cultures (11.5%); in four cases E. faecalis was found and in two 
cases, E. faecium was found. Enterococci were detected accurately (>2) from blood agar 
(Table 1), except for one E. faecium strain which did not result in proper growth. Sepsityper 
characterised all E. faecalis cultures and one E. faecium culture accurately (>2).
The McNemar test was used to investigate the statistical significance of the obtained results. 
From the analysis of the total amount of blood cultures tested, it was shown that the direct 
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smear method always showed signifi cantly better results compared to identifi cation directly 
from positive blood cultures (all methods), p ≤ 0.001. The Sepsityper method showed to lead 
to signifi cantly better results compared to the MolYsis enrichment, p=0.000. No signifi cant 
difference was observed between the C/W method and MolYsis (p=0.11) and the C/W 
method and Sepsityper (p=0.19). When only the blood cultures containing Gram positives 
were analysed, by using the McNemar test, it was again shown that the direct smear method 
was always signifi cantly better compared to analysis directly from blood cultures, p ≤ 0.002. 
Sepsityper proved to be signifi cantly better compared to the MolYsis treatment, p=0.008. 
The C/W method was comparable to Sepsityper and MolYsis. As the direct smear method for 
all Gram-negative-containing blood cultures always resulted in correct identifi cation, these 
results were not used for McNemar analysis. The C/W method and the Sepsityper method 
performed on positive blood cultures (Gram-negative bacteria) lead to signifi cantly better 
results compared to MolYsis (p ≤ 0.01), but not when compared to each other.
Figure 2. Overview of results obtained with different bacterial isolation methods from positive 
blood cultures in comparison to results obtained with the direct smear method directly from 
blood agar.
a The overall results are depicted obtained after the analysis of all bottles included in this study. 
b Specifi c results obtained from the 47 bottles containing Gram-negative bacteria. c The data of the 52 
bottles in which Gram-positive bacteria were found are shown. C/W; centrifugation/washing method. 
Statistical signifi cance was analysed by using the McNemar test, see the Results section for details.
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The time needed to process positive cultures with the described methods varied. Sepsityper 
was fast (20 min) and easy to use, while MolYsis (50 min) had quite some incubation steps, 
took a lot of hands-on time and did not lead to reliable results. The centrifugation method is 
a good alternative (30 min), especially for Gram-negative pathogens, as it is cheap to use 
and shows promising results for this group of microorganisms. In contrast, the commercially 
available methods are more expensive (the list price in The Netherlands for the Sepsityper 
and Molzym methods are 4 and 8 Euros per test, respectively).
In preliminary experiments, BacT/ALERT bottles with charcoal were also analysed by using 
the Sepsityper method (Bruker) and the method described by Moussaoui et al. [14], using 
serum separation tubes. Bottles containing charcoal never showed reliable results and 
mostly resulted in “no peaks found”, as the charcoal was always isolated with the bacteria 
from the positive cultures.
Spiked aerobe cultures with reduced incubation times
To decrease the time-to-result even more, aerobe BacT/ALERT blood culture bottles were 
spiked with approximately 1.000, 100, and 10 colony forming units (CFU) of S. aureus (ATCC 
25923) or E. coli (ATCC 25922) per bottle (representative of 100, 10 and 1 CFU/ml blood) 
and were incubated for 7 h in order to be able to obtain results within one working day (8 h). 
Sepsityper was used in combination with MALDI-TOF MS for bacterial identification from these 
bottles, as this method proved to be superior in previous experiments. After 7 h of incubation 
in the BacT/ALERT 3D system, a 1-ml aliquot was taken from each bottle and processed as 
described in the Sepsityper manual. The culture bottles were placed back in the BacT/ALERT 
3D system to determine the time to positivity for each bottle and to use these bottles as 
positive controls for the Sepsityper procedure the next day. All experiments were performed 
three times (independently). Reduced incubation times of 7 h did not result in a peak pattern; 
no peaks were detected even after the manual selection of areas on the target plate. The S. 
aureus-spiked bottles were flagged positive after 16 h (1.000 CFU), 17.5 h (100 CFU) and 19.5 
h (10 CFU) by the BacT/ALERT 3D system, and did show correct identification (≥1.7 x <2 or 
>2) of S. aureus with the Sepsityper method. The E. coli-spiked cultures were flagged positive 
after 12 h (1.000 CFU), 13 h (100 CFU), and 14 h (10 CFU) by the BacT/ALERT 3D system, and 
were correctly identified (>2) as containing E. coli by MALDI-TOF MS analysis. As 1 ml might 
be a low amount of material to analyse after only 7 h of incubation, it was hypothesised that 
an increase in the sample volume might lead to the reliable identification of S. aureus-spiked 
aerobe cultures; therefore, the centrifugation/washing method (4 ml) was tested as well as the 
Sepsityper method, for which 2 ml was used (the chemicals from the kit were increased in 
the same ratio). Again, for both methods, no reliable identification was found as a result, but 
the positive bottles did show the reliable identification of S. aureus the next day (≥1.7 x <2 or 
>2). As a last effort, a new protocol was investigated which was published by Moussaoui et al. 
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[14] and describes the use of serum separation tubes (Becton Dickinson). This protocol was 
optimised for 3.5 ml of culture material and combined with the saponin pre-treatment step as 
described by Lupetti et al. [20]. The results indicated a non-reliable identifi cation after 7 h of 
incubation for S. aureus-spiked cultures. The positive bottles did result in reliable identifi cation 
(≥1.7 x <2) the next day.
Discussion
In this study, Sepsityper was shown to be the best method for positive aerobe BacT/ALERT 
blood cultures as 79/101 cultures were correctly identifi ed (78%). By using the MolYsis Basic 
(Molzym) method, 50.5% of all bottles were correctly identifi ed, and the centrifugation/
washing method according to Ferreira et al. [11] resulted in a correct identifi cation rate of 
65% of all cultures. In the current literature, a correct identifi cation rate of between 30 and 
90% is described [10, 12, 14, 15, 17], and this is in agreement with the data from this study. 
Christner et al. [15] and Moussaoui et al. [14] both describe high correct identifi cation rates 
of approximately 90%, which is higher than the 78% found in this study. The most important 
difference is the use of BACTEC cultures (compared to BacT/ALERT cultures) in those studies. 
In addition, a clear difference was observed between the identifi cation of Gram-negative 
versus Gram-positive bacteria, 96% versus 66%, respectively (Sepsityper), which confi rms 
the observations of previous studies [11, 12].
Streptococci were found to be problematic pathogens for MALDI-TOF MS identifi cation 
directly from positive cultures. In three cases, S. pneumoniae had to be detected by LytA 
real-time PCR, because no growth was observed on agar media, as the bacteria died in the 
bottles. In these three specifi c cases, no reliable identifi cation from the positive cultures was 
possible with all of the tested methods. For the other bottles containing streptococci (n=9), 
the direct identifi cation from blood culture material resulted mostly in unreliable identifi cation 
(<1.7) as well, while the identifi cation from agar media was not problematic for the majority 
(7/9 cases). The problems encountered in this study have also been observed by others [12].
In pilot experiments, it was found that anaerobe bottles more frequently resulted in unreliable 
data. Therefore, in this study, only positive aerobe BacT/ALERT cultures were used. The 
reason for the better performance of aerobe cultures might be found in the fact that the 
most commonly detected bacteria grow better in aerobe culture circumstances. This can, 
subsequently, result in a higher bacterial load in aerobe culture bottles and, subsequently 
in better MALDI-TOF MS spectra. Further studies should focus on the usage of anaerobe 
BacT/ALERT blood cultures for the optimal implementation of MALDI-TOF MS in the clinical 
microbiology laboratory. In contrast, for BACTEC bottles, several groups have described 
similar results for both positive aerobe and anaerobe cultures [10, 15]. This observation needs 
to be properly addressed in the future.
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Previously, we showed  the possibility of reduced incubation times for blood cultures spiked 
with staphylococci (1 CFU/ml blood); only 5 h of pre-incubation was sufficient to detect 
staphylococci when using real-time PCR as an analytical tool [4]. In this study, a pre-incubation 
of 7 h was investigated by using S. aureus-and E. coli-spiked BacT/ALERT bottles for 
subsequent rapid direct analysis with MALDI-TOF MS. Several approaches were undertaken 
but these never resulted in reliable results.  It has been described that at least >108 CFU/ml 
need to be present in culture material in order to obtain a spectra that resembles that from a 
pure culture, and at 106 CFU/ml, the spectra resembles that of a sterile culture [15]. This can 
be the explanation for the results obtained in this study. It remains unexplained why unreliable 
data have been obtained when 4 ml was used after 7 h of incubation.
In this study, S. aureus-containing cultures were never misidentified as CoNS and vice 
versa. Ferroni et al,[16] showed similar results with positive BacT/ALERT bottles concerning 
staphylococci. This may contribute to the discrimination of contamination versus true infection. 
Another positive effect of MALDI-TOF MS identification is that CoNS are now more frequently 
identified to the species level. This group of microorganisms is increasingly described in the 
literature in relation to infection [21, 22], making it clinically relevant to investigate this group 
of pathogens in more detail.
Positive BacT/ALERT bottles were tested immediately in the morning (9 am). If bottles 
became positive during the night in the BacT/ALERT 3D system, they remained in the culture 
machine until 8.30 am, and the time to positivity (TTP) was not registered for this study. 
Bottles were kept at room temperature, when positive, between 8.30 am and 6 pm (working 
hours); subsequently, they were stored for 1 week at 35°C. Bottles that became positive in 
the afternoon were tested the next day. However, if only Sepsityper is used for the analysis, 
positive bottles can be collected several times a day; for example every 2 h, starting at 8.30 
am, with the last round at 5.00 pm.
The results of this study implicate that routine diagnostics can be optimised when positive 
blood cultures can be processed by Sepsityper followed by MALDI-TOF MS, as schematically 
represented in Figure 3b. Pathogen identification can be available within 20 min (depending on 
the number of positive cultures that need to be processed), in contrast to the current workflow 
(approximately 1-2 days; see Figure 3a). This rapid direct identification of microorganisms 
from positive cultures can have a major impact in the clinic. Patient-tailored treatment 
decisions can be made more rapidly, but the final antibiotic therapy can only be installed if 
antibiotic susceptibility results are available.  Although Sepsityper was superior in this study, 
alternatives to this approach exist and clinical microbiology laboratories with a lower budget 
might implement the centrifugation/washing method for positive cultures containing Gram-
negative pathogens and apply the Sepsityper method only for positive cultures containing 
Gram-positive pathogens. Another alternative might be the usage of the spot subculture agar 
plates (materials and methods) for cultures which became positive early in the morning and 
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Figure 3. Schematic representation of the current (a) and possible new diagnostic workfl ow (b).
Every positive culture (anaerobe cultures need further research) will be processed by Sepsityper 
and analysed by using MALDI-TOF MS to have optimal speed for the identifi cation of pathogens. 
Additionally, Gram staining and subculture on agar media will be started for antibiotic susceptibility 
testing and, when necessary, these agar media can be used for MALDI-TOF MS when the direct 
identifi cation from cultures is unsuccessful.
A
B
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Sepsityper for cultures that became positive later during the day. At the end of the working 
day, these spot subcultures contain enough bacteria for MALDI-TOF MS analysis via the 
direct smear method. Unfortunately, it is still not possible to use MALDI-TOF MS for antibiotic 
susceptibility testing or for detection of virulence factors. Additional studies are needed for this.
In summary, after the analysis of more than 100 positive aerobe BacT/ALERT cultures with 
three different processing methods, it can be concluded that Sepsityper is superior for the 
detection of pathogens directly from positive aerobe BacT/ALERT cultures by MALDI-TOF 
MS in comparison to processing cultures by MolYsis or the centrifugation/washing method. 
Gram-negative pathogens are easier to identify from cultures compared to Gram-positive 
microorganisms. Reduced incubation (7 h) of S. aureus-and E. coli-spiked aerobe BacT/
ALERT cultures did not result in reliable identification with all of the methods tested.
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Abstract
For patients suffering from bloodstream infections (BSI) molecular diagnostics from whole 
blood holds promise to provide fast and adequate treatment. However, this approach is 
hampered by the need of large blood volumes.
Three methods for pathogen DNA isolation from whole blood were compared, i.e. an 
enzymatic method (MolYsis, 1-5 ml), the novel non-enzymatic procedure (Polaris, 1-5 ml), 
and a method that does not entail removal of human DNA (Triton-Tris-EDTA EasyMAG, 
200 µl). These methods were evaluated by processing blood spiked with 0 -1000 CFU/ml 
of Staphylococcus aureus, Pseudomonas aeruginosa and Candida albicans. Downstream 
detection was performed with real-time PCR assays.
Polaris and MolYsis processing followed by real-time PCRs enabled pathogen detection 
at clinically relevant concentrations of 1-10 CFU/ml blood. By increasing sample volumes, 
concurrent lower cycle threshold (Ct) values were obtained at clinically relevant pathogen 
concentrations, demonstrating the benefit of using larger blood volumes. A 100% detection 
rate at a concentration of 10 CFU/ml for all tested pathogens was obtained with the Polaris 
enrichment, whereas comparatively lower detection rates were measured for MolYsis (50-
67%) and EasyMAG (58-79%). For the samples with a concentration of 1 CFU/ml Polaris 
resulted in most optimal detection rates of 70-75% (MolYsis 17-50% and TTE-EasyMAG 
20-36%). The Polaris method was more reproducible, less labour intensive, and faster (45 
minutes (including Qiagen DNA extraction) vs. 2 hours (MolYsis)).
In conclusion, Polaris and MolYsis enrichment followed by DNA isolation and real-time PCR 
enables reliable and sensitive detection of bacteria and fungi from 5 ml blood. With Polaris 
results are available within 3 hours, showing potential for improved BSI diagnostics.
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Introduction
Bloodstream infections (BSI) can be caused by a wide variety of pathogens and remain a 
signifi cant cause of morbidity and mortality especially in the Intensive Care Unit [1-3]. This 
could be signifi cantly improved by pathogen-tailored antibiotic and antifungal treatment [4]. 
This requires a fast identifi cation of the infecting pathogen. Rapidly administered, targeted 
therapy is also important to reduce the risk of resistance development among pathogens. 
Current practice for pathogen identifi cation in BSI consists of time-consuming (24-72 hours) 
blood cultures. To be able to provide fast and patient tailored treatment, identifi cation of 
the pathogen should be available as soon as possible, as patients in septic shock with 
inappropriate treatment have signifi cantly lower survival rates [4, 5].
Culture-independent identifi cation techniques, such as molecular diagnostics, will shorten 
time to result. Pathogen levels in blood of BSI patients can be as low as 1-10 colony forming 
units (CFU) per ml, therefore several millilitres of blood may be required to reach clinically 
relevant sensitivity. This poses a problem since the amount of human DNA and haemoglobin 
present in such samples inhibit the pathogen-specifi c PCR [6]. In order to reach similar 
sensitivities as blood cultures, where input is in the order of 10-20 ml per blood culture set, 
pathogen DNA enrichment methods should precede the identifi cation PCR.
Recently, several molecular diagnostic tests for whole blood became commercially available 
(SepsiTest (Molzym), MagicPlex Sepsis Real-Time Test (Seegene), VYOO (SIRS Lab), and 
SeptiFAST (Roche)) and were evaluated by several independent research groups [7-13]. 
However, none of the abovementioned tests combines pathogen DNA enrichment with fast 
identifi cation, they provide either pathogen DNA enrichment or fast sensitive detection. Only 
the Molzym test enables pathogen DNA enrichment based on enzymatic removal of human 
DNA (MolYsis) using an input volume of 1 to 5 ml whole blood [14, 15]. However, the method 
is labour-intensive and the use of enzymes may make this test less stable. We therefore 
tested and evaluated a novel non-enzymatic and more rapid pathogen DNA enrichment 
method for blood samples, designated Polaris.
The main goal of this study was to evaluate the Polaris method and to compare its performance 
to the MolYsis method and a method that does not entail removal of human DNA (Triton-Tris-
EDTA - EasyMAG) [16]. These methods were compared using whole blood samples spiked 
with frequently recovered BSI microorganisms Staphylococcus aureus, Pseudomonas 
aeruginosa and Candida albicans, representing Gram-positive and Gram-negative bacteria, 
and a fungus, respectively.
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Materials and Methods
Ethics statement
In The Netherlands, healthy blood donors have to sign an informed consent form when 
donating blood at the Sanquin institute. In this form, medical research purposes are 
mentioned. Research institutes can buy this blood, and donors are anonimised. Therefore, 
no additional informed consent was required
Spiking experiments
EDTA blood from healthy human volunteers was obtained from Sanquin (bloodbank, 
Eindhoven, The Netherlands).  Staphylococcus aureus (ATCC 25923), Pseudomonas 
aeruginosa (ATCC 27853), and Candida albicans (ATCC 90028) were used for spiking. All 
microorganisms were cultured overnight (O/N) on blood agar plates (TSA plates with 5% 
Sheep Blood, Fischer scientific, Aalst, Belgium). Subsequently, the cells were grown to mid 
log phase in Brain Hearth Infusion broth (S. aureus) or LB (P. aeruginosa) to ensure having 
a majority of actively growing cells. C. albicans was in mid log phase after the O/N culturing 
step. Hereafter, a ten-fold serial dilution was made in PBS (Merck, Darmstadt, Germany) 
and before spiking a live/dead staining (Life Technologies, Gent, Belgium) was performed 
as described by the manufacturer, to determine the ratio between live and dead pathogens 
(criterium used >90% living bacteria). This was performed to confirm that the majority of cells 
is intact since the MolYsis and Polaris method will not allow enrichment of damaged cells and 
free DNA. To determine the CFU per ml, 100 μl from several dilutions were plated onto blood 
agar plates and cultured O/N. Blood was spiked with the different dilutions, yielding 0-1000 
CFU/ml blood. Reference samples consisted of similar amounts of pathogens taken from the 
PBS dilution series directly subjected to lysis and extraction. See Figure 1 for an overview of 
the experimental set-up.
DNA isolation methods
Pathogen DNA was isolated with three different methods. The Triton-Tris-EDTA (TTE) pre-
treatment procedure (input 200 μl blood) followed by EasyMAG isolation (BioMérieux, Marcy 
L’Etoile, France) was performed as described by Peters et al. [16]. The MolYsis complete 5 
kit was used for pathogen DNA isolation from 1 and 5 ml spiked whole blood as described by 
the manufacturer (Molzym GmbH, Bremen, Germany).
Details of the Polaris technology (Biocartis, Mechelen, Belgium) are described elsewhere 
(patents WO2012168003 A1 and WO2011070507 A1). For Polaris (Figure 2), 1 or 5 ml blood 
was mixed with an equal volume of selective lysis buffer (SLB) for 3 minutes, to lyse blood cells 
and fragment the released human DNA and then 1 or 5 ml neutralization buffer was added. 
The selective lysis is based on a mild detergent to degrade the human cell membranes but 
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Figure 2. Overview of the Polaris method.
Whole blood is depicted, consisting of human cells and DNA, and some pathogens. In the fi rst 
step, human cells and DNA are degraded and pathogens remain intact. In the second step, intact 
pathogens are pelleted by centrifugation. Finally, this pellet is washed and pathogens are lysed. 
Subsequently, DNA can be isolated (not depicted). WBC, white blood cell; RBC, red blood cell; SLB, 
selective lysis buffer; BLB, bug lysis buffer.
Figure 1. Flowchart of the experimental set-up.
SA, S. aureus; PA, P. aeruginosa; CA, C. albicans; CFU, colony forming unit.
not the bacterial and fungal cell walls. An elevated pH will ensure degradation of the released 
nucleic acids. Therefore, this method focuses on the enrichment of the intact bacteria and 
fungi from blood and not potential free pathogen DNA. The selective lysis reaction needs to 
be controlled in time as Gram-negative bacteria might be lysed upon prolonged exposure. 
Therefore an equal volume of neutralization buffer is added after 3 min. This buffer will 
ensure a complete arrest of the selective lysis treatment by lowering of the pH and dilution 
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Table 1. Overview of primers and probes used for pathogen detection. 
Pathogen gene Forward primer Reverse primer Probe (FAM-BHQ1)
P. aeruginosa regA TGCTGGTGGCACAG-
GACAT
TTGTTGGTG-
CAGTTCCTCATTG
CCAGATGCTTTGCCT-
CAACGTCG
S. aureus tuf TCCTGGTTCAATTA-
CACCACATACTG
GGAAATAGAATTGTG-
GACGATAGTTTGA
TGATAATACGTATACT-
TATGC
C. albicans ITS-2 GGAGGGCATGCCT-
GTTTG
CAAGTCGTATTGCT-
CAACACCAA
TCGTTTCTCCCT-
CAAACCGCTGGG
of the detergent to an ineffective concentration. At this moment in time, the pathogens will 
remain intact. Consecutively, suspensions were centrifuged for 15 minutes (5 ml protocol) or 
10 minutes (1 ml protocol) at 2791 x g. Pellets were resuspended in 1 ml washing buffer and 
centrifuged for 10 minutes at maximum speed in a Eppendorf centrifuge. Resulting pellets 
were thoroughly resuspended in 200 µl bacterial lysis buffer (BLB) and incubated for 10 
minutes at 95ºC on a thermomixer set at 1000 rpm. After addition of 20 µl neutralization 
buffer 2, lysates were further processed for DNA purification using QIAamp blood mini kit 
columns (Qiagen, Venlo, The Netherlands) or the generic program of the EasyMAG device.
Real-time PCR
The RNAseP kit (Life technologies, Gent, Belgium) was used to measure the amount of human 
DNA. Species-specific real-time PCRs were performed to investigate the performance of 
each method. For detection of S. aureus the tuf gene based LightCycler 2.0 assay was used 
[17]. The primers and probes for detection of S. aureus, P. aeruginosa, and C. albicans are 
depicted in Table 1. PCR mix consisted of 12.5 µl Taqman Universal fast 2x mastermix (Applied 
Biosystems), 300 nM primers, 200 nM probe, and 10 µl sample (1/10 of total eluate), water 
was added to an end volume of 25 µl. PCRs were performed on the Biorad CFX-96 under the 
following conditions; 3 min 95°C followed by 50 cycles of 15 sec at 95°C and 1 min at 60°C.
Statistical analysis
For analysis of the results the Fisher’s exact test and one-way ANOVA were performed in 
SPSS (Version 19.0. Armonk, NY: IBM Corp). For one-way ANOVA analysis, the Bonferroni’s 
correction for multiple comparisons was performed for comparison of the obtained Ct-values 
(RNAseP) for the different methods. For both statistical methods, a p-value less than 0.05 
was considered significant.
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Results
Performance of Polaris: effect of sample volume
To test the effect of sample volume on sensitivity of the Polaris procedure, a range of pathogen 
concentrations was spiked in 1 and 5 ml whole blood samples from healthy volunteers. 
Consistently lower cycle threshold (Ct) values were obtained in the PCRs when pathogen DNA 
enrichment was performed on 5 ml instead of 1 ml (Figure 3, grey bars (left side 1 ml, right 
side 5 ml)). The difference in Ct value was less pronounced in the lower ranges of pathogen 
concentration (1 CFU/ml). However, at this concentration a higher detection rate (S. aureus 
12.5% (1 ml) versus 70% (5 ml); P. aeruginosa 44% (1 ml) versus 75% (5 ml); C. albicans 75% 
for both 1 and 5 ml) was observed for the 5 ml samples compared to those derived from 1 ml, 
indicating that a 5 ml sample provides a higher sensitivity than a 1 ml sample. Furthermore, the 
Ct-values indicate that all tested pathogens were detected with similar effi ciencies (Figure 4). 
The selective enrichment and the pathogen lysis step perform well for the different classes of 
pathogens, i.e. fungal, Gram-positive and Gram-negative bacterial organisms. At the same 
time, this demonstrates that no pathogens are lost during the selective lysis step.
Polaris-processed spiked blood samples were compared to reference samples, containing 
the same amount of pathogens, but then directly lysed in BLB. At all pathogen concentrations 
tested, the Polaris-processed samples yielded similar Ct values as the reference samples 
(Figure 4), demonstrating the absence of inhibition in the blood-derived samples. All non-
spiked blood samples were negative in the PCRs.
Effect of elution volume in DNA extraction
Next, it was investigated which DNA purifi cation method following Polaris enrichment would 
result in optimal detection, QIAamp (elution in 100 µl EB buffer as in protocol) or EasyMAG 
(elution in 25 μl), followed by PCR where in both cases 10 µl eluate was used. To that end, 
11 different 5 ml blood samples each containing 1 CFU/ml of S. aureus were processed 
using Polaris. Five samples were purifi ed using the QIAamp blood mini kit and six samples 
were processed on the EasyMAG. Using the EasyMAG generic protocol, 5 out of 6 samples 
were positive in the S. aureus PCR. With QIAamp only 3 out of 5 samples resulted in PCR 
signals. These preliminary results show that the combination of Polaris and EasyMAG makes 
it possible to put an equivalent of 10/25 x 5 ml= 2 ml blood in one PCR reaction and obtain 
an 5/6 detection rate at a concentration of 1 CFU/ml.
Human DNA is effi ciently removed
To assess human DNA removal capacity of the different methods, an RNAseP PCR was 
performed. The obtained Ct-values (Figure 5) show that the TTE-EasyMAG method removed 
the least amount of human DNA (lowest Ct-value for RNAseP). One-way ANOVA analysis 
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Figure 3. Comparison of Polaris and MolYsis methods using 1 ml and 5 ml spiked whole blood 
samples.
The grey bars represent the Polaris samples (1 or 5 ml whole blood), and the white bars represent the 
MolYsis isolated samples (1 or 5 ml whole blood). SEM is shown. The numbers in the bars represent 
the sample numbers.
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Figure 4. Polaris pathogen DNA isolation from reference (PBS) compared to 5 ml whole blood.
The indicated pathogens were spiked in 5 ml whole blood or processed as reference samples as 
described in the Materials and Methods. For all pathogens similar Ct values were obtained when 
isolated from PBS or whole blood. The grey bars represent the spiked 5 ml whole blood samples and 
the white bars the reference samples. SEM is shown. The numbers in the bars represent the sample 
numbers.
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Figure 5. Human DNA removal by different procedures.
Ct value comparison of the RNAseP PCR for all pathogen DNA isolation procedures. RNAseP is 
a marker to measure human DNA removal after pathogen DNA isolation. Standard deviations are 
shown of at least 6 independent experiments. One-way ANOVA analysis indicated that TTE-EasyMAG 
removes the least amount of human DNA as compared to all other methods (p < 0.001), except when 
compared to MolYsis 1 ml (p = 0.156). MolYsis 5 ml removes most human DNA as compared to all 
other methods (p < 0.000). Significant differences were also found when comparing Polaris 1 ml with 
both MolYsis 1 ml (p = 0.002) and 5 ml (p < 0.000), and when comparing MolYsis 1 ml with MolYsis 5 
ml (p < 0.000).
indicated that this was statistically significant to all other methods (p < 0.001), except when 
compared to MolYsis 1 ml (p = 0.156). The MolYsis method for 5 ml of whole blood removes 
most human DNA as compared to all other methods (p < 0.000). Significant differences were 
also found when comparing Polaris for 1ml whole blood with both MolYsis for 1 ml (p = 0.002) 
and the MolYsis method for 5 ml whole blood (p < 0.000), and when comparing MolYsis for 
1 ml with MolYsis for 5 ml whole blood (p < 0.000). No significant difference in human DNA 
removal capacity was found between the Polaris methods for different volumes of whole 
blood (p = 0.548).
The lower Ct value for RNAseP in Figure 5 showed that the amount of residual human DNA 
was higher in the 1 ml MolYsis protocol than in the 5 ml MolYsis protocol. For the 1 ml protocol 
the volume of blood in the total lysate is 1/1.5 or 66%, whereas in the 5 ml protocol this is 5/9 
or 55%. In comparison, the 1 ml Polaris protocol was more efficient in DNA removal than the 
1 ml MolYsis protocol, whereas for the 5 ml protocols (MolYsis versus Polaris) it was the other 
way around. However, both the MolYsis and the Polaris method removed sufficient human 
background so no interference with the specific pathogen PCR was detected.
Loonen.indd   110 30-10-2013   8:15:29
Pathogen DNA isolation from large volumes of whole blood to improve molecular diagnosis of BSI  |  111
7
Comparison of Polaris, TTE-EasyMAG and MolYsis
The TTE-EasyMAG procedure yielded higher Ct values for most samples compared to the 
Polaris samples (up to 6 Ct difference). Polaris and MolYsis resulted in comparable Ct values 
for all pathogens (Figure 3). Both MolYsis and Polaris enabled detection of clinical relevant 
pathogen concentrations of 1-10 CFU/ml. In general, the variation in Ct values was much 
larger for MolYsis-processed samples than for samples processed with Polaris (Figure 3).
Calculations of detection rates, i.e. percentages of positive PCRs, demonstrated a detection 
rate of 100% for all pathogens at a concentration of 10 CFU/ml for the Polaris procedure 
(Table 2). The TTE-EasyMAG procedure performed much worse in this respect with a 
detection rate of only 58%, 60%, and 79% for 10 CFU/ml S. aureus, C. albicans, and P. 
aeruginosa, respectively. MolYsis resulted in a detection rate of 50%, 67%, and 58% for 
10 CFU/ml S. aureus, C. albicans, and P. aeruginosa, respectively. Processing samples 
containing 1 CFU/ml never resulted in a 100% detection rate for the tested methods. The 
best results were obtained with Polaris as a 70% detection rate was obtained for S. aureus, 
and 75% for both C. albicans and P. aeruginosa. MolYsis detection rates at this pathogen 
concentration varied between 17 and 50%, and TTE-EasyMAG between 20-36%. All non-
spiked blood samples were negative in the PCRs.
Table 2. Detection rates (percentage of positive PCRs) of 3 different DNA isolation methods in 
dilutions series of 1-1000 CFU/ml.
CFU/ml
1000 100 10 1 p a,b,c
P.
 a
er
ug
in
os
a Polaris 5 ml 100% (12/12) 100% (12/12) 100% (12/12) 75% (9/12) a (p=0.01)
MolYsis 5 ml 83% (10/12) 92% (11/12) 58% (7/12) 17% (2/12) b (p=0.06)
TTE-EasyMAG 100% (8/8) 92% (11/12) 79% (11/14) 36% (5/14) c (p=0.39)
C
. a
lb
ic
an
s Polaris 5 ml 100% (12/12) 83% (10/12) 100% (12/12) 75% (9/12) a (p=0.04)
MolYsis 5 ml 92% (11/12) 83% (10/12) 67% (8/12) 25% (3/12) b (p=0.08)
TTE-EasyMAG 100% (10/10) 100% (10/10) 60% (6/10) 30% (3/10) c (p=1.00)
S
. a
ur
eu
s Polaris 5 ml 100% (6/6) 100% (10/10) 100% (12/12) 70% (7/10) a (p=0.63)
MolYsis 5 ml 100% (8/8) 75% (6/8) 50% (4/8) 50% (4/8) b (p=0.07)
TTE-EasyMAG 100% (6/6) 90% (9/10) 58% (7/12) 20% (2/10) c (p=0.32)
Fisher’s exact test performed on 1 CFU/ml samples, statistically signifi cant when p ≤ 0.05. a; Polaris 
versus MolYsis, b; Polaris versus TTE-EasyMAG, c; MolYsis versus TTE-EasyMAG.
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The Fisher’s exact test was performed to show significant differences between the obtained 
detection rates (1 CFU/ml) with the different pathogen DNA isolation methods for each 
pathogen. There was never a significant difference found, in detection rate, when comparing 
TTE-EasyMAG with MolYsis (5 ml) or Polaris (5 ml) for all tested pathogens. However, TTE-
EasyMAG compared with Polaris showed to have lower p-values (p between 0.06 – 0.08) 
as when compared with MolYsis (p between 0.32 – 1.00). For P. aeruginosa, Polaris had a 
significant better detection rate when compared to MolYsis (p = 0.01). This difference was 
also seen for C. albicans (p = 0.04). No significant difference in detection rate for S. aureus 
was found between Polaris and MolYsis (p = 0.63).
Discussion
In this study, different pathogen DNA isolation methods for whole blood were compared. We 
showed that both MolYsis and Polaris enrichment followed by DNA isolation and real-time 
PCR enabled reliable and sensitive detection of bacteria and fungi from 5 ml blood. MolYsis 
and the TTE-EasyMAG procedure resulted in a lower number of positive PCRs (detection 
rate) as compared to Polaris, especially in the lower limit of detection (1-10 CFU/ml).
The detection rates for P. aeruginosa and S. aureus detection are similarly high at a pathogen 
concentration of 1 CFU/ml when using Polaris (9/12 vs. 7/10) (Table 2). In contrast, using 
MolYsis enrichment, the detection rate for P. aeruginosa is considerably lower than that for 
Gram-positive S. aureus detection (2/12 vs. 4/8). Possibly, Gram-negative bacteria which 
generally are considered to be more fragile than Gram-positives may be negatively affected 
by the chaotropic buffer used in the MolYsis protocol to lyse human cells [18]. Furthermore, 
the Ct values obtained in the C. albicans PCR are lower compared to Ct values obtained in 
the other PCRs. This might be the result of copy number variations (5 versus single copy) 
[19]. However, the detection limits of all PCRs are similar.
Human DNA, which can interfere in the PCR reaction, was not removed when the TTE-
EasyMAG procedure was used. In contrast, Polaris and MolYsis enrichment resulted in 
substantial removal of human DNA as was shown by the RNAseP results and the fact that 
the reference and whole blood samples showed similar Ct values. There are differences in 
the ratio of blood and lysis buffer volumes between the 1 and 5 ml MolYsis protocols.  It was 
noticed that when using MolYsis the 1 ml blood lysates were much more viscous than the 
5 ml lysates. Apparently, DNAse treatment is much less efficient in the more viscous 1 ml 
lysate. This might also explain the high variability in residual human DNA levels in the 1 ml 
MolYsis protocol.
In general, Ct values obtained after Polaris processing were much more constant than those 
after MolYsis processing. Several steps in the MolYsis procedures may contribute to this 
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variation. Next to the chaotropic buffer mentioned above, the use of an enzyme to degrade 
DNA may yield variable results, due to enzyme instability. Furthermore, bacterial lysis is 
based on a mix of lytic enzymes and proteinase K. The Polaris procedure does not use 
chaotropic agents nor enzymes, but only chemicals that should remain stable over time. 
Furthermore, it was demonstrated that Polaris pathogen enrichment can be combined with 
both QIAamp and EasyMAG (generic) DNA purifi cation. The preliminary data showed that 
Polaris combined with EasyMAG DNA purifi cation holds most promise to obtain reliable data 
at borderline concentrations of 1 CFU/ml. The benefi t of using more concentrated DNA as 
input (EasyMAG) in the PCR was not negatively affected by concurrent concentration of 
inhibitory substances.
Polaris and MolYsis have shown to be valuable in spiked blood samples since they can 
handle large blood volumes. Clinical evaluation of Polaris is presently ongoing in comparison 
to MolYsis, which is clinically validated. Preliminary results of this ongoing study (Emergency 
Care Unit, Jeroen Bosch Hospital) show that both pathogen enrichment procedures work 
for clinical samples. Residual blood was collected, left over from standard diagnostics, 
from patients with blood cultures positive for S. aureus (1 culture) or S. pneumoniae (2 
cultures) (data not shown). This approach limited the volume of usable blood to 1 ml for each 
method. Polaris was followed by DNA purifi cation using EasyMAG. We were able to detect 
S. pneumoniae and S. aureus in all 3 samples with corresponding positive blood cultures, 
indicating promising potential for both the Polaris and MolYsis procedure in clinical use.
Several molecular sepsis diagnosis tests have become commercially available recently, i.e. 
Roche’s SeptiFAST, Seegene’s MagicPlex Sepsis Test, VYOO (SIRS lab) and Molzym’s 
SepsiTest. It has been shown, by independent research groups, that these diagnostic tests 
are complementing conventional culture techniques [12, 13, 20, 21]. Especially in antibiotic-
treated patients, molecular diagnostics can provide identifi cation under conditions where 
blood cultures remain negative. Recent publications by Kühn and Wellinghausen [11, 12] 
show the value of Molzym’s SepsiTest. Both described that the initial analysis, indicating the 
absence or presence of pathogens, can be performed in approximately 4 hours. Subsequent 
sequencing needs to be performed for specifi c pathogen identifi cation. This approach has the 
advantage that any pathogen will be identifi ed, but it takes an additional 4 hours (in an optimal 
setting) to obtain that result. Still, pathogen identifi cation is available within one working day, 
which is faster compared to conventional culture techniques that take at least 24-72 hours for 
pathogen identifi cation. Assays like SeptiFAST and Seegene’s MagicPlex Sepsis Test have 
other limitations. In the SeptiFAST procedure no enrichment of pathogen DNA is included, 
this limits the maximal useable input  blood volume to 1.5 ml with an equivalent of only 
0.167 ml blood present in the PCR reaction. The detection system used in the SeptiFAST 
method enables rapid identifi cation of 25 pathogens by multiplex real-time PCR followed by 
melting curve analysis. Seegene’s MagicPlex real-time PCR test can be used in combination 
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with MolYsis pathogen enrichment. The real-time PCR test enables the detection of 90 BSI 
causing pathogens, but only 27 pathogens can be identified to the species level. The main 
disadvantage of the Seegene system is the fact that one first needs to create an amplicon 
bank via conventional PCR. Next, the vial containing PCR amplicons needs to be opened 
for subsequent signal amplification in a real-time PCR instrument. Most routine diagnostic 
laboratories would not allow this setup, as contamination risks exist. Polaris enrichment can 
be combined with established sepsis tests to be able to ensure broad pathogen detection 
from clinical samples.
In conclusion, Polaris and MolYsis enrichment followed by DNA isolation and real-time PCR 
enables reliable and sensitive detection of bacteria and fungi from 5 ml blood. However, 
Polaris is slightly more sensitive and faster providing pathogen identification within 3 
hours. To further enable its clinical value, Polaris is currently being automated in a closed 
disposable cartridge to reduce the hands on time to 1-2 min, to be faster, and less prone 
to contamination. Furthermore, the combination of the Polaris cartridge with commercially 
available sepsis tests is currently being evaluated in a prospective clinical study using 5 ml 
whole blood.
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Abstract
Bloodstream infections (BSI) are associated with high morbidity and mortality. Fast and 
accurate identification of the etiologic pathogen is, therefore, of clinical importance. Molecular 
assays for pathogen detection from whole blood are currently available. However, their exact 
clinical value remains to be determined and these assays are still expensive. The use of 
biomarkers may assist the physician in preselecting patients for immediate molecular testing 
besides blood culture.
In this study, 140 patients with ≥ 2 systemic inflammatory response syndrome criteria and 
clinical signs of infection presenting at the emergency department of our hospital were included. 
C-reactive protein (CRP), neutrophil-lymphocyte count ratio (NLCR), procalcitonin (PCT) and 
soluble urokinase plasminogen activator receptor (suPAR) levels were determined. One ml 
residual EDTA blood was obtained and selective pathogen DNA isolation was performed 
with MolYsis (Molzym). DNA samples were analysed for the presence of pathogens, using 
both the commercially available MagicPlex Sepsis Test (Seegene) and SepsiTest (Molzym), 
and results were compared to blood culture results.
Fifteen patients had to be excluded from the study, leaving 125 patients for further analysis. Of 
the 125 patient samples analysed, 27 presented with positive blood cultures of which 7 were 
considered to be contaminants. suPAR, PCT, and NLCR values were significantly higher 
in patients with positive blood cultures compared to patients without (p < 0.001). Receiver 
operating characteristic curves of the 4 biomarkers for differentiating bacteremia from non-
bacteremia showed the highest area under the curve (AUC) for PCT (0.806 (95% confidence 
interval 0.699-0.913)). When compared to blood cultures, the sensitivity, specificity, positive 
predictive value (PPV), and negative predictive value (NPV) for SepsiTest and MagicPlex 
Sepsis Test were 11%, 96%, 43%, 80%, and 37%, 77%, 30%, 82%, respectively.
In conclusion, both molecular assays perform poorly when one ml whole blood is used from 
emergency care unit patients. NLCR is a cheap, fast, easy to determine, and rapidly available 
biomarker, and therefore seems most promising in differentiating BSI from non-BSI patients 
for subsequent pathogen identification using molecular diagnostics.
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Introduction
Bloodstream infection (BSI) is a potential life-threatening condition that requires early 
diagnosis and rapid pathogen identifi cation to initiate correct antibiotic or antifungal therapy 
[1-3]. BSI patients frequently display characteristic symptoms of Systemic Infl ammatory 
Response Syndrome (SIRS) [4]. In general, blood culture sets are collected when ≥ 2 SIRS 
symptoms are recognized and infection is suspected. Blood cultures are regarded as the 
“gold standard” for the detection of viable bacterial and fungal organisms from blood, but are 
time-consuming. Furthermore, the sensitivity of blood cultures decreases signifi cantly when 
antibiotic therapy has been started before blood samples are taken [5, 6], or when fastidious 
or slow-growing pathogens need to be cultured.
Molecular assays may improve BSI diagnostics. Recently, several molecular assays 
became commercially available which can be used for pathogen detection from whole 
blood. SepsiTest (Molzym), a broad-range SYBR Green based real-time polymerase chain 
reaction (PCR) assay followed by sequencing, has been investigated in clinical studies and 
is considered a valuable tool in addition to blood cultures [7, 8]. Compared to blood cultures, 
the diagnostic sensitivity and specifi city of the SepsiTest PCR were described to be 87.0 and 
85.8%, respectively [8]. MagicPlex Sepsis Test (Seegene) screens for 90 pathogens and 3 
resistance markers (mecA, vanA, vanB). Subsequently, 27 pathogens can be identifi ed to the 
species level. Recently, MagicPlex Sepsis Test has been investigated for rapid detection of 
invasive candidiasis in pediatric patients, and was shown to have a sensitivity and specifi city 
of 50% and 94%, respectively [9]. Currently no literature is available on the performance of 
MagicPlex Sepsis Test for detection of BSI in adults.
Several limitations of molecular assays currently exist. First, they require special pathogen 
DNA enrichment to detect the low number of pathogens present in whole blood samples. 
Second, technical expertise is required to perform the tests. Third, the clinical value of 
molecular assays remains to be elucidated. And fi nally, the DNA tests available are still 
expensive. These restrictions prevent molecular assays to become the next “gold standard” 
for diagnosis of BSI as it is diffi cult and costly to implement them in daily laboratory practise. 
Biomarkers can be used to preselect suspected BSI patients for additional DNA based 
assays.
Several biomarkers have been described as either being associated with the presence of BSI 
or suggested to have prognostic value for outcome of BSI. The most widely studied marker 
is C-reactive protein (CRP), which is an acute-phase protein released by the liver after the 
onset of infl ammation. CRP is mostly used to assess the presence of infection and sepsis 
[10]. Procalcitonin (PCT) is the prohormone of calcitonin and was fi rst reported as a marker 
of infl ammation in 1993 [11]. Several studies have been published which investigated its 
clinical value in the diagnosis of bacterial infections, especially sepsis [12, 13]. Zahorec et 
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al. were the first to propose to use the ratio of neutrophil and lymphocyte counts (neutrophil 
lymphocyte count ratio (NLCR)) as an additional marker of infection in clinical practice [14]. 
In patients with suspected community-acquired infection in an emergency care setting the 
NLCR proved to be a simple biomarker with discriminatory capacity in predicting bacteremia. 
Recently, it was shown that this marker can be used in the prediction of bacteremia in patients 
admitted to the emergency department [15].
The soluble form of the urokinase plasminogen activator receptor (suPAR) has gained 
growing interest because it is proposed as a predictor of disease severity and case fatality 
in patients with bacteremia [16]. suPAR plays a role in various immunological functions 
and is expressed on various cell types including neutrophils, lymphocytes, macrophages, 
endothelial cells and tumor cells [17]. The two biomarkers that have been most studied in 
patients with sepsis are CRP and PCT, both of which are described to be markedly elevated 
in patients with sepsis [18, 19].
In this study, we evaluated the ability of various biomarkers (CRP, PCT, suPAR, and NLCR) 
to predict BSI in patients with suspected community-acquired BSI upon admission to the 
emergency department (ED). Furthermore, the performances of two commercially available 
molecular assays were examined and compared to blood culture results.
Materials and Methods
Ethics statement
Individual patient consent was not obtained since all data used in this study were acquired 
retrospectively from the laboratory information system (LIS) without any additional blood 
sampling. The Internal Review Board of the Jeroen Bosch Hospital approved anonymous 
use of remnant whole blood, serum, and data retrieved from the LIS and waived the need for 
informed consent.
Patients and microbiology
In this retrospective study, 140 patients presenting at the ED with ≥ 2 SIRS criteria as described 
by Bone et al. [4] were included during November-December 2011 and October-December 
2012. Additional inclusion criteria were, (1) age above 18 years, (2) clinical suspicion of 
infection, (3) blood cultures ordered, (4) EDTA blood and serum drawn simultaneously 
with blood cultures, and (5) sufficient remnant EDTA blood and serum volume available for 
analysis. Fifteen patient samples were excluded from the study because of an alternative 
diagnosis without infection, leaving 125 patients for further analysis.
Blood cultures were drawn by the medical staff during the observation period in the ED. 
Routinely, two pairs of aerobic and anaerobic bottles were obtained and incubated for a 
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maximum of 5 days (BacT/ALERT; bioMérieux, Marcy L’Etoile, France). All isolates from 
positive blood cultures were identifi ed at the species level by using standard microbiological 
procedures including MALDI-TOF mass spectrometry (Bruker Daltonics GmbH, Bremen, 
Germany). Positive blood cultures with Gram-positive skin bacteria, e.g. coagulase-negative 
staphylococci (CoNS) or infrequently isolated environmental bacteria were considered to be 
contaminants, and therefore excluded from statistical analysis.
After performing standard diagnostics, 1 ml remnant EDTA blood (per patient) was frozen
(-80˚C) in DNA free UMD tubes (Molzym, Bremen, Germany) until further processing. UMD 
tubes stabilize specimens, including whole blood, through avoidance of damage of pathogens 
by freeze-thaw effects. A minimum of 500 µl serum was frozen (-80˚C) for retrospective 
determination of suPAR and procalcitonin levels.
Biomarkers determination
CRP levels were measured with the Dimension Vista 1500 (Siemens Healthcare diagnostics). 
WBC counts were determined on a Sysmex XE-2100 hematology analyzer (Sysmex 
Corporation, Kobe, Japan). Neutrophil-Lymphocyte Count Ratio (NLCR) was determined 
by dividing the absolute neutrophil count by the absolute lymphocyte count. To additionally 
determine suPAR and PCT levels, serum was thawed on ice. suPAR levels were determined 
by using the suPARnostic ELISA kit (Virogates, Copenhagen, Denmark) according to the 
manufacturer’s instructions, and PCT levels were measured using the Cobas E411 (Roche 
Diagnostics).
Molecular assays
UMD tubes containing 1 ml EDTA blood were thawed on ice. Subsequently, the UMD blood 
was used for pathogen DNA isolation with the semi-automated MolYsis method (Molzym, 
Bremen, Germany) as described by the manufacturer. Pathogen DNA was stored at -20˚C 
until further processing.
The obtained pathogen DNA was analysed with two molecular assays (1) SepsiTest 
(Molzym, Bremen, Germany), and (2) MagicPlex Sepsis Test (Seegene, Seoul, Korea). Both 
molecular assays were used as described in the manufacturers’ manuals and can be used in 
combination with MolYsis pathogen DNA isolation.
SepsiTest is a broad-spectrum real-time PCR test using SYBR Green followed by sequencing 
of the positive samples. This test is able to detect more than 345 species within one working 
day (8 hours, including pathogen DNA isolation). Results were considered positive if 
sequencing was successful.
MagicPlex Sepsis Test is a real-time PCR test that screens for pathogens as well as for 
methicillin (mecA) and vancomycin (vanA and vanB) resistance at once. After creation of an 
amplicon bank via normal PCR, screening for more than 90 pathogens to the genus level and 
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resistance markers is performed. Results are available within 5 hours (including pathogen 
DNA isolation). Subsequent selective identification of pathogens (only 27 pathogens can be 
identified to the species level) is possible within an additional 30 minutes. The 21 bacterial 
pathogens that can be identified to the species level are: Pseudomonas aeruginosa, 
Acinetobacter baumannii, Stenotrophomonas maltophilia, Serratia marcescens, Bacillus 
fragilis, Salmonella typhi, Klebsiella pneumoniae, Escherichia coli, Klebsiella oxytoca, 
Enterobacter cloacae, Proteus mirabilis, Enterobacter aerogenes, Staphylococcus aureus, 
Staphylococcus epidermidis, Staphylococcus haemolyticus, Streptococcus agalactiae, 
Streptococcus pyogenes, Streptococcus pneumoniae, Enterococcus faecalis, Enterococcus 
faecium, and Enterococcus gallinarum. In this study, the selective identification step for fungi 
was not performed (Candida albicans, Candida tropicalis, Candida parapsilosis, Candida 
glabrata, Candida krusei, and Aspergillus fumigatus).
Statistical analyses
Patients were divided in two groups, with or without positive blood cultures. The Chi-Square 
test was used to determine statistical differences based on age and gender distribution 
between the groups. With regard to the continuous variables, CRP, PCT, NLCR and suPAR, 
we firstly judged for fit to the normal distribution using stem-and-leaf plots and quantile-
quantile plots. As our data did not follow a normal distribution, Mann-Whitney U tests were 
performed for comparison of variables in different groups. Receiver operating characteristics 
(ROC) curve analyses were performed for the single biomarkers and combinations in 
predicting blood culture positivity. ROC curves displayed sensitivity versus 1-specificity such 
that area under the curves (AUC) varied from 0.5-1.0, with higher values indicating increased 
discriminatory ability. A p-value of less than 0.05 was considered statistically significant. 
Statistical analyses were performed using SPSS (Version 19.0. Armonk, NY: IBM Corp).
Results
Patients and microbiology
Of the 125 patient samples analysed, 27 patients (21.6%) presented with positive blood cultures 
(Table 1). In ten patients with positive blood cultures, E. coli was identified, in six patients 
Staphylococcus spp. including one S. aureus isolate, and in three patients Streptococcus spp. 
More Gram-negative bacteria were recovered (16/27, 59%) as compared to Gram-positive 
bacteria (11/27, 41%). All positive culture sets grew bacterial species, and no fungi were 
detected. Seven out of the 27 blood culture isolates were considered to contain contaminants 
of which five belonged to the group of CoNS. When excluding contaminants from the total 
results, 20/125 patients presented with clinically relevant positive blood cultures (16%).
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Table 1. Microorganisms grown from positive blood cultures.
Gram-positive bacteria Gram-negative bacteria
Clostridium paraputrifi cum *Brevundimonas diminuta
*Propionibacterium spp. Enterobacter cloacae
Staphylococcus aureus Escherichia coli (10)
*Staphylococcus capitis (2) Klebsiella pneumoniae
*Staphylococcus epidermidis Proteus mirabilis
*Staphylococcus hominis (2) Proteus vulgaris
Streptococcus gallolyticus Salmonella group C
Streptococcus pneumoniae
Viridans streptococci
11 (41%) 16 (59%)
*Considered as contaminant. Number between () indicates number of cultures positive with this 
pathogen.
Table 2. Data of study population and results for C-reactive protein (CRP), procalcitonin (PCT), 
soluble urokinase plasminogen activator receptor (suPAR), and neutrophil-lymphocyte count ratio 
(NLCR).
Positive Blood 
Culture
Negative Blood 
Culture
p-value AUC
Age (years) mean ± SD 68.9 (± 17.3) 60.4 (± 18.0) 0.018
Gender 17 Male / 10 Female 57 Male / 41 Female 0.653
CRP mean (± SD) (mg/L) 105 (± 105) 119 (± 110) 0.886 0.485
Median (range) 88 (8-371) 93 (1-490)
PCT mean (± SD) (ng/mL) 11.1 (± 25.2) 2.0 (± 10.3) < 0.001 0.806
Median (range) 1.0 (0.039-100) 0.2 (0.02-100)
suPAR mean (± SD) (ng/mL) 10.0 (± 6.2) 6.2 (± 3.4) < 0.001 0.793
Median (range) 8.7 (2.9-26.1) 5.5 (2.1-29.6)
NLCR mean (± SD) 23.0 (± 15.0) 12.2 (± 9.1) < 0.001 0.770
Median (range) 18.4 (7.1-56.5) 9.9 (0.89-44.1)
Median and range, mean and standard deviation (SD) are displayed. p-value less than 0.05 is 
statistically signifi cant (Chi-Square and Mann-Whitney U test), area under curve (AUC) is linked to 
Figure 1.
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Relevant demographic data are depicted in Table 2. No significant difference was found 
when comparing gender distribution in both groups (with or without positive blood culture). 
However, patients with a positive blood culture were significantly older (68.9 ± 17.3 years; 
mean ± SD) as compared to patients with a negative blood culture (60.4 ± 18.0 years) 
(p = 0.018).
Biomarkers
Mean CRP levels between both groups (positive and negative blood culture) were similar 
(105 ± 105 versus 119 ± 110 mg/L, p = 0.886) (Table 2). PCT levels were significantly different 
(p < 0.001) between patients with and without positive blood cultures (11.1 ± 25.2 versus 2.0 
± 10.3 ng/mL). The NLCR was also significantly different in both groups, showing a mean 
of 23.0 ± 15.0 in patients with positive blood cultures. In the group with negative cultures a 
mean of 12.2 ± 9.1 was found (p <0.001). A mean suPAR level of 10.0 ± 6.2 ng/mL was found 
in the patient group having blood culture proven BSI as compared to a level of 6.2 ± 3.4 ng/
mL in the patient group with negative blood cultures (p < 0.001).
In our study population, 4 patients died as a result of sepsis complications. Blood culture 
results, NLCR, CRP, PCT, and suPAR levels in these patients were as follows: patient 
I) K. pneumoniae, 48.0, 228.0 mg/L, 100.0 ng/mL, 21.6 ng/mL, patient II) S. epidermidis 
(considered contaminant), 8.9, 165.0 mg/L, 1.04 ng/mL, 4.0 ng/mL, patient III) S. gallolyticus, 
22.3, 76.0 mg/L, 0.255 ng/mL, 16 ng/mL, and patient IV) negative blood culture, 38.3, 42.0 
mg/L, 0.065 ng/mL, 37.0 ng/mL.
ROC curve analysis showed that PCT had the highest area under the curve (AUC) for 
differentiating patients with blood culture proven BSI from patients without: 0.806 (95% 
confidence interval (CI) 0.699-0.913) (Figure 1). AUC values for the other biomarkers were 
as follows: suPAR 0.793 (95% CI 0.660-0.926), NLCR 0.770 (95% CI 0.662-0.879), and CRP 
0.485 (95% CI 0.344-0.626). Regarding combinations of biomarkers, combining NLCR and 
suPAR was most promising and resulted in an AUC of 0.815.
Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) 
for predicting blood culture proven BSI for PCT, NLCR and suPAR and combinations are 
depicted in Table 3. A 100% sensitivity and NPV were obtained when combining NLCR cut-
off ≥ 10 with suPAR cut-off  ≥ 6.2 ng/mL. However, specificity and PPV were low, i.e. 27% 
and 22%, respectively. By using only NLCR with a cut-off ≥ 10, sensitivity, specificity, PPV, 
and NPV were 85%, 51%, 26%, and 94%, respectively.
Molecular assays
In Table 4 the results of the molecular assays are depicted and compared to the blood 
culture results. When using SepsiTest, only three EDTA blood samples were found positive, 
S. gallolyticus, S. pneumoniae, and K. pneumoniae were correctly identified as found in 
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blood cultures. In contrast, MagicPlex Sepsis Test resulted in 12 positive PCR samples out of 
27 blood culture positives. Detection of S. aureus, E. coli (6/10), E. cloacae, and P. mirabilis 
by MagicPlex Sepsis Test corresponded with blood culture results. The blood sample of one 
patient with a S. capitis blood culture isolate was only positive for mecA gene by MagicPlex 
Sepsis Test but not for Staphylococcus spp. MagicPlex Sepsis Test detected K. pneumoniae 
in the blood sample of one patient with a S. hominis blood culture isolate, while S. epidermidis 
was identifi ed in blood from a patient with S. gallolyticus BSI.
SepsiTest resulted in four additional PCR positives blood samples from blood culture negative 
patients, i.e. Corynebacterium tuberculostearicum, Shigella sonnei/fl exneri, Malassezia spp., 
and Cryptococcus spp. MagicPlex Sepsis Test resulted in an additional 23 PCR positive blood 
Figure 1. Receiver operating characteristic curves of four biomarkers for differentiating 
bacteremia from non-bacteremia.
C-reactive protein (CRP), neutrophil-lymphocyte count ratio (NLCR), procalcitonin and soluble 
urokinase plasminogen activator receptor (suPAR) are compared in respect to prediction of positive 
blood culture.
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Table 3. Comparison of performance characteristics of the biomarkers and combinations in 
predicting bacteremia using different cut-off values. 
Sensitivity Specificity PPV NPV
NLCR ≥ 10 85 51 26 94
NLCR ≥ 12 70 65 29 91
suPAR ≥ 6.2 ng/mL 85 58 29 95
suPAR ≥ 7.5 ng/mL 80 77 42 95
PCT ≥ 2 55 86 44 90
NLCR ≥ 10 and/or suPAR ≥ 6.2 ng/mL 100 27 22 100
NLCR ≥ 10 and/or PCT ≥ 2 ng/mL 95 49 28 98
NLCR ≥ 12 and/or suPAR ≥ 7.5 ng/mL 90 48 26 96
NLCR ≥ 12 and/or PCT ≥ 2 ng/mL 90 61 32 97
Abbreviations, PPV: positive predictive value, NPV: negative predictive value, NLCR: neutrophil-
lymphocyte count ratio, suPAR: soluble urokinase plasminogen activator receptor, PCT: procalcitonin.
Table 4. Overview of the results obtained with the molecular assays (SepsiTest and MagicPlex 
Sepsis Test) in comparison to blood culture results. 
Blood Cultures MolYsis + SepsiTest MolYsis + MagicPlex Sepsis Test
Positive Culture (27) Positive PCR/Sequencing (3) Positive PCR (12)
Streptococcus gallolyticus S. gallolyticus Staphylococcus epidermidis
Streptococcus pneumoniae S. pneumoniae Negative
Viridans Streptococcus spp. Negative Negative
Staphylococcus aureus Negative S. aureus
Clostridium paraputrificum Negative Negative (not in kit)
Escherichia coli (10) Negative (10) E. coli (5), mix S. aureus/E. coli (1), 
negative (4)
Enterobacter cloacae Negative E. cloacae
Klebsiella pneumoniae K. pneumoniae Negative
Proteus mirabilis Negative P. mirabilis
Proteus vulgaris Negative Negative
Salmonella spp. Negative Negative
Contaminants (7) Negative (7) Negative (5), K. pneumoniae 
(culture Staphylococcus hominis), 
mecA (culture Staphylococcus 
capitis)
Additional PCR positives 4 23
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samples from culture negative patients: S. epidermidis (13), other CoNS (not in identifi cation 
kit) (2), S. pneumoniae (2), fungi (2), P. aeruginosa (2), A. baumannii (1), and K. oxytoca (1).
In this study, the sensitivity, specifi city, PPV, and NPV for SepsiTest and MagicPlex Sepsis 
Test (using blood culture as “gold standard”) were 11%, 96%, 43%, 80%, and 37%, 77%, 
30%, 82%, respectively. Negative and positive controls, included in each assay, showed 
adequate results indicating that each assay was performed correctly.
Discussion
Early identifi cation of the pathogen causing BSI is essential for its adequate treatment, and 
it has been shown that when this treatment is initiated rapidly this will decrease BSI related 
mortality [20, 21]. Several tools are available which can be used and combined for optimal 
patient care: blood cultures, serum biomarkers, and potentially molecular assays for whole 
blood analysis.
Here, we studied the potential discriminating power of several biomarkers in the prediction of 
BSI in patients with SIRS and community-acquired infections presenting at the emergency 
department. In addition the performance of molecular assays was compared to the diagnostic 
yield of standard blood cultures. PCT, NLCR and suPAR are able to differentiate SIRS 
patients with and without blood culture proven bacteremia. The additional value of molecular 
assays in predicting BSI was low.
In this study, all patients fulfi lled ≥ 2 SIRS criteria and showed signs of infection, while only 
16% presented with clinically relevant positive blood cultures (20/125). When including the 
blood culture contaminants, 22% of the patients had positive blood cultures (27/125). Other 
studies describe similar numbers. In a study analysing 104 patients of a surgical intensive 
care unit (ICU), Lodes et al. found that 20% of the drawn blood culture sets became positive 
[22]. Fitting et al. found 23% positive blood cultures in their ICU patient population [23]. 
However, Hoenigl et al. reported a positivity rate of 41% in a patient population from the 
emergency department [24]. Hoenigl et al. and Lodes et al. both used the BACTEC blood 
culture system as compared to the BacT/ALERT system used in this study. It has been 
described that BACTEC media has faster time to detection and increased bacterial recovery 
over the BacT/ALERT media [25]. Besides differences in culture systems, only two blood 
culture sets were drawn which were incubated for fi ve days (this study), while Hoenigl et al. 
collected three pairs of blood cultures per patient and incubated for a maximum of seven 
days [24]. It remains diffi cult, however, to directly compare these study results as patient 
characteristics including disease severity might also differ besides culture methods.
PCT has been described to strongly correlate with the extent and severity of bacterial 
infections [26]. PCT is most frequently used in the management of infection and sepsis. 
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Mencacci et al. have investigated if PCT serum levels could predict a positive PCR result 
(SeptiFAST, Roche) [27]. They found that PCT (cut-off value ≥ 0.37 ng/ml) could be used in 
an unselected population of patients with fever and suspected sepsis to predict SeptiFAST 
PCR results. We have shown that PCT, as compared to the other biomarkers in this study, 
has the highest specificity in predicting bacteremia in SIRS patients. However, as PCT is an 
expensive biomarker, pre-screening of SIRS patients for further DNA analysis using PCT 
might be less cost-effective.
The use of suPAR levels at the emergency department has mostly been described in relation 
to categorizing patients according to their disease severity [28]. In this study, significant 
differences were found for suPAR levels between SIRS patients with and without positive 
blood cultures. However, only 2/4 patients who died had high suPAR levels (>16 ng/mL). 
The suPAR levels of these patients were found between 4.4 – 26 ng/mL. More studies, 
investigating suPAR levels in patients from the emergency department, need to be performed 
to clarify the usefulness of this relatively new biomarker.
De Jager et al. have described the NLCR in relation to predicting bacteremia at the emergency 
department [15]. NLCR (cut-off ≥10) was shown to have a higher prognostic accuracy as 
compared to other biomarkers. In this study, prediction of community-acquired bacteremia 
using a NLCR cut-off ≥10 resulted in a sensitivity, specificity, PPV, and NPV of 85%, 51%, 
26%, and 94%, respectively. Based on NLCR (cut-off  ≥10), 65/118 patients in our study 
would have been selected for molecular analysis. A higher cut-off value, i.e. ≥12, results 
in decreased sensitivity but increased specificity. However, it is important to avoid SIRS 
patients to be falsely considered as negative BSI cases. For pre-screening purposes high 
sensitivity is preferred.
In this study, we investigated the performances of two molecular assays as compared to 
blood cultures. The sensitivities and specificities for SepsiTest were 11% and 96% compared 
to 37% and 77% for MagicPlex Sepsis Test. In this study, MagicPlex Sepsis Test and blood 
cultures showed similar results in 72% of the samples (both positive and negative samples). 
No reports were found describing the performance MagicPlex Sepsis Test in adult SIRS 
patients. Therefore, we can only compare the obtained SepsiTest results to other published 
studies. Kuhn et al. described a sensitivity of 85% for SepsiTest in patients with endocarditis 
[7]. Wellinghausen et al. describe a concordance of 86% for SepsiTest PCR and blood 
cultures in ICU patients with SIRS or sepsis [8]. Although, in this study, a concordance of 
82% was found between SepsiTest and blood cultures for patients presenting with SIRS 
symptoms at the emergency department, the sensitivity compared to the blood culture gold 
standard was only 11%. Different patient populations were used (ICU versus emergency 
department), and this might explain the difference in patient-related sensitivity (85% and 
82.4% versus 11% in this study). The performance of molecular assays is mostly investigated 
in ICU patient populations [8, 23, 29]. In general, more critically ill patients are hospitalized 
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at the ICU as compared to the ED. We speculate that the ICU patient population might suffer 
from higher bacterial loads which can be more easily detected from one ml whole blood. It 
would be interesting to study bacterial loads in different patient populations.
Four patients from our study population died, and 3 of those patients had positive blood cultures 
(Klebsiella pneumoniae, Streptococcus gallolyticus and Staphylococcus epidermidis). 
SepsiTest correctly identifi ed K. pneumoniae and S. gallolyticus, whereas MagicPlex Sepsis 
Test did not identify these pathogens from whole blood. As these patients died, this might 
indicate that these patients were more critically ill and suffered from higher bacterial loads, 
as has been described by Peters et al. [30]. It is unknown why MagicPlex Sepsis Test did not 
show positive PCR signals in the whole blood samples of these specifi c patients.
SepsiTest resulted in four PCR positive samples from blood culture negative patients. 
Three out of these four can be considered contaminants as these can be found on skin 
(Corynebacterium tuberculostearicum, Malassezia spp., and Cryptococcus spp). However, 
Shigella sonnei/fl exneri is a clinically signifi cant pathogen that was not detected with blood 
culture. MagicPlex Sepsis Test resulted in an additional 23 PCR positive samples in blood 
culture negative patients. CoNS species (15) can be considered contaminants, however, 
S. pneumoniae (2), fungi (2), P. aeruginosa (2), A. baumannii (1), and K. oxytoca (1) are 
clinical relevant pathogens. Prospective studies are needed to investigate the clinical value 
of additional positive samples using molecular diagnostics.
Molecular-based technologies are emerging as promising tools, in addition to blood cultures, 
for rapid identifi cation of the etiological agents of BSI [31, 32].  However, several limitations 
exist (i.e. costs and the need for special equipment) which negatively affect the implementation 
of these techniques for routine laboratory diagnostics [33]. A limitation of this study is the 
use of only one ml residual whole blood for molecular analysis. It has been shown that 
detection rates obtained using molecular assays are higher when 5 ml whole blood is used 
as compared to only one ml [34]. However, in this study residual whole blood, which was left 
after performing standard diagnostic tests, was used and only one ml whole blood could be 
processed and not 5 ml. More detailed investigation is necessary to select the best molecular 
assay available today. Furthermore, only prospective studies should be performed, using 
at least 5 ml (or more) whole blood from suspected BSI patients. This should allow more 
optimal detection of pathogens from whole blood. Besides that, cost effectiveness analysis 
is needed to study the effect of implementation of a molecular assay on patient samples 
preselected, for instance based on NLCR results, in addition to blood cultures.
In summary, of all the biomarkers studied, PCT, suPAR and NLCR are suitable to differentiate 
SIRS patients with and without positive blood cultures. NLCR is a rapidly available, cheap, 
and easy to determine biomarker. Therefore, NLCR is a promising biomarker to preselect 
suspected BSI patients for molecular analysis besides blood culture. Unfortunately, the 
molecular assays available to date are not yet suitable for analysis of one ml remnant whole 
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blood samples from patients at the emergency care unit. In addition, the clinical significance 
of DNA positivity in blood samples which remain culture negative needs further investigation.
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Abstract
Bloodstream infections (BSI) pose serious health risks and can be life threatening. To detect 
the pathogen(s) involved and monitor BSI treatment most molecular methods to date focus 
on DNA. However, the analyses of RNA in BSI may have several advantages. Due to its 
shorter half-life, the presence of RNA may better relate to viability of pathogens, and due to 
its occurrence as multi-copy target, it may increase test sensitivity. We therefore investigated 
the presence of various nucleic acids targets (DNA, rRNA and mRNA) of Staphylococcus 
aureus during bacterial growth and antibiotic induced killing in relation to viability.
S. aureus was cultured to log phase and spiked in Todd Hewitt (TH) broth and whole blood 
of healthy human volunteers. Viability of S. aureus after flucloxacillin treatment (0, 1, 3 and 
6 days) was assessed by culture on bloodagar plates. In addition, the presence of S. aureus 
DNA, rRNA, and mRNA were determined by real-time PCR of the 16S rDNA and tuf gene.
S. aureus spiked in TH broth without antibiotics grew from day 0-6 and DNA (tuf and 16S), 
and 16S rRNA remained detectable during this whole period. During flucloxacillin treatment 
S. aureus lost viability from day 3 onwards, while the 16S rRNA-gene and its RNA transcripts 
remained detectable. However, tuf mRNA became undetectable from day 3 onwards. When 
spiking S. aureus in whole blood instead of broth no bacterial growth was seen, neither in 
the absence nor in the presence of flucloxacillin. Accordingly, no increase in DNA and RNA 
levels of both 16S rDNA and the tuf gene were detected.
In conclusion, the results indicate that DNA and rRNA can be detected in flucloxacillin treated 
S. aureus cultures that do not further contain culturable bacteria. mRNA, in contrast, was 
only detectable from samples with culturable bacteria. Thus, mRNA might be a promising 
marker to measure active S. aureus bloodstream infection and possibly monitor antibiotic 
effects.
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Introduction
Bacteremia is defi ned as the presence of viable bacteria in the bloodstream [1]. The current 
gold standard method for the detection of microorganisms in the bloodstream is blood 
culture and subsequent identifi cation of the bacteria by conventional (sometimes automated) 
biochemical techniques or MALDI-TOF MS [2-4]. An important advantage of this method is 
that only viable microorganisms are detected. A major disadvantage of the method is that the 
time-to-results is long (24-72 hours) due to the involvement of culturing steps. Because fast 
and accurate diagnosis is of crucial importance for patients suffering from BSI, molecular 
(real-time) PCR applications are increasingly being applied to decrease time to pathogen 
identifi cation, thereby improving patient outcome [5-8]. However, all commercially available 
sepsis tests (SeptiFAST (Roche), SepsiTest (Molzym), and MagicPlex Sepsis Test (Seegene)) 
are based on DNA detection. DNA is a stable molecule and the presence of DNA of a certain 
pathogen does not provide information about the viability status of that pathogen as the 
DNA can originate from either living or dead pathogens [9-12]. In contrast to DNA, bacterial 
messenger RNA molecules have a half-live of only minutes [13]. For that reason, several 
studies have evaluated the detection of mRNA as a marker for the presence of actively 
growing bacteria [9, 11, 14-18]. Some of these studies have focused on detection of viable 
pathogens from food and environmental samples [14], while other studies focused on human 
disease and viability of pathogens from spiked culture broths (i.e. Borrelia burgdorferi, E. coli, 
Salmonella typhi, Shigella sonnei, Mycobacterium smegmatis) [10, 11, 17, 19]. Few studies 
used clinical specimens (Mycobacterium tuberculosis from sputum samples, Aspergillus spp 
from blood samples, Chlamydia trachomatis from cervical smears and urine) [12, 15, 16]. If 
RNA markers can be used to assess pathogen viability for BSI, the application of PCR based 
methods on RNA (cDNA) would be of great signifi cance.
BSI can be caused by numerous pathogens [20]. In this study, the most commonly detected 
Gram-positive bacterium; S. aureus was chosen for reconstruction experiments. To 
investigate which nucleic acid molecule most favourably correlates to the viability status of 
S. aureus, DNA and rRNA of 16S rRNA gene, and DNA and mRNA levels of the tuf gene 
were measured in response to antibiotic therapy. The aim of this work was to fi nd a suitable 
marker for S. aureus viability to be able to improve BSI diagnostics.
Materials and Methods
Bacterial strain and growth conditions
S. aureus (ATCC 25923) was used for reconstruction (spiking) experiments. Todd Hewitt 
(TH) broth was inoculated with S. aureus and cultured overnight at 35ºC. Subsequently, a 
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Figure 1. Overview of the experimental setup.
CFU, colony forming unit.
1:100 dilution was made in fresh TH broth (5 ml) for additional culturing to exponential phase 
(optical density 0.2 at 600 nm; approximately 1 x 107 cells/ml).
Spiking of S. aureus in TH broth and whole blood
See Figure 1 for an overview of the experimental setup. S. aureus bacteria grown in 
exponential phase were diluted in either TH broth or pooled (of similar blood type, i.e. O+), 
1 day old, residual whole blood from healthy volunteers. The 100 and 10 colony forming 
units (CFU)/ml dilutions were made in 2 tubes with an end volume of 10 ml TH broth or 
whole blood, respectively. To one tube an overdose of flucloxacillin (floxapen 5 µg/ml, 1 
ml, Actavis, Baarn, the Netherlands) was added (to kill the bacteria) and to the other 1 ml 
physiological salt solution, this was used as a control. Both tubes were placed on a shaker 
at room temperature. On days 0, 1, 3, and 6, 200 µl samples were taken from both tubes 
(flucloxacillin treated and untreated) for DNA and RNA isolation. Additionally, 100 µl was 
taken to determine CFU/ml on blood agar plates (Tryptone Soya Agar with sheep blood, 
Oxoid Deutschland GmbH, Wesel, Germany). Bacterial death was defined as the inability of 
producing colonies on bloodagar.
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DNA and RNA isolation
The obtained 200 µl samples (TH broth and whole blood) were centrifuged at 14.000 rpm for 
2 min. The supernatant was removed and the pellet was washed once with 200 µl ultra-pure 
water and centrifuged for 2 minutes at 14.000 rpm. The obtained pellet was resuspended in 
20 µl lysozym (12.5%) and 75 µl lysostaphin (100 µg/ml) and incubated for 30 min at 37 ºC 
while shaking (1000 rpm). RLT buffer with ß-mercaptoethanol (1:100) (Qiagen RNA blood 
mini kit) was added and the samples were stored at -80ºC until all time points were collected. 
The EasyMAG (BioMérieux, Marcy L’Etoile, France) was used for DNA isolation by using the 
specifi c B protocol. RNA was isolated by using the RNA blood mini kit (Qiagen), according 
to manufacturer’s instructions. DNAse treatment was performed as described in the manual 
provided (Qiagen RNA blood mini kit) using columns to degrade the DNA in the samples.
cDNA synthesis with random primers
Reverse transcription was performed on RNA samples using the SuperScript™II First-Strand 
Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, USA, according to manufacturer’s 
protocol). Each sample was split in two for the plus and minus reverse transcriptase reaction 
to check DNA degradation (DNAse treatment on column).
Real-Time PCR for tuf and 16S rRNA
See Table 1 for an overview of the used primers and probes (tuf and 16S rDNA). The 
16S rDNA primers, specifi c for most clinically relevant staphylococci, were described by 
Matsuda et al. [21]. However, the 16S rDNA forward primer was slightly modifi ed to adapt 
to proper annealing temperature. An XS- probe (Biolegio, Nijmegen, The Netherlands) for 
Staphylococcus spp. detection based on 16S was specifi cally designed. The PCR mix used 
has been described previously [22]. Additionally, tuf or 16S primers (900 nM), tuf or 16S 
probe (200 nM), and 5 µl sample were added to obtain an fi nal volume of 20 µl. The PCR 
program used was described previously [23]. Both PCRs were run in white plates on the 
LightCycler 480 II (Roche Diagnostics).
Table 1. Primers and probes used in this study.
Gene Forward primer 5’-3’ Reverse primer 5’-3’ Probe 5’-3’ Reference
tuf tcctggttcaattacaccacat-
actg
ggaaatagaattgtggacga-
tagtttga
FAM- tgata-
atacrtawacttctgc-BHQ1
[23]
16S acggtcttgctgtcactta tacacatatgttcttccctaataa VIC-gtaacggcttaccaag-
gc-BHQ1
[21]
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Results
Detection of S. aureus DNA, rRNA, and mRNA after antibiotic treatment from TH 
broth
In absence of flucloxacillin the S. aureus bacteria continued to grow. At day 0, on average 
330 ± 28 (average ± SD) CFU/ml were detected on bloodagar plates (Table 2). At days 1, 3, 
and 6 the CFU/ml increased to > 1000 CFU/ml. In contrast, bacterial growth was arrested 
in flucloxacillin (antibiotic) treated samples and no colonies were detected on bloodagar at 
days 3 and 6.
Simultaneously, samples were taken for DNA and RNA isolation. In the absence of 
flucloxacillin, Ct values of both 16S (DNA and rRNA) and tuf (DNA and mRNA) decreased in 
time (Figure 2). In the presence of flucloxacillin, DNA of the 16S rDNA gene and the tuf gene 
were detected until day 6, while bloodagar plates indicated absence of culturable S. aureus 
on day 3. 16S rRNA also remained detectable up to 6 days of treatment. However, tuf mRNA 
could not be detected on days 3 and 6. The data indicate that S. aureus DNA and rRNA can 
still persist in the absence of viable bacteria as demonstrated using culture.
The Ct values obtained on day zero are similar for both 16S DNA and rRNA with(out) 
flucloxacillin. This is not true for tuf DNA and mRNA. Ct values obtained for tuf mRNA are on 
average 2 Ct higher as compared to tuf DNA (day 0).
These results demonstrate that tuf mRNA is the nucleic acid target that could only be detected 
from samples which contain culturable bacteria. DNA and rRNA targets could be detected 
in flucloxacillin treated S. aureus cultures that do not further contain culturable bacteria. This 
experiment was performed twice on independent days, and showed similar results.
S. aureus viability measurements from spiked whole blood
In order to mimic a bloodstream infection, whole blood samples instead of TH broth were 
spiked with log phase S. aureus and growth was measured both in presence and absence 
Table 2. Plate counts of Staphylococcus aureus samples with or without flucloxacillin treatment from 
TH broth.
Flucloxacillin Yes No Yes No
Average SD Average SD
Days 0 290 14 330 28
1 255 7 ∞ ND
3 0 0 ∞ ND
6 0 0 ∞ ND
Numbers represent colony forming units/ml
∞; uncountable plate due to large amount of colonies, ND; not determined
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Table 3. Plate counts of Staphylococcus aureus with or without fl ucloxacillin treatment from TH broth, 
fresh whole blood (1 h) and remnant whole blood (1 day). 
TH broth Fresh whole blood Remnant whole 
blood
Flucloxacillin Yes No Yes No Yes No
Days 0 20 22 10 4 3 6
1 14 ∞ 2 3 1 1
3 0 ∞ 2 1 0 3
6 0 ∞ 1 0 0 0
Numbers represent colony forming units/ml
∞; uncountable plate due to large amount of colonies
of fl ucloxacillin. Furthermore, a more clinical signifi cant initial bacterial load was used of 10 
CFU/ml (instead of 100 CFU/ml). The plate counts (Figure 3) show that in both presence 
and absence of fl ucloxacillin bacterial numbers decrease. DNA and RNA measurements of 
16S and tuf also showed growth arrest, both in presence and absence of fl ucloxacillin, as 
no decrease in Ct values was observed in time (0-6 days) (Figure 3), this in contrast to the 
results obtained by using spiked TH broth in absence of fl ucloxacillin (Figure 2).
The Ct values obtained by detecting 16S DNA and rRNA are lower as compared to the Ct 
values for tuf DNA and mRNA. A difference of at least 6 Ct was observed when comparing 
16S rRNA levels to tuf mRNA levels. When comparing Ct values for DNA detection of both 
genes the differences were less pronounced, but still signifi cant (approximately 3 Ct). A 
clear difference was observed between the spiked TH broth samples (Figure 2) and the 
spiked whole blood samples at day zero (Figure 3). Ct values for 16S DNA and rRNA 
were comparable in TH broth (day 0), but not in whole blood. For tuf DNA and mRNA this 
phenomenon was also observed, in whole blood the Ct values for tuf mRNA were lower than 
for tuf DNA (day 0). Furthermore, there seemed to be a trend towards higher Ct values from 
day 0-6, independent of fl ucloxacillin, for both 16S rRNA and tuf mRNA in whole blood. This 
confi rms the culture results obtained from whole blood.
In addition, it was investigated whether fresh (max. 1 hour) and residual (1 day old) whole 
blood differed in their performances as medium for bacterial culture. TH broth was used as 
a control: in the absence of fl ucloxacillin large amounts of colonies were detected up to 6 
days of culture, while in the presence of fl ucloxacillin colonies were detected on days 0 and 
1, and no colonies were detected on bloodagar plates on days 3 and 6 (Table 3). Plate counts 
from spiked blood samples did not resemble those obtained from spiked TH broth samples. 
The initial plate count on day 0, while initiated from the same log phase culture, was half or 
less when compared to the count on day 0 for TH broth samples. However, no signifi cant 
differences were observed between fresh and residual blood samples both in presence or 
absence of fl ucloxacillin.
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Discussion
For patient survival it is important to provide fast and accurate identification of BSI causing 
pathogens. Only viable microorganisms can be cultured, and fastidious or damaged 
organisms can be present in whole blood but often remain culture negative. Molecular 
diagnostics might provide solutions for these problems, as pathogens in antibiotic treated 
patients who remain culture negative (due to presence of antibiotics in the bloodstream) 
can be identified by PCR [24, 25]. As BSI is defined as the presence of viable pathogens 
in the bloodstream, it might be important for a molecular assay to allow pathogen viability 
measurements from whole blood.
The results that were obtained after spiking S. aureus in TH broth, with and without 
flucloxacillin, indicated that tuf mRNA might be a more promising marker to measure viability 
than DNA and rRNA. Tuf mRNA levels correlated with the culture results from both TH broth 
and whole blood, whereas 16S DNA, 16S rRNA and tuf DNA levels did not. These data 
confirm results from previous studies [9, 10, 15, 18].
The S. aureus bacteria used in this study seemed to die in whole blood (growth reduction 
on agar plates in absence of flucloxacillin) or enter a state in which they are viable but non-
culturable (VBNC) [26-28]. Bacteria enter the VBNC state in response to stress, such as 
starvation, incubation outside the growth temperature range, or oxygen concentration [28]. 
In this study, several stressful conditions might have been present. S. aureus was cultured in 
whole blood in which white cells might inhibit bacterial growth [29]. Additionally, incubation 
took place at room temperature (RT) for 6 days, and waste products were not removed from 
the culture tube. In future studies, it might be useful to remove the white blood cells from 
whole blood before spiking (buffy coat), and incubate the samples at 35°C instead of RT to 
create better growth conditions. Furthermore, different S. aureus strains need to be tested 
to confirm our results.
In this study, bacteria were considered dead when they were unable to produce colonies on 
bloodagar. However, as mentioned before, bacteria can enter a viable by non-culturable state 
(VBNC) under stressful conditions [26, 30]. Bacteria that are not culturable can potentially still 
be viable and infective. A limitation of this study is that bacterial viability was only measured 
by colony formation on bloodagar plates. In future studies additional methods to assess 
bacterial viability might be included, for instance the Live/Dead BacLight Bacterial Viability 
Kit (Invitrogen). This kit provides two nucleic acid stains (green-fluorescent SYTO 9 dye and 
red-fluorescent propidium iodide (PI)) to be able distinguish live bacteria (intact membranes) 
from dead bacteria (compromised membranes). PI is a cell membrane impermeable dye and 
can only enter compromised pathogens [31]. Another option to differentiate live from dead 
pathogens is exposure to the dye propidium monoazide (PMA) followed by real-time PCR. 
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PMA cannot penetrate viable cells with intact cytoplasmic membranes [32]. The PMA dye 
can enter dead pathogens and bind DNA, thereby inhibiting PCR amplifi cation.
It has clearly been demonstrated that tuf mRNA mostly resembles culture results (in both TH 
broth and whole blood). Both DNA and rRNA remain detectable even when culture results 
are negative. The Ct values obtained for S. aureus spiked in TH broth are different from 
those in the whole blood. Because a lower amount of S. aureus bacteria (10 CFU/ml) was 
spiked in whole blood, as compared to TH broth (100 CFU/ml), one would expect the Ct value 
to be 3,3 (1 log) higher in whole blood samples. This difference of approximately 3 Ct was 
seen in whole blood as compared to TH broth for DNA (both 16S and tuf) . However, the Ct 
values obtained for tuf mRNA and 16S rRNA (t=0) were higher in TH broth as compared to 
whole blood (approximately 2 and 5 Ct, respectively). Both RNA targets (tuf and 16S) seem 
to be expressed at a higher level in whole blood. This unexpected phenomenon might be a 
result of the difference in environment (blood versus broth). This confi rms fi ndings reported 
by Cenciarini et al. who showed that it is diffi cult to compare RNA viability markers for one 
pathogen kept in different conditions [14].
In this study, detection of mRNA and rRNA was performed by using reverse-transcription 
real-time PCR (RT-PCR). Birch et al. investigated the use of PCR, RT-PCR and nucleic 
acid sequence based amplifi cation (NASBA) for assessment of bacterial viability [33]. They 
found that NASBA offered the highest sensitivity of the three methods tested. However, 
presence of residual fl iC DNA and mRNA could be detected by NASBA 30 hours post-death 
(culture negative). Other studies have shown that RNA detection by NASBA could be used 
to monitor infections after antibiotic treatment [12, 19]. These contradictory fi ndings again 
demonstrate that it is important to thoroughly investigate which RNA target is suitable for 
viability measurement of a certain pathogen. In future studies, it would be interesting to use 
the NASBA technology in addition to RT-PCR.
In this study, results were obtained from as little as 200 µl whole blood. Larger volumes 
of blood are needed to be able to detect clinical relevant bacterial loads [34]. As bacterial 
enrichment is a prerequisite to be able to detect bacteria from whole blood, RNA isolation 
methods should include such an approach. Both Polaris (Biocartis, Mechelen, Belgium) 
and MolYsis (Molzym GmbH, Bremen, Germany) have developed suitable techniques for 
pathogen DNA enrichment from large volumes of blood [34]. However, these enrichment 
strategies are not suitable for RNA isolation. A small pilot study indicated that the fi rst steps, 
of both the MolYsis and the Polaris pathogen enrichment methods, in which human cells and 
DNA were removed, did not kill the pathogens present in the whole blood samples as shown 
by positive cultures (data not shown). It would be interesting to investigate if enrichment 
of pathogens, with either Polaris or MolYsis, can be combined with existing RNA isolation 
procedures to obtain pathogen RNA from large volumes (5 ml) of blood.
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Several studies have to date been published which describe the superiority of a mRNA target 
in the detection of viable bacteria [12, 15-17, 33]. BSI can be the result of a broad scala of 
pathogens and, in this study, S. aureus was chosen for initial reconstruction experiments 
to show proof of principle. At present several commercial sepsis tests are available and 
it remains to be seen if these can be used for pathogen identification and simultaneous 
assessment of viability.
In conclusion, this study clearly demonstrated that detection of S. aureus tuf mRNA, in 
contrast to DNA and rRNA, correlates to bacterial viability status as determined by culture. 
Therefore, tuf mRNA might be a promising marker to measure active S. aureus bloodstream 
infection. After development of RNA isolation procedures from large volumes of whole blood, 
future clinical studies are needed to validate the preliminary findings obtained in this study.
Loonen.indd   144 30-10-2013   8:15:44
Tuf mRNA might be a promising marker to detect viable S. aureus in blood of bacteremic patients  |  145
9
References
 1. M, S., in Stedman’s Medical Dictionary1995, Md: Lippincott Williams & Wilkins: Baltimore.
 2. Loonen, A.J., et al., An evaluation of three processing methods and the effect of reduced 
culture times for faster direct identifi cation of pathogens from BacT/ALERT blood cultures by 
MALDI-TOF MS. Eur J Clin Microbiol Infect Dis, 2012. 31(7): p. 1575-83.
 3. Riedel, S. and K.C. Carroll, Blood cultures: key elements for best practices and future 
directions. J Infect Chemother, 2010. 16(5): p. 301-16.
 4. van Veen, S.Q., E.C. Claas, and E.J. Kuijper, High-throughput identifi cation of bacteria and 
yeast by matrix-assisted laser desorption ionization-time of fl ight mass spectrometry in 
conventional medical microbiology laboratories. J Clin Microbiol, 2010. 48(3): p. 900-7.
 5. Fraser, A., et al., Benefi t of appropriate empirical antibiotic treatment: thirty-day mortality and 
duration of hospital stay. Am J Med, 2006. 119(11): p. 970-6.
 6. Gaibani, P., et al., Blood culture systems: rapid detection--how and why? Int J Antimicrob 
Agents, 2009. 34 Suppl 4: p. S13-5.
 7. Wallet, F., et al., Preliminary clinical study using a multiplex real-time PCR test for the 
detection of bacterial and fungal DNA directly in blood. Clin Microbiol Infect, 2010. 16(6): p. 
774-779.
 8. Yanagihara, K., et al., Evaluation of pathogen detection from clinical samples by real-time 
polymerase chain reaction using a sepsis pathogen DNA detection kit. Crit Care, 2010. 14(4): 
p. R159.
 9. Hellyer, T.J., et al., Detection of viable Mycobacterium tuberculosis by reverse transcriptase-
strand displacement amplifi cation of mRNA. J Clin Microbiol, 1999. 37(3): p. 518-23.
 10. Iyer, R., et al., Detection of Borrelia burgdorferi Nucleic Acids after Antibiotic Treatment Does 
Not Confi rm Viability. J Clin Microbiol, 2013. 51(3): p. 857-62.
 11. Josephson, K.L., C.P. Gerba, and I.L. Pepper, Polymerase chain reaction detection of 
nonviable bacterial pathogens. Appl Environ Microbiol, 1993. 59(10): p. 3513-5.
 12. Morre, S.A., et al., Monitoring of Chlamydia trachomatis infections after antibiotic treatment 
using RNA detection by nucleic acid sequence based amplifi cation. Mol Pathol, 1998. 51(3): p. 
149-54.
 13. Arraiano, C.M., S.D. Yancey, and S.R. Kushner, Stabilization of discrete mRNA breakdown 
products in ams pnp rnb multiple mutants of Escherichia coli K-12. J Bacteriol, 1988. 170(10): 
p. 4625-33.
 14. Cenciarini, C., et al., Infl uence of long time storage in mineral water on RNA stability of 
Pseudomonas aeruginosa and Escherichia coli after heat inactivation. PLoS One, 2008. 3(10): 
p. e3443.
 15. Jou, N.T., et al., Single-tube, nested, reverse transcriptase PCR for detection of viable 
Mycobacterium tuberculosis. J Clin Microbiol, 1997. 35(5): p. 1161-5.
 16. Loeffl er, J., et al., Nucleic acid sequence-based amplifi cation of Aspergillus RNA in blood 
samples. J Clin Microbiol, 2001. 39(4): p. 1626-9.
 17. Sheridan, G.E., et al., Detection of mRNA by reverse transcription-PCR as an indicator of 
viability in Escherichia coli cells. Appl Environ Microbiol, 1998. 64(4): p. 1313-8.
 18. Simpkins, S.A., et al., An RNA transcription-based amplifi cation technique (NASBA) for the 
detection of viable Salmonella enterica. Lett Appl Microbiol, 2000. 30(1): p. 75-9.
 19. van der Vliet, G.M., et al., Assessment of mycobacterial viability by RNA amplifi cation. 
Antimicrob Agents Chemother, 1994. 38(9): p. 1959-65.
 20. Wisplinghoff, H., et al., Nosocomial bloodstream infections in US hospitals: analysis of 24,179 
cases from a prospective nationwide surveillance study. Clin Infect Dis, 2004. 39(3): p. 309-17.
 21. Matsuda, K., et al., Sensitive quantitative detection of commensal bacteria by rRNA-targeted 
reverse transcription-PCR. Appl Environ Microbiol, 2007. 73(1): p. 32-9.
 22. Huijsmans, C.J., et al., Comparative analysis of four methods to extract DNA from paraffi n-
embedded tissues: effect on downstream molecular applications. BMC Res Notes, 2010. 3: p. 
239.
Loonen.indd   145 30-10-2013   8:15:44
146  |  Chapter 9
23. Loonen, A.J., et al., Acceleration of the direct identification of Staphylococcus aureus versus 
coagulase-negative staphylococci from blood culture material: a comparison of six bacterial 
DNA extraction methods. Eur J Clin Microbiol Infect Dis, 2011. 30(3): p. 337-42.
24. Mauro, M.V., et al., Diagnostic utility of LightCycler SeptiFast and procalcitonin assays in the 
diagnosis of bloodstream infection in immunocompromised patients. Diagn Microbiol Infect 
Dis, 2012. 73(4): p. 308-11.
25. Wellinghausen, N., et al., Diagnosis of bacteremia in whole-blood samples by use of a 
commercial universal 16S rRNA gene-based PCR and sequence analysis. J Clin Microbiol, 
2009. 47(9): p. 2759-65.
26. Davey, H.M., Life, death, and in-between: meanings and methods in microbiology. Appl 
Environ Microbiol, 2011. 77(16): p. 5571-6.
27. Keer, J.T. and L. Birch, Molecular methods for the assessment of bacterial viability. J Microbiol 
Methods, 2003. 53(2): p. 175-83.
28. Oliver, J.D., The viable but nonculturable state in bacteria. J Microbiol, 2005. 43: p. 93-100.
29. Hogman, C.F., et al., White cells protect donor blood against bacterial contamination. 
Transfusion, 1991. 31(7): p. 620-6.
30. Trevors, J.T., Can dead bacterial cells be defined and are genes expressed after cell death? J 
Microbiol Methods, 2012.
31. Deligeorgiev, T.G., S. Kaloyanova, and J.J. Vaquero, Intercalating Cyanine Dyes for Nucleic 
Acid Detection. Recent Patents on Materials Science, 2009(2): p. 1-26.
32. Nocker, A., C.Y. Cheung, and A.K. Camper, Comparison of propidium monoazide with 
ethidium monoazide for differentiation of live vs. dead bacteria by selective removal of DNA 
from dead cells. J Microbiol Methods, 2006. 67(2): p. 310-20.
33. Birch, L., et al., A comparison of nucleic acid amplification techniques for the assessment of 
bacterial viability. Lett Appl Microbiol, 2001. 33(4): p. 296-301.
34. Loonen, A.J., et al., Comparison of pathogen DNA isolation methods from large volumes of 
whole blood to improve molecular diagnosis of bloodstream infections. PLoS One, 2013. 8(8): 
p. e72349.
Loonen.indd   146 30-10-2013   8:15:44
Chapter 10
Summary, General Discussion and Future Perspectives
Loonen.indd   147 30-10-2013   8:15:46
148  |  Chapter 10
Bloodstream infections (BSIs) still remain increasing in incidence [1-6]. BSI is associated 
with high mortality and increased healthcare costs [7, 8]. Optimal management of BSI is 
dependent on several factors including recognition of the disease, laboratory tests and 
treatment. Rapid and accurate identification of the etiologic agent is crucial to be able to 
initiate pathogen specific antibiotic therapy and decrease mortality rates [9, 10]. In case 
of the most serious bloodstream infections associated with septic shock, time is a crucial 
factor. The survival rate of severe sepsis decreases from 80% if appropriate therapy is given 
within one hour to less than 10% if effective therapy is not provided within 24 hours [11]. 
Furthermore, appropriate treatment might slow down the emergence of antibiotic resistant 
strains.
Culture-based methods are still considered to be the “gold standard” for the detection and 
identification of pathogens causing BSI. When blood cultures are detected as positive 
by the automated culture system, Gram staining is performed followed by subculture on 
solid media, and (semi-automated) biochemical testing for species identification. Finally, a 
complete antibiotic susceptibility profile can be provided based on cultured colonies, which 
allows the start of pathogen-tailored antibiotic therapy (Figure 1).
Figure 1. Overview of the conventional diagnostic process for BSI.
When blood culture positivity is detected by the automated culture system, Gram staining is 
performed, followed by subculture on agar media, and biochemical testing for pathogen identification. 
A complete antibiotic susceptibility profile is usually obtained by analysing growth inhibition on solid 
media. AST; antibiotic susceptibility testing.
This conventional workflow is extremely time-consuming and can take up several days. 
Furthermore, fastidious and slow-growing microorganisms, as well as antibiotic pre-treated 
samples can be falsely negative. The main aim of this thesis was to study different strategies 
to improve the conventional laboratory diagnostic steps for BSI (Figure 1). These approaches 
include protein-based (MALDI-TOF mass spectrometry) and nucleic acid-based (polymerase 
chain reaction (PCR)) identification from subculture, blood cultures, and whole blood to 
decrease time-to results. In addition, also pathogen enrichment and DNA isolation methods, 
to enable optimal pathogen DNA recovery from these clinical specimens, were investigated.
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10.1 BSI diagnostics from blood cultures and subcultures
Polymerase chain reaction
Gram-positive bacteria (i.e. S. aureus, CoNS, and Enterococcus spp.) are frequently 
recovered pathogens from blood cultures [12]. Therefore, we developed two real-time PCR 
duplex assays for detection of S. aureus, CoNS, and Enterococcus spp. Subsequently these 
assays were clinically evaluated by using; 1) growth positive blood cultures containing Gram-
positive cocci, and 2) one ml residual whole blood from patients at the intensive care unit 
(ICU) (Chapter 2). The duplex assays, based on the tuf gene, enabled fast and accurate 
detection from positive blood cultures. In a small pilot study using one ml residual whole 
blood samples of suspected BSI patients from the intensive care unit (ICU), the developed 
PCR assays combined with a sensitive bacterial DNA isolation method have shown potential 
value. In 18 out of the 22 patients (82%) identical results were found when comparing blood 
culture and PCR.
Simultaneously, we investigated the possibility of reduced blood culture incubation in the 
automated culture system (Chapter 3). Six different bacterial DNA extraction protocols 
were compared to be able to fi nd the best method for pathogen DNA isolation from blood 
cultures. This method was used to isolate pathogen DNA, and subsequently PCR was 
performed on blood culture bottles after only a few hours of culture. The MolYsis Plus kit 
(Molzym) in combination with the specifi c B protocol of the EasyMAG resulted in the best 
isolation of bacterial DNA from BacT/ALERT (bioMérieux) blood culture bottles. After initial 
spiking experiments (S. aureus) a detection limit of 10 CFU/ml could be detected by using 
the developed tuf based PCR. BACTEC (BD) blood culture bottles resulted in an one log 
lower detection limit. After an incubation step of only 5 hours S. aureus and CoNS could 
be detected from BacT/ALERT blood culture material by using the in-house PCR assay. By 
using this reduced incubation time it was possible to identify S. aureus and CoNS within one 
working day. Results were available at least 19 hours faster as compared to the conventional 
diagnostic process. In a study performed by Gebert et al. [13] similar results were reported. 
They showed a decrease of 5.0-8.7 hours in spiking experiments and an average time 
gain of 10.7 hours was obtained when the method was applied on true clinical specimens. 
Laboratories with a 24 hours setup will benefi t most from this approach. More research is 
needed to determine which incubation time is suitable for most encountered pathogens. The 
tuf gene based real-time PCR described is only valuable for patients suspected of having 
a Staphylococcus spp. or Enterococcus spp. bloodstream infection. As BSI can be caused 
by a variety of pathogens, species-specifi c PCRs seem less valuable when optimal time-to 
results are required. The developed tuf gene based real-time PCR can be extended with 
other targets to be able to detect the most frequently cultured pathogens from blood cultures. 
This fl exibility allows that the assay can be adjusted to the local epidemiology depending on 
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the predominant patient group, i.e. covering pathogens found most frequently at a certain 
department or in a specific patient population [12, 14]. Future studies could also make use of 
e.g. the multi-probe assay as described by Hansen et al. [15] or the commercially available 
Prove-it Sepsis test (MobiDiag, Helsinki, Finland) [16]. However, as both of these tests are 
developed for pathogen identification from growth positive blood cultures it remains to be 
investigated whether they are sensitive enough to be used on blood culture bottles which are 
not yet growth positive.
MALDI-TOF MS
Infections due to Gram-positive organisms are one of the leading causes of morbidity and 
mortality. A US study showed a high prevalence of Gram-positive bacteria in BSI patients; 
the most frequently isolated pathogens were CoNS (31%) [12]. CoNS are normal inhabitants 
of human skin and mucous membranes. They have long been considered as culture 
contaminants, but as they are increasingly cultured, the role of CoNS as pathogens needs 
further investigation. Consequently, rapid and reliable determination of CoNS to the species 
level might be clinically relevant. Phenotypic methods, according to Kloos and Schleifer, 
have long been the “gold standard” for identification of CoNS to the species level [17]. The 
API ID 32 Staph strip (bioMérieux) and the automated VITEK 2 (bioMérieux) have improved 
phenotypic identification of CoNS spp. Furthermore, a variety of genes, 16S rRNA [18], 
sodA [19], and tuf [20, 21] are described to be suitable targets for genotypic CoNS spp. 
identification. Matrix Assisted Laser Desorption Ionisation- Time of Flight mass spectrometry 
(MALDI-TOF MS) allows examination of protein profiles from bacteria, and has been shown 
to work in a fast and accurate manner [22, 23]. To be able to find the most suitable method 
for fast CoNS identification we compared five methods i.e. the VITEK 2 (bioMérieux), the 
ID 32 Staph strip (bioMérieux), partial 16S rDNA gene sequencing (MicroSeq, Applied 
Biosystems), partial tuf gene sequencing (in-house), and MALDI-TOF MS (Bruker Daltonics) 
on the same set of CoNS strains (Chapter 4). The results obtained in this study demonstrated 
the good performance of MALDI-TOF MS for identification of CoNS, a correct identification 
rate of 99.3% was achieved. Tuf gene sequencing is the most suitable alternative for MALDI-
TOF MS. Heikens et al. also demonstrated that tuf gene sequencing is a good approach for 
identification of CoNS (5/57 incorrect ID) [20]. When fast and accurate identification of CoNS 
is needed, MALDI-TOF MS is the method of choice. This has also been demonstrated by 
others [24, 25].
It remains a challenge in daily practice to distinguish clinically significant CoNS from 
contaminant strains. As the most optimal method for CoNS identification was found to be 
MALDI-TOF MS, this technique was employed to study the clinical relevance of CoNS 
speciation (Chapter 5). Most CoNS infections are a result of the use of medical devices 
such as prosthetic devices and (intravenous) catheters [26]. However, S. lugdunensis 
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and S. schleiferi have been reported as etiologic agents of BSI and endocarditis, and S. 
saprophyticus as a cause of urinary tract infections [27]. We have shown that speciation of 
CoNS could be helpful in establishing whether a patient is suffering from an actual CoNS 
bloodstream infection. The CoNS species most commonly found in bloodstream infections 
was S. epidermidis. However, in our study, S. epidermidis was also the most common blood 
culture contaminant. In addition, we found that S. haemolyticus was very often associated 
with BSI, whereas others were mostly found to be contaminants. This means that CoNS 
identifi cation can be of clinical value to differentiate true pathogens from contaminants. 
CoNS speciation combined with the opinion of the clinical microbiologist might prove to be 
optimal for patient care. Moreover, molecular diagnostic tests should be able to detect the 
most clinically relevant CoNS species and more in-depth prospective studies are needed to 
confi rm our fi ndings.
More rapid direct identifi cation of microorganisms from positive cultures can have major 
impact in the clinic. Therefore, we investigated the possibility of direct identifi cation of 
bacteria from positive aerobe BacT/ALERT blood cultures with MALDI-TOF MS. In addition, 
it was evaluated if reduced time-to-identifi cation from blood cultures could be achieved 
with reduced incubation times (7 hours) of S. aureus-and E. coli-spiked BacT/ALERT blood 
cultures (Chapter 6). When blood cultures are used in combination with MALDI-TOF MS, 
human cells need to be removed from the specimen to eliminate interference from human 
proteins in the analysis. Therefore, different protocols were analysed for their performance 
in bacterial enrichment and removal of these aspecifi c proteins. Our results showed that 
bacterial identifi cation can be available within 20 min by using SepsiTyper (Bruker Daltonics), 
but also depends on the number of positive cultures that need to be processed. In contrast, 
the conventional workfl ow needs approximately 1-2 days to be able to report the bacterial 
species from positive blood cultures. Reduced incubation (7 h) of S. aureus-and E. coli-
spiked aerobe BacT/ALERT cultures did not result in reliable identifi cation. An alternative to 
the proposed workfl ow of using positive blood cultures for MALDI-TOF MS identifi cation is 
the use of spot subculture on agar plates. This subculture entails culturing of positive blood 
culture material for approximately four hours. In general, after four hours enough bacteria will 
be available for MALDI-TOF MS analysis via the direct smear method (colonies from solid 
media). Blood cultures which become positive in the morning can be identifi ed by this spot 
subculture. Pathogen identifi cation with MALDI-TOF MS, directly from positive blood cultures 
can be performed on blood cultures which become growth positive later during the day. 
Szabados et al. reported low sensitivity (30%) for MALDI-TOF MS for direct identifi cation from 
positive BacT/ALERT blood culture bottles [28]. But then again, others have demonstrated 
the successful use of positive blood cultures, both BACTEC as well as BacT/ALERT bottles, 
as starting point for pathogen identifi cation with MALDI-TOF MS [29-35].
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MALDI-TOF MS can decrease time-to identification. However, it has been shown that a 
microbial load of 107-108 CFU/ml is necessary to obtain protein spectra [29]. This indicates 
that pre-culture steps remain necessary for optimal results. Furthermore, it is not yet possible 
to use MALDI-TOF MS for antibiotic susceptibility testing. The first steps towards antibiotic 
susceptibility testing with MALDI-TOF MS have been undertaken [36, 37], but it is not possible 
to provide a complete AST profile yet.
10.2 BSI diagnostics directly from whole blood
Sample preparation
Pathogen detection and identification from whole blood is the only way to circumvent culture 
steps. Sample preparation is crucial to be able to remove human background cells and DNA, 
and to simultaneously enrich pathogens to detect the low bacterial loads [38].
Detection of pathogen DNA from whole blood is a promising approach for rapid diagnosis 
of BSI, permitting an earlier start of pathogen specific therapy. This is important, as it has 
been described that the use of inappropriate antimicrobial therapy can result in increased 
mortality [10, 39]. In addition, misuse and incorrect administration of antibiotics have led to the 
development of resistant bacterial strains, and this results in adverse patient outcome [40]. 
In order to reach similar sensitivities as blood cultures, several pathogen DNA enrichment 
strategies were evaluated (Chapter 7). Spiking experiments, using S. aureus, Pseudomonas 
aeruginosa, and Candida albicans, indicated that both Polaris and MolYsis enrichment 
followed by DNA isolation and species-specific singleplex real-time PCRs enabled reliable 
and sensitive detection of bacteria and fungi from 5 ml blood. Because the EasyMAG can 
only process 200 µl whole blood, the detection rates with this method were not satisfactory. 
Polaris was most sensitive (highest detection rates, 100% for all samples containing 10 CFU/
ml) and results were available within 3 hours.
In our study, both the MolYsis and the Polaris method removed sufficient human background 
DNA. No interference with the specific pathogen PCRs was detected. It has been shown by 
others that selective lysis of blood cells and the subsequent (non)-enzymatic degradation of 
released human DNA ensures a more sensitive detection of pathogen DNA [41, 42]. Handschur 
et al, showed, using total DNA extracts from whole blood, unspecific signals occurred in 
general 16S rDNA PCRs as a result of the amplification of human sequences [41]. Therefore, 
they developed an enrichment method for the analysis of blood samples. Clinical samples 
(whole blood) showed similar results as compared to standard blood culture methods. The 
enrichment method allowed specific and sensitive detection of pathogens in PCR assays. 
Hansen et al. have shown that the combination of performing an enrichment step and using 
larger sample volumes increased the detection limit from spiked whole blood to 50 CFU per 
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ml [42]. Our results are also very promising and showed that large volumes of whole blood 
need to be processed to ensure optimal detection rates. The pathogen enrichment strategies 
and DNA isolation procedures need to be further developed, integrated and automated to 
circumvent contamination risks and to decrease turnaround time. Furthermore, the pathogen 
enrichment strategies need to be investigated in well-defi ned clinical specimens with often 
low bacterial loads. Species-specifi c singleplex PCRs are not very useful for molecular 
diagnostics of BSI from whole blood, as BSI can be caused by a broad scala of pathogens. 
Clinical studies need to be conducted in which pathogen enrichment strategies are combined 
with broad-range (i.e. SepsiTest, Molzym) or multiplex PCRs (i.e MagicPlex Sepsis Test, 
Seegene) permitting an earlier administration of appropriate therapy. Nevertheless, it was 
demonstrated that sensitive pathogen detection and identifi cation from whole blood was 
possible within three hours.
DNA-based BSI diagnostics
The use of PCR assays for detection and identifi cation of pathogens causing BSI from whole 
blood, offers the fastest alternative as compared to blood cultures. Results can be available 
within a few hours as opposed to a few days. Moreover, it has been shown by others that 
prior antibiotic treatment does not negatively affect the performance of the PCR [43-45]. It 
has been reported that it is possible to decrease mortality with adequate treatment if sepsis 
is recognized in an early stage [46, 47].
In Chapter 8, one aspect was to investigate the ability of various biomarkers (C-reactive 
protein (CRP), procalcitonin (PCT), soluble urokinase plasminogen activator receptor 
(suPAR), and neutrophil-lymphocyte count ratio (NLCR)) to predict BSI. PCT, suPAR and 
NLCR were capable of differentiating patients with bacteremia from patients without in an 
emergency care unit (ECU). The discriminative power of PCT is in accordance with other 
reports which show that PCT is a more specifi c marker for BSI as compared to CRP [48-
50]. However, as PCT is an expensive biomarker, pre-screening of SIRS patients using 
PCT might be less cost-effective. Increased serum levels of suPAR positively correlate 
with the activation level of the immune system. However, suPAR levels are increased in 
relation to several conditions besides BSI [51, 52], i.e. cancer [53], HIV [54], malaria [55, 56], 
tuberculosis [57, 58], arthritis [59, 60], and even liver fi brosis [61]. suPAR is a non-specifi c 
marker of infl ammation, but higher suPAR levels are associated with increased mortality 
[62]. Although suPAR levels can be measured within 30 minutes, it is still an expensive 
and unspecifi c marker for BSI, rendering it unsuitable for pre-screening of suspected BSI 
patients. NLCR can be readily available when patients with SIRS present at the emergency 
department. De Jager et al. have described the NLCR in relation to predicting bacteremia at 
the emergency department [63]. NLCR was reported to have a higher prognostic accuracy 
as compared to other biomarkers. In our study, prediction of community-acquired bacteremia 
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using a NLCR cut-off ≥10 resulted in a sensitivity and negative predictive value of 85% and 
94%, respectively. NLCR is a cheap and easy to determine biomarker making it the most 
promising for future studies.
Also, the performance of two different commercially available molecular assays was 
examined and compared to blood culture results (Chapter 8). One ml residual whole blood 
of patients with suspected community-acquired BSI from the ECU was collected and used for 
selective pathogen DNA isolation with MolYsis (Molzym). DNA was analysed with SepsiTest 
(Molzym) and MagicPlex Sepsis Test (Seegene). When compared to blood culture results 
the performance of both tests was very poor (sensitivity, specificity, positive predictive value 
(PPV), and negative predictive value (NPV) for SepsiTest and MagicPlex Sepsis Test were 
11%, 96%, 43%, 80%, and 37%, 77%, 30%, 82%, respectively). This poor performance might 
be due to several causes. Pathogen DNA should be obtained from larger volumes of whole 
blood, 5-10 ml, as we have shown that detection rates are higher as compared to using only 1 
ml whole blood. This indicates that only prospective studies can be performed, because this 
required whole blood volume is not left after performing standard diagnostic tests. To enable 
optimal detection rates, it might be necessary, besides the use of larger blood volumes, to use 
the entire DNA sample (eluate) in PCR analysis. Furthermore, the performance of molecular 
assays should be studied in different well-defined patient populations. Most studies focus 
on the performance of molecular assays in critically ill patients from the ICU or even mixed 
patient populations in which better performances of molecular diagnostics have been found 
[44, 64-68]. Avolio et al. investigated 144 blood samples from patients presenting at the 
ECU with suspected sepsis [69]. In total 53 samples out of 144 (37%) were positive by blood 
cultures or SeptiFAST PCR. In 30/53 positive cases (56.6%) both methods identified the 
same organisms. However, in 13/53 cases (24.5%) blood cultures identified pathogens not 
detected by PCR, and in 10 cases (18.9%) SeptiFAST PCR gave positive results, whereas the 
blood cultures remained negative. Tsalik et al. also evaluated SeptiFAST PCR in 263 patient 
from the emergency department, and compared results to blood cultures. PCR identified an 
additional 24 organisms that blood culture failed to detect [70]. These results also support our 
findings and confirm that future studies are still a necessity to find explanations for discrepant 
results between blood cultures and PCR. Molecular diagnostics on whole blood facilitates 
the detection and identification of the etiologic agent of BSI within a few hours. Despite the 
discrepancies between blood cultures and PCR results, the first steps towards molecular 
pathogen diagnostics have been undertaken. Currently, blood cultures are still needed, but 
PCR allows more rapid initiation of pathogen-tailored antimicrobial therapy in patients.
Role of RNA detection in BSI diagnostics
Bacteremia is defined as the presence of viable bacteria in the bloodstream [71]. Detection of 
DNA by PCR does not provide information about the viability status of a pathogen as the DNA 
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can originate from either living or dead pathogens [72-75]. Therefore, we attempted to fi nd a 
marker that enabled us to measure S. aureus viability to be able to improve BSI diagnostics 
(Chapter 9). Our results clearly demonstrated that detection of S. aureus tuf mRNA correlated 
best with bacterial viability status (after antibiotic treatment) as determined by culture, while 
DNA (tuf and 16S rDNA) and rRNA (16S rRNA) detection could not be used to confi rm viability.
Cenciarini et al. showed that RNA targets differ greatly between bacterial species and different 
physiological conditions [76]. Future studies should attempt to fi nd a panel of mRNA markers, 
which can be used to sensitively detect the most important BSI pathogens from whole blood, 
and indicate viability status at the same time. Additional (clinical) studies are required to 
confi rm our preliminary fi ndings.
10.3 Conclusions and future perspectives
All evaluated improvements for the laboratory diagnosis of BSI are displayed in bold black 
boxes in Figure 2. In summary, the results presented in this thesis clearly show the potential 
of both MALDI-TOF MS and PCR based methods for improved detection and identifi cation, 
of pathogens causing BSI, from both blood cultures and subcultures (upper part in Figure 2). 
Implementation of these methods potentially reduce time-to-results, offer high sensitivity and 
specifi city, and can improve the laboratory process for BSI, as previously discussed.
Figure 2. Overview of the evaluated improvements for the laboratory diagnosis of BSI.
The bold black boxes represent the new approaches to decrease time-to-results for pathogen 
detection and identifi cation from colonies (subculture), positive blood cultures and whole blood.
SIRS; systemic infl ammatory response syndrome, NLCR; neutrophil-lymphocyte count ratio, 
MALDI-TOF MS; matrix assisted laser desorption/ionisation- time of fl ight mass spectrometry, PCR; 
polymerase chain reaction, AST; antibiotic susceptibility testing.
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Direct pathogen detection and identification from whole blood is the only approach which 
currently enables time-to-results within a few hours (lower part in Figure 2). It has been 
shown that pathogen enrichment from 5 ml whole blood results in a better detection rate as 
compared to 1 ml. Furthermore, BSI is caused by a broad scala of pathogens and the most 
frequently detected and most clinically relevant pathogens should be included in molecular 
assays. At present, AST is mainly determined by growth inhibition on solid media and this is 
very time-consuming as culture steps are still required. Future diagnostic assays should be 
able to process at least 5-10 ml whole blood to ensure optimal detection rates. The amount 
of pathogens that can be identified should be extended, and complete antibiotic resistance 
screening should be included. Furthermore, our results seem to indicate that future assays 
should be able to screen for the presence of certain mRNA targets as these molecules seem 
to be better indicators for viable pathogens rather than the presence of DNA or rRNA, which 
will reflect dead pathogens as well. These different aspects should, ideally, be incorporated 
in one rapid and simple point of care diagnostic test which allows both pathogen DNA/RNA 
detection and AST, and is characterized by a “sample in, results out” principle. Results 
should be available as soon as possible and no special technical skills should be required. 
Currently, no commercially available molecular sepsis test for whole blood combines 
pathogen enrichment for large volumes of whole blood with rapid pathogen detection and 
identification. Seegene’s MagicPlex Sepsis Test, when combined with MolYsis pathogen 
enrichment, approaches this ideal scenario the closest, but still takes approximately six 
hours and does not provide complete identification of the pathogens. To be able to create this 
future diagnostic assay, pathogen DNA enrichment and isolation should first be improved by 
reducing turnaround time. The commercially available MolYsis pathogen enrichment method 
takes at least two hours, depending on the number of samples to be processed. Pathogen 
enrichment combined with DNA isolation needs to be fully automated to reduce hands-on-
time and contamination risks. Polaris (Biocartis) is currently being automated in a closed 
disposable cartridge. When available, this Polaris cartridge needs to be evaluated for 10 ml 
whole blood, also in a clinical setting.
It will be difficult to incorporate complete AST in one assay, because antibiotic resistance is 
the result of a large number of genes and complex regulatory mechanisms. Microarray based 
assays have been developed to study the presence of large panels of antibiotic resistance 
genes [77, 78]. However, microarray based tests often require special laboratory equipment 
and highly skilled personnel. Real-time PCR can be employed to detect clinically relevant 
antibiotic resistance genes from clinical samples (e.g. whole blood). Several commercially 
available sepsis test already offer detection of a small panel of antibiotic resistance genes 
(i.e. VYOO (SIRS-Lab), MagicPlex Sepsis Test (Seegene)). However, these available panels 
should be extended when more antibiotic resistance markers and virulence factors become 
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available. Diagnostic tests that provide a complete antimicrobial susceptibility profi le from 
whole blood are needed to be able to quickly initiate pathogen-specifi c antibiotic therapy.
New developments are being introduced that might be a starting point for rapid pathogen 
identifi cation and AST at the same time. An example is the next generation sequencing 
technology. Salipante et al. already demonstrated that next generation sequencing can be 
used to identify bacterial species in heterogeneous clinical specimens [79]. They used deep 
sequencing for a collection of sputum samples from cystic fi brosis patients and detected 
pathogens in specimens that were not positive by standard clinical culture methods, especially 
when fastidious bacteria were involved. Next generation sequencing technologies will, most 
likely, soon be able to provide high-resolution genotyping and will eventually be implemented 
in the fi eld of clinical microbiology.
The current trends in molecular diagnostics for infectious diseases are moving towards 
automated, high-throughput technologies, such as next generation sequencing, and will 
provide an enormous amount of data. Bioinformaticians and/or company developed software 
packages are needed to guide us through these gigantic datasets.
As a result of the improvements presented in this thesis a signifi cant reduction in turnaround 
time can be achieved for the laboratory diagnosis of BSI. Molecular diagnostic tests on large 
volumes of whole blood of BSI patients will, when optimised, improve patient care and reduce 
morbidity and mortality rates. However, future prospective studies are still required to prove 
our fi ndings and determine if the whole blood approach is cost-effective. Whether either 
sensitive multiplex PCR assays or next generation sequencing, with pathogen enrichment, 
will be the basis for a simple point of care test in which rapid pathogen identifi cation and AST 
from large volumes of whole blood can be combined, remains to be seen in the future.
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Het aantal patiënten met een bloedbaaninfectie (BBI) neemt nog steeds toe. BBIs kenmerken 
zich door hoge mortaliteit en toenemende zorgkosten. Optimale behandeling van een BBI 
is afhankelijk van een aantal factoren, zoals het herkennen van de BBI, het uitvoeren van 
laboratoriumtesten en het initiëren van een correcte (pathogeen specifieke) behandeling. 
Om een patiënt met een pathogeen specifiek antibioticum te kunnen behandelen, is het van 
belang het micro-organisme (pathogeen) welke de BBI veroorzaakt snel te detecteren en 
te identificeren. Wanneer een BBI tot een septische shock leidt, is tijd van cruciaal belang. 
Als bij een ernstige sepsis niet binnen het uur snel en adequaat behandeld wordt, daalt 
de overlevingskans van een patiënt van 80% naar minder dan 10%, wanneer adequate 
behandeling pas wordt gestart na 24 uur. Tevens zal het toedienen van een pathogeen 
specifiek antibioticum het ontstaan van resistente stammen afremmen.
De “gouden standaard” voor detectie en identificatie van pathogenen die BBI veroorzaken 
bestaat nog steeds uit kweekmethoden. Wanneer bloedkweken positief worden bevonden 
door het geautomatiseerde kweeksysteem, zal vervolgens een Gramkleuring worden 
uitgevoerd. Dit wordt dan gevolgd door het inzetten van een subkweek op verschillende 
voedingsbodems. De kolonies die ontstaan op de voedingsbodems, kunnen worden gebruikt 
voor (geautomatiseerde) biochemische testen. De resultaten van die biochemische testen 
zorgen in de meeste gevallen voor pathogeen identificatie. Tot slot zullen ook antibiotica 
gevoeligheidstesten worden ingezet, waarna de patiënt van breedspectrum antibiotica op 
een pathogeen specifieke behandeling kan worden overgezet (Figuur 1).
Figuur 1. Het conventionele diagnostiek proces voor bloedbaaninfecties.
Wanneer bloedkweken positief worden bevonden door het geautomatiseerde kweeksysteem, zal een 
Gramkleuring worden uitgevoerd. Vervolgens zal er een subkweek worden ingezet op verschillende 
voedingsbodems, waarna (geautomatiseerde) biochemische testen worden ingezet voor pathogeen 
identificatie. Een volledige antibiotica gevoeligheidsbepaling bestaat vaak uit het onderzoeken van 
de mate van remming, op de groei van bacteriën in aanwezigheid van verschillende antibiotica. AGB; 
antibiotica gevoeligheidsbepaling.
Dit conventionele proces neemt vaak minimaal een paar dagen in beslag. Daarnaast is bekend 
dat bloedkweken, die micro-organismen met complexe voedingseisen, of micro-organismen 
welke langzaam groeien en/of bloed van patiënten bevatten die al antibioticum behandeling 
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ondergaan, vals negatief kunnen blijven. Het belangrijkste doel van dit onderzoek was het 
bestuderen van verschillende strategieën, om zo het bestaande laboratoriumproces voor een 
BBI te verbeteren (Figuur 1). Deze strategieën omvatten eiwit gebaseerde methoden, zoals 
MALDI-TOF massa spectrometrie, maar ook methoden voor het aantonen van nucleïnezuren 
(DNA/RNA), zoals de polymerase ketting reactie (PCR). Deze technologieën zijn toegepast 
op subkweken (kolonies op een voedingsbodem), maar ook op (positieve) bloedkweken en 
volbloed (direct uit de patiënt), om zo de tijd tot resultaten te verkorten. Daarnaast is ook 
aandacht besteedt aan monstervoorbereiding voor de verschillende klinische materialen.
11.1 BBI diagnostiek uit bloedkweken en subkweken
Polymerase ketting reactie (PCR)
Grampositieve bacteriën (bijvoorbeeld Stafylococcus aureus, coagulase-negatieve 
stafylococcen (CoNS) en Enterococcus spp.), worden vaak aangetoond in bloedkweken. 
We hebben daarom 2 real-time PCR duplex testen ontwikkeld voor detectie van S. aureus, 
CoNS en Enterococcus spp. Deze testen zijn klinisch geëvalueerd door gebruik te maken 
van: 1) positieve bloedkweken met Grampositieve kokken en 2) 1 ml restant volbloed van 
intensive care unit (ICU) patiënten met een BBI verdenking (Hoofdstuk 2). De duplex 
testen, gebaseerd op het tuf gen, maakten het mogelijk om snel en accuraat pathogenen te 
identifi ceren vanuit positieve bloedkweken. In een kleine studie waarin 1 ml restbloed werd 
gebruikt van ICU patiënten met een BBI verdenking, werden de ontwikkelde PCR testen 
gecombineerd met een gevoelige bacterieel DNA isolatie methode. In 18/22 patiënten (82%) 
werden identieke resultaten verkregen tussen bloedkweek en PCR.
Tegelijkertijd hebben we onderzocht of het mogelijk was om pathogenen te identifi ceren uit 
bloedkweken, die nog niet positief waren bevonden door het automatische kweeksysteem 
(Hoofdstuk 3). Zes verschillende pathogeen DNA isolatiemethoden voor bloedkweekmateriaal 
werden vergeleken, om zo de beste methode te vinden voor DNA isolatie uit bloedkweken. 
De beste methode werd gebruikt om pathogeen DNA te isoleren uit bloedkweek fl essen, 
welke maar enkele uren in het kweeksysteem hadden gestaan. Op dit geïsoleerde DNA werd 
de ontwikkelde PCR ingezet. De MolYsis Plus methode (Molzym GmbH, Bremen, Duitsland) 
gecombineerd met het specifi ek B programma op de EasyMAG resulteerde in de beste 
isolatie van bacterieel DNA uit BacT/ALERT bloedkweek fl essen (bioMérieux, Marcy L’Etoile, 
Frankrijk). Reconstructie experimenten met S. aureus resulteerde in een detectielimiet van 
10 kolonie vormende eenheden (CFU)/ml volbloed met de ontwikkelde tuf gebaseerde PCR. 
BACTEC (BD) bloedkweek fl essen resulteerde in een 1 log lagere detectielimiet. Na een 
incubatiestap van de BacT/ALERT bloedkweek fl essen van 5 uur, konden zowel S. aureus 
als CoNS worden aangetoond, dit door gebruik te maken van de real-time PCR testen. 
Loonen.indd   165 30-10-2013   8:15:53
166  |  Chapter 11
Door deze verkorte incubatiestap toe te passen, konden S. aureus en CoNS in 1 werkdag 
geïdentificeerd worden. In vergelijking met het conventionele diagnostiek proces, waren de 
resultaten 19 uur eerder beschikbaar. Gebert et al. hebben vergelijkbare resultaten laten 
zien. Zij hebben ook reconstructie experimenten uitgevoerd en een reductie van 5.0-8.7 
uur bereikt, echter, in klinische monsters lieten ze zelfs een gemiddelde reductie in tijd tot 
pathogeen identificatie van 10.7 uur zien. Laboratoria die 24-uur per dag actief zijn zouden 
de meeste winst kunnen behalen met deze strategie. Meer onderzoek is nodig, om vast te 
stellen welke incubatietijd geschikt is voor de meest voorkomende pathogenen. De tuf real-
time PCR is enkel inzetbaar voor patiënten met een verdenking op een BBI veroorzaakt door 
Stafylococcus spp. of Enterococcus spp. BBIs kunnen echter veroorzaakt worden door een 
breed scala aan pathogenen en dit maakt soortspecifieke PCRs minder waardevol, wanneer 
er een optimale tijd tot resultaten nodig is. De ontwikkelde real-time PCR kan aangepast 
worden, zodat de meest voorkomende BBI pathogenen aangetoond kunnen worden uit 
bloedkweken. Deze flexibiliteit zorgt ervoor, dat de test aangepast kan worden aan de 
lokale epidemiologie, of een specifieke patiëntengroep. Toekomstige studies zouden ook 
gebruik kunnen maken van de multi-probe test, zoals beschreven door Hansen et al., of de 
commercieel verkrijgbare Prove-it Sepsis test (MobiDiag, Helsinki, Finland). Deze testen zijn 
echter ontwikkeld voor pathogeen identificatie uit positieve bloedkweken. Het zal moeten 
blijken of deze testen gevoelig genoeg zijn, om gebruikt te kunnen worden op bloedkweken, 
die nog niet positief zijn bevonden door het automatische kweeksysteem.
MALDI-TOF MS
Infecties door Grampositieve bacteriën kenmerken zich door hoge morbiditeit en mortaliteit. 
Een Amerikaanse studie heeft aangetoond, dat in patiënten met een BBI vaak Grampositieve 
bacteriën worden gevonden. De meest geïsoleerde groep van pathogenen uit bloedkweken 
waren CoNS (31%). CoNS komen voor op de huid en de slijmvliezen van de mens. Ze zijn 
lange tijd beschouwd als bron van besmetting van bloedkweken, maar omdat ze steeds meer 
worden gekweekt hebben de CoNS meer aandacht gekregen en wordt hun rol als pathogeen 
beter onderzocht. Snelle en betrouwbare determinatie van CoNS op species niveau zou 
daarom klinisch relevant kunnen zijn. Fenotypische methoden (biochemische testen) volgens 
Kloos en Schleifer zijn lange tijd de gouden standaard geweest voor identificatie van CoNS 
op species niveau. De API 32 Staph strip (bioMérieux) en de geautomatiseerde VITEK 2 
(bioMérieux) hebben de fenotypische manier van identificeren verbeterd. Een aantal genen, 
zoals 16S rRNA, sodA en tuf, zijn geschikt voor genotypische identificatie van CoNS. Analyse 
van eiwitprofielen van micro-organismen is mogelijk met Matrix Assisted Laser Desorption 
Ionisation-Time, of Flight massa spectrometrie (MALDI-TOF MS). Deze nieuwe techniek is 
geschikt om snel en accuraat micro-organismen te identificeren. We hebben 5 methoden 
vergeleken op dezelfde CoNS stammen, om zo de beste methode te vinden voor CoNS 
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identifi catie: 1) VITEK 2, 2) ID 32 Staph strip, 3) 16S rDNA gen sequencing (MicroSeq, Applied 
Biosystems), 4) tuf gen sequencing en 5) MALDI-TOF MS (Bruker Daltonics) (Hoofdstuk 4). 
De verkregen resultaten toonden aan, dat MALDI-TOF MS de beste methode was voor 
CoNS species identifi catie, 99.3% van de CoNS stammen werden correct geïdentifi ceerd. 
Sequensen van het tuf gen is het meest geschikte alternatief. Heikens et al. hebben ook 
aangetoond, dat tuf gen sequencing een goede manier is, om CoNS te identifi ceren (5/57 
correct geïdentifi ceerd). Wanneer snelle en accurate identifi catie van CoNS nodig is, blijkt 
MALDI-TOF MS de meest geschikte methode. Dit is ook door anderen aangetoond.
Het blijft een uitdaging in de dagelijkse praktijk, om klinisch relevante CoNS te onderscheiden 
van CoNS stammen die de bloedkweek fl es hebben besmet. De meest optimale methode 
voor CoNS identifi catie was MALDI-TOF MS. Deze technologie werd ingezet om de 
klinische relevantie van het identifi ceren van CoNS op species niveau in kaart te brengen 
(Hoofdstuk 5). De meeste CoNS infecties zijn het gevolg van het gebruik van medische 
hulpmiddelen, zoals protheses en (intraveneuze) catheters. S. lugdunensis en S. schleiferi 
worden echter ook gevonden als veroorzaker van BBI en endocarditis en S. saprofyticus als 
veroorzaker van urineweginfecties. We hebben aangetoond, dat identifi catie van CoNS op 
species niveau kan bijdragen aan het vaststellen, of een patiënt daadwerkelijk lijdt aan een 
CoNS BBI. De CoNS species die het meest gevonden werd bij BBIs was S. epidermidis, 
maar deze CoNS soort was tevens ook de meest gevonden bloedkweekfl es besmetting. 
Daarnaast hebben we aangetoond, dat S. haemolyticus het meest geassocieerd werd met 
BBI en de meeste andere CoNS soorten toch vaak als besmetting van de kweekfl es konden 
worden bestempeld. Dit betekent dat CoNS identifi catie van klinisch belang kan zijn, om 
zo een pathogeen van potentiële besmetting te kunnen onderscheiden. CoNS identifi catie 
gecombineerd met het medisch inzicht van de arts-microbioloog, zou kunnen leiden tot een 
optimalere patiëntenzorg. Moleculaire diagnostische testen zouden alle klinisch relevante 
CoNS soorten moeten kunnen detecteren. Vervolgstudies zijn nodig om onze bevindingen 
te staven.
Snellere identifi catie van micro-organismen direct uit positieve bloedkweken, kan grote 
impact hebben in de kliniek. Om die reden hebben we onderzocht, of het mogelijk was om 
bacteriën direct te identifi ceren uit positieve aerobe BacT/ALERT bloedkweken met behulp 
van MALDI-TOF MS. Daarnaast is geëvalueerd of verkorte incubatie (7 uur) van S. aureus en 
Escherchia coli bevattende BacT/ALERT bloedkweekfl essen, gecombineerd met identifi catie 
door middel van MALDI-TOF MS, mogelijk was (Hoofdstuk 6). Wanneer bloedkweken 
worden gebruikt als startmateriaal voor MALDI-TOF MS zullen de humane cellen moeten 
worden verwijderd, om storing van humane eiwitten in de analyse te voorkomen. Daarom 
zijn verschillende methoden geanalyseerd en is onderzocht welke methode het meest 
geschikt is voor het verwijderen van deze aspecifi eke eiwitten. Uit de resultaten bleek dat 
bacteriële identifi catie mogelijk is binnen 20 minuten uit positieve bloedkweken, wanneer er 
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gebruik wordt gemaakt van SepsiTyper (Bruker Daltonics). Dit is natuurlijk ook afhankelijk 
van de te verwerken hoeveelheid bloedkweken. Het conventionele diagnostiekproces 
neemt ongeveer 1-2 dagen in beslag. In de reconstructie experimenten heeft verkorte 
incubatie (7 uur) van aerobe S. aureus, of E. coli bevattende BacT/ALERT bloedkweken 
geen betrouwbare identificatie opgeleverd. Een alternatief, voor het gebruik van positieve 
bloedkweken in combinatie met MALDI-TOF MS pathogeen identificatie, is het gebruiken 
van spot-subkweken op voedingsbodems. Deze spot-subkweek bestaat uit het kweken van 
positief bloedkweek materiaal gedurende ongeveer 4 uur op een voedingsbodem. Over het 
algemeen zijn er na 4 uur genoeg micro-organismen op de voedingsbodem aanwezig, welke 
gebruikt kunnen worden voor MALDI-TOF MS. Bloedkweken die ’s ochtends positief worden, 
zouden via deze spot-subkweek geanalyseerd kunnen worden en bloedkweken die later op 
de werkdag positief worden kunnen direct worden gebruikt (m.b.v. SepsiTyper). Szabados et 
al. beschreef een lage sensitiviteit (30%) wanneer positieve BacT/ALERT bloedkweek flessen 
werden gebruikt voor MALDI. Anderen toonden aan dat MALDI-TOF MS zeer geschikt is voor 
pathogeen identificatie uit positieve bloedkweken, zowel BacT/ALERT als BACTEC flessen.
MALDI-TOF MS kan zorgen voor een snellere tijd tot identificatie, maar de hoeveelheid 
pathogenen aanwezig in de bloedkweekfles zijn daarbij van cruciaal belang. Er moeten 
minimaal 107-108 CFU/ml aanwezig zijn, om een goed eiwitprofiel te verkrijgen. Dit betekent 
dat kweekstappen nog noodzakelijk zijn om resultaten te kunnen genereren. Het is tevens 
nog niet mogelijk om MALDI-TOF MS te gebruiken voor antibiotica gevoeligheidsbepalingen 
(AGB). De eerste stappen richting AGB met MALDI-TOF MS zijn gezet, maar het is nog niet 
mogelijk een compleet antibiogram te verkrijgen.
11.2 BBI diagnostiek direct uit volbloed
Monstervoorbereiding
Pathogeen detectie en identificatie direct uit volbloed is de enige manier om kweekstappen 
te omzeilen. Monstervoorbereiding is dan van cruciaal belang om humane cellen en DNA te 
kunnen verwijderen, en tegelijkertijd pathogenen te verrijken, om zo de kleine hoeveelheid 
bacteriën aan te kunnen tonen.
Detectie van pathogeen DNA uit volbloed is een veelbelovende strategie, om snel een BBI 
te kunnen diagnosticeren en dus snel pathogeen specifieke therapie te kunnen starten. Dit is 
heel belangrijk omdat bekend is, dat het gebruik van een onjuist antibioticum kan resulteren 
in toenemende mortaliteit. Daarnaast is beschreven dat gebruik van een inadequaat 
antibioticum en fout gebruik van een antibioticum, leiden tot de ontwikkeling van resistente 
stammen, wat weer schadelijk is voor de patiënt. Om gelijkwaardige gevoeligheden te bereiken 
als met de bloedkweken zijn verschillende pathogeen DNA verrijkingmethoden onderzocht 
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(Hoofdstuk 7). Reconstructie-experimenten met S. aureus, Pseudomonas aeruginosa en 
Candida albicans hebben aangetoond, dat pathogeen verrijking en DNA isolatie uit 5 ml 
volbloed, met zowel Polaris (Biocartis) als MolYsis (Molzym), gevolgd door soortspecifi eke 
real-time PCRs betrouwbare en gevoelige detectie tot gevolg had. De EasyMAG kan maar 
200 µl volbloed verwerken en daarom waren de detectiepercentages met deze methode 
teleurstellend. Polaris was de meest gevoelige methode (hoogste detectiepercentages, 
100% score voor de monsters met 10 CFU/ml). Resultaten waren binnen 3 uur beschikbaar.
In onze studie hebben we laten zien, dat zowel Polaris, als MolYsis voldoende humane 
achtergrond verwijderde. Er is geen storing geobserveerd in de soortspecifi eke PCRs. 
Anderen hebben ook laten zien, dat de selectieve lysis van bloedcellen en (niet)-enzymatische 
degradatie van humaan DNA een meer betrouwbare detectie van pathogeen DNA tot gevolg 
heeft. Handschur et al. toonden in een 16S rDNA PCR, dat wanneer ze gebruik maakten van 
DNA monsters waar de humane achtergrond niet was verwijderd, ze veel aspecifi eke signalen 
oppikten door de aanwezigheid van humaan DNA. Daarom hebben ze een verrijkingsmethode 
ontwikkeld voor de analyse van bloedmonsters. Klinische monsters (volbloed) lieten 
vergelijkbare resultaten zien, wanneer ze die vergeleken met de bloedkweek uitslagen. De 
ontwikkelde verrijkingsmethode zorgde voor specifi eke en gevoelige detectie van pathogenen 
in PCR testen. Hansen et al. hebben aangetoond, dat een betere detectielimiet (50 CFU/
ml) kan worden verkregen, wanneer een verrijkingsmethode en het gebruik van grotere 
volumes volbloed werden gecombineerd. De resultaten van onze studie zijn veelbelovend 
en hebben duidelijk laten zien, dat grote volumes volbloed moeten worden gebruikt om 
goede detectiepercentages te bewerkstelligen. De pathogeen verrijkingsmethoden en DNA 
isolatie procedures moeten verder worden ontwikkeld, geïntegreerd en geautomatiseerd, 
dit om sneller resultaat te verkrijgen en besmettingsrisico’s te verlagen. Daarnaast moeten 
deze methoden worden onderzocht in goed gedefi nieerde klinische monsters, waar vaak 
lage hoeveelheden pathogenen aanwezig zijn. Soortspecifi eke PCRs zijn niet nuttig voor 
moleculaire diagnostiek van BBIs uit volbloed, omdat BBIs kunnen worden veroorzaakt door 
vele verschillende micro-organismen. Er moeten klinische studies worden uitgevoerd waarin 
pathogeen verrijkingsmethoden worden gecombineerd met breed dekkende (SepsiTest, 
Molzym), of multiplex PCRs (MagicPlex Sepsis Test, Seegene). Enkel op die manier kan er 
sneller doelgericht behandeld worden. Niettemin zijn we momenteel in staat, om binnen drie 
uur pathogenen te detecteren en identifi ceren uit volbloed.
DNA gebaseerde diagnostiek voor BBI
In vergelijking met bloedkweken bieden PCR testen voor detectie en identifi catie van BBI 
veroorzakende pathogenen het snelste alternatief. Resultaten kunnen binnen enkele uren 
beschikbaar zijn, in plaats van na een paar dagen. Bovendien beïnvloed voorafgaand 
antibioticum gebruik de PCR niet. Men heeft aangetoond dat het mogelijk is, om mortaliteit 
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te verlagen met adequate antibioticum therapie, wanneer sepsis snel wordt herkend. In 
Hoofdstuk 8 is onderzocht, of er een biomarker (C-reactive protein (CRP), procalcitonine 
(PCT), soluble urokinase plasminogen activator receptor (suPAR) en neutrofiel-lymfocyt 
count ratio (NLCR)) in staat is BBI te voorspellen in patiënten, die behandeld worden op 
de eerste hulp. PCT, suPAR en NLCR kunnen allen ingezet worden om patiënten met en 
zonder bacteriëmie te onderscheiden. Het onderscheidende vermogen van PCT komt 
overeen met de literatuur, waarin ook bevestigd wordt dat PCT een specifiekere biomarker 
is voor BBI dan CRP. PCT is echter wel een dure biomarker bepaling en pre-screening 
van SIRS patiënten met PCT, zou daarom minder kosteneffectief kunnen zijn. Hoge serum 
waarden van suPAR correleren met verschillende aandoeningen naast BBI, bijvoorbeeld 
kanker, HIV, malaria, tuberculose, artritis en zelfs leverfibrose. suPAR is een aspecifieke 
marker voor ontsteking, maar hoge suPAR waarden zijn geassocieerd met hogere kans op 
overlijden. suPAR waarden kunnen binnen 30 minuten beschikbaar zijn, maar omdat het een 
dure en aspecifieke marker voor BBI is, is deze biomarker ongeschikt voor pre-screening 
van BBI verdachte patiënten. NLCR is snel beschikbaar nadat patiënten zich melden bij 
de eerste hulp (met SIRS symptomen en infectie verdenking). De Jager et al. hebben 
onderzoek gedaan naar NLCR in relatie tot het voorspellen van bacteriëmie op de eerste 
hulp en deze biomarker kwam als beste uit de studie. Onze studie heeft aangetoond dat 
het voorspellen van bacteriëmie, met NLCR waarden ≥ 10, resulteert in een sensitiviteit en 
negatief voorspellende waarde van respectievelijk 85% en 94%. NLCR is een goedkope en 
simpel te bepalen biomarker en daarom het meest geschikt voor vervolg studies.
Ook zijn twee verschillende commercieel verkrijgbare moleculaire testen geëvalueerd, en 
de resultaten zijn vergeleken met bloedkweek uitslagen van dezelfde patiënt (Hoofdstuk 8). 
Eén ml restant volbloed van eerste hulp patiënten met een BBI verdenking is verzameld 
en gebruikt voor selectieve pathogeen DNA isolatie met MolYsis (Molzym). Het verkregen 
DNA werd geanalyseerd met SepsiTest (Molzym) en MagicPlex Sepsis Test (Seegene). De 
resultaten werden vergeleken met de uitslagen van de bloedkweken en waren teleurstellend 
(sensitiviteit, specificiteit, positief voorspellende waarde en negatief voorspellende waarde 
voor SepsiTest en MagicPlex Sepsis Test waren respectievelijk 11%, 96%, 43%, 80% en 
37%, 77%, 30%, 82%). Er zijn verschillende verklaringen voor deze resultaten. Pathogeen 
DNA zou moeten worden geïsoleerd uit grotere volumes volbloed, namelijk 5-10 ml. We 
hebben eerder laten zien dat detectiepercentages hoger zijn, wanneer meer dan 1 ml bloed 
wordt gebruikt. Dit betekent dat enkel prospectieve studies kunnen worden uitgevoerd, 
omdat er niet voldoende restbloed over is na het uitvoeren van standaard diagnostiek testen. 
Om optimale detectiepercentages te kunnen garanderen, zou naast het gebruik van een 
hoger volume bloed, ook het volledige DNA monster gebruikt moeten worden voor PCR 
analyse. Bovendien moeten de prestaties van moleculaire testen bestudeerd worden in 
verschillende goed gedefinieerde patiëntengroepen. De meeste studies onderzoeken de 
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mogelijkheden van moleculaire testen in de meest kritisch zieke patiënten, bijvoorbeeld 
van de ICU en soms wordt zelfs een mix van patiëntengroepen gebruikt. In die studies, 
presteren de moleculaire testen vaak wel goed. Avolio et al. heeft 144 bloedmonsters van 
eerste hulp patiënten onderzocht en in totaal waren er 53 positief (37%) met bloedkweek 
en SeptiFAST (Roche). In 30/53 gevallen hebben de bloedkweken pathogenen opgeleverd, 
die niet met PCR aangetoond waren en in 10 gevallen leidde SeptiFAST PCR tot positieve 
resultaten, die niet bevestigd werden met kweek. Tsalik et al. heeft ook de SeptiFAST PCR 
geëvalueerd en gebruikte daarvoor bloedmonsters van 263 eerste hulp patiënten. Ook in 
deze studie werden de PCR resultaten vergeleken met bloedkweek uitslagen. PCR heeft 24 
extra positieve monsters opgeleverd, welke niet zijn opgepikt met bloedkweek. De resultaten 
van Avolio en Tsalik ondersteunen de gegevens uit ons onderzoek en bevestigen dat meer 
onderzoek nodig is, om een verklaring te kunnen geven voor de discrepanties tussen PCR 
en kweek. Moleculaire diagnostiek op volbloed faciliteert de detectie en identifi catie van 
het pathogeen welke de BBI veroorzaakt binnen enkele uren. Ondanks de discrepanties 
tussen PCR en bloedkweken kunnen we stellen, dat de eerste stappen naar moleculaire 
detectie van pathogenen gezet zijn. Momenteel blijven bloedkweken nog noodzakelijk, maar 
PCR zou ervoor kunnen zorgen, dat patiënten sneller pathogeen specifi eke antibioticum 
behandeling kunnen krijgen.
De rol van RNA detectie in BBI diagnostiek
Bacteriëmie is gedefi nieerd, als de aanwezigheid van levende bacteriën in de bloedbaan. 
Detectie van pathogeen DNA met behulp van PCR geeft echter geen informatie over de 
levensvatbaarheid van een pathogeen. Dit DNA kan namelijk afkomstig zijn van zowel 
dode, als levende pathogenen. We hebben daarom getracht een marker te vinden die ons 
in staat stelt om de levensvatbaarheid van S. aureus te meten, om zo de BBI diagnostiek 
te verbeteren (Hoofdstuk 9). Onze resultaten lieten duidelijk zien, dat de detectie van S. 
aureus tuf mRNA het best correleerde met de bacteriële levensvatbaarheid (na antibioticum 
behandeling), zoals gedemonstreerd met kweek. DNA (Tuf en 16S rDNA) en rRNA (16S 
rRNA) konden niet worden gebruikt, om de levensvatbaarheid te onderzoeken.
Cenciarini et al. hebben aangetoond, dat verscheidene RNA transcripten erg variëren tussen 
verschillende bacteriesoorten en fysiologische omstandigheden. Toekomstige studies 
zouden moeten trachten een mRNA panel samen te stellen welke gebruikt kan worden, 
om zo gevoelig mogelijk de meest belangrijke BBI pathogenen aan te tonen uit volbloed 
en daarnaast kan aantonen of de micro-organismen nog levensvatbaar zijn. Er zijn meer 
(klinische) studies nodig om onze voorlopige resultaten te bevestigen.
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11.3 Conclusies en toekomstvisies
Alle geëvalueerde methoden voor verbetering van het diagnostiekproces voor BBI zijn 
weergegeven in de dikke zwarte boxen in Figuur 2. Samenvattend, de gepresenteerde 
resultaten in dit proefschrift hebben duidelijk de potentie van zowel MALDI-TOF MS en 
PCR gebaseerde methoden laten zien. Beide strategieën leiden tot verbeterde detectie en 
identificatie van pathogenen, die BBIs veroorzaken uit zowel bloedkweken, als subkweken 
(bovenste deel Figuur 2). Implementatie van deze methoden kan leiden tot verkorte tijd tot 
resultaten, ze bieden hoge sensitiviteit en specificiteit. Tevens kunnen deze methoden het 
laboratoriumproces van BBI verbeteren.
Momenteel is directe detectie en identificatie van pathogenen uit volbloed de enige 
benadering, die het mogelijk maakt binnen een paar uur resultaten te genereren (onderste 
deel Figuur 2). Pathogeen verrijking uit 5 ml bloed resulteert in een beter detectiepercentage 
in vergelijking tot 1 ml bloed. Omdat BBIs het gevolg kunnen zijn van een breed scala aan 
pathogenen, zou een moleculaire test de meest voorkomende en de meest klinische relevante 
moeten kunnen aantonen. Momenteel wordt de AGB nog steeds uitgevoerd door middel van 
het meten van groeiremming op voedingsbodems. Aangezien hier kweekstappen voor nodig 
Figuur 2. Overzicht van de geëvalueerde stappen voor verbetering van de 
laboratoriumdiagnostiek voor bloedbaaninfecties.
De dikke zwarte boxen in het flowschema tonen de manieren, onderzocht in dit proefschrift, welke 
kunnen leiden tot snellere pathogeen detectie en identificatie vanuit subkweek (kolonies op een 
voedingsbodem), positieve bloedkweken en bloed. Afkortingen; SIRS; systemic inflammatory 
response syndrome (algehele ontstekingsreactie van het lichaam), NLCR; neutrophil-lymphocyte 
count ratio, MALDI-TOF MS; matrix assisted laser desorption/ionisation- time of flight mass 
spectrometry (techniek voor analyse op basis van eiwitspectrum), PCR; polymerase chain reaction 
(DNA vermeerderingstechniek), AGB; antibiotica gevoeligheidsbepaling.
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zijn, is dit erg tijdrovend. Toekomstige diagnostische testen zouden in staat moeten zijn, om 
minimaal 5-10 ml volbloed te verwerken, dit om optimale detectiepercentages te kunnen 
garanderen. Het aantal pathogenen dat aangetoond kan worden moet worden uitgebreid en 
volledige AGB zou moeten worden toegevoegd. De verkregen resultaten in dit onderzoek, 
wijzen tevens uit, dat toekomstige testen zouden moeten kunnen screenen op bepaalde 
mRNA transcripten. mRNA lijkt een betere marker, om levende pathogenen aan te tonen. 
Dit in tegenstelling tot DNA of rRNA, welke ook van dode pathogenen afkomstig kunnen 
zijn. Deze verschillende aspecten zouden idealiter moeten worden gebundeld in 1 simpele 
point of care test, welke zowel in staat is pathogeen DNA/RNA te detecteren en identifi ceren 
en een volledige antibiotica gevoeligheidbepaling uit kan voeren. De test zou gekenmerkt 
moeten worden door een simpel “monster in, resultaten uit” principe. Resultaten moeten zo 
snel mogelijk beschikbaar zijn en tevens zouden geen speciale technische vaardigheden 
noodzakelijk moeten zijn voor het uitvoeren van deze toekomstige test. Momenteel is er 
nog geen sepsis test commercieel verkrijgbaar, die pathogeen verrijking voor grote volumes 
volbloed combineert met snelle pathogeen detectie en identifi catie. De test die dit ideale 
scenario het beste benaderd, is de MagicPlex Sepsis Test van Seegene, gecombineerd 
met pathogeen verrijking met MolYsis (Molzym). Deze combinatie neemt echter ook nog 
zeker 6 uur in beslag en levert geen volledige identifi catie van alle pathogenen. Om deze 
toekomstige diagnostische test te creëren, zal eerst pathogeen verrijking en pathogeen 
DNA isolatie uit volbloed moeten worden geoptimaliseerd. De commercieel verkrijgbare 
MolYsis pathogeen verrijking methode neemt minimaal 2 uur tijd in beslag, afhankelijk van 
het te verwerken aantal monsters, om pathogeen DNA te verkrijgen uit volbloed. Pathogeen 
verrijking gecombineerd met DNA isolatie moet volledig geautomatiseerd worden, dit om 
handelingen en besmettingrisico’s te reduceren. Polaris (Biocartis) wordt momenteel volledig 
geautomatiseerd in een gesloten wegwerp cassette. Wanneer deze cassette beschikbaar 
wordt gesteld voor onderzoek, zal deze eerst geëvalueerd moeten worden voor 10 ml 
volbloed, ook in een klinische omgeving.
Het zal erg moeilijk worden om volledige AGB te incorporeren in 1 test, omdat antibiotica 
resistentie het resultaat is van een groot aantal genen en complexe regulatiemechanismen. 
Microarray gebaseerde testen zijn al ontwikkeld, om grote aantallen antibiotica resistentie 
genen te onderzoeken. Het nadeel van microarrays is, dat ze speciale laboratoriumapparatuur 
vereisen en daarnaast is het vereist, dat technisch vaardige mensen deze testen inzetten. 
Real-time PCR kan ook ingezet worden, om klinisch relevante antibiotica resistentie genen 
aan te tonen uit klinische monsters, bijvoorbeeld uit volbloed. Enkele commercieel verkrijgbare 
sepsis testen bieden al de mogelijkheid, om een klein panel van antibiotica resistentie genen 
aan te tonen. Voorbeelden zijn VYOO (SIRS-Lab) en MagicPlex Sepsis Test (Seegene). 
Deze bestaande panels moeten worden uitgebreid, wanneer meer antibiotica resistentie 
markers en virulentiefactoren beschikbaar komen. Diagnostische testen die een volledige 
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AGB uit volbloed bewerkstelligen, zijn nodig om snel een pathogeen specifiek antibioticum 
toe te kunnen dienen aan een patiënt met een BBI.
Nieuwe ontwikkelingen doen hun intree in de medische wereld en zouden de start kunnen 
zijn voor snelle pathogeen identificatie gecombineerd met een volledige AGB. Een voorbeeld 
hiervan is next generation sequencing (NGS). Salipante et al. heeft al aangetoond, dat 
NGS kan worden gebruikt, om bacteriën te identificeren uit heterogene klinische monsters. 
Ze gebruikte de diep sequensen technologie op een collectie van sputum monsters van 
patiënten met cystische fibrose en toonden pathogenen aan in monsters, die negatief waren 
met de standaard kweekmethoden (hier waren vooral micro-organismen in het spel met 
complexe voedingseisen). NGS methoden zullen waarschijnlijk snel in staat zijn, om met 
hoge resolutie genotypes te bepalen en zullen uiteindelijk geïmplementeerd worden in de 
klinische microbiologie.
De huidige trends in het veld van moleculaire diagnostiek voor infectieziekten, bewegen 
richting geautomatiseerde high-throughput technologieën, zoals NGS, en zullen enorme 
hoeveelheden data gaan genereren. Meer mensen met bioinformatica achtergrond en/of 
ontwikkelde software pakketen, zullen nodig zijn om deze gigantische hoeveelheid aan data 
te verwerken.
De resultaten gepresenteerd in dit proefschrift laten zien, dat de laboratorium diagnostiek 
voor BBI significant sneller kan. Moleculaire testen op grote volumes volbloed van BBI 
patiënten kunnen, wanneer ze geoptimaliseerd zijn, de patiëntenzorg verbeteren en 
potentieel de morbiditeit en mortaliteit verlagen. Toekomstige prospectieve studies zijn 
echter nog nodig, om onze bevindingen te bevestigen en om vast te stellen of de volbloed 
strategie kosteneffectief is. De toekomst zal moeten uitwijzen of gevoelige multiplex PCR 
testen of NGS, gecombineerd met pathogeen verrijking uit grote volumes bloed, de basis zal 
gaan vormen voor een simpele point of care test.
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Dankwoord
Het einde van deze fase in mijn leven is in zicht en dit zijn de laatste woorden en zinnen, die ik 
mag schrijven om mijn proefschrift af te ronden. Het is een heftige periode geweest met veel 
dieptepunten, maar gelukkig ook vele hoogtepunten. Ik heb deze tijd mogen delen met veel 
mensen die stuk voor stuk belangrijk voor mij zijn geweest, zonder hun was dit proefschrift 
er waarschijnlijk nooit gekomen.
Allereerst wil ik mijn promotor prof. dr. Cathrien Bruggeman, en copromotoren Adriaan 
en Petra bedanken voor de goede begeleiding en kritische houding de afgelopen 5 jaar. 
Ik weet nog goed dat ik voor het eerst met Adriaan van Eindhoven naar Maastricht ben 
gereisd, om kennis te maken met Cathrien en Petra. Er moest nog een onderzoek opgezet 
gaan worden en iedereen was nog wat onzeker. Bedankt voor het vertrouwen dat jullie in 
me hebben gesteld. Ik heb het ervaren als een bijzonder prettige samenwerking. Adriaan, 
de afgelopen 5 jaar heb jij me vooral onder je vleugels genomen en ik wil jou dan ook in 
het bijzonder bedanken voor de goede samenwerking. De vele adviezen en motiverende 
woorden hebben me er doorheen gesleept. Zoals je weet, was het vaak echt een uitdaging 
om de vele werkplekken en mijn onderwijstaak te combineren met het onderzoek. Ik snap nu 
eigenlijk nog steeds niet hoe jij al je taken en je grote gezin met elkaar combineert.
Dan natuurlijk een welgemeend woord van dank voor Fontys Hogeschool Toegepaste 
Natuurwetenschappen, in het bijzonder oud-directeur Mw. dr. Marthie Meester. Beste 
Marthie, dankzij jou sta ik hier vandaag natuurlijk ook. Je hebt altijd vertrouwen gehad in 
een goede afloop en me binnen Fontys gesteund daar waar mogelijk. Ook wil ik graag Paul 
Boelens bedanken, jij hebt me wegwijs gemaakt in het onderwijs en antwoord gegeven op de 
vele vragen die ik had tijdens mijn eerste jaar als docent. Mijn collega IBIS kantoorgenootjes, 
Carla, Joost, Yvonne, Wilfried, Vincent, Ömür, Jan, Gertruud en Lilian wil ik bedanken voor 
de geboden flexibiliteit en het bieden van een luisterend oor. Speciaal voor Jan en Vincent, 
nog even een Chuck Norris fact: “Chuck Norris’s tears could cure all infectious diseases, too 
bad he never cries”. Els, ook jij bedankt voor het invallen als ik weer eens een congres had op 
mijn onderwijsdag. Gies Evens en Ron Dankers wil ik beide bedanken, omdat ze onmisbaar 
waren voor mij, als promovenda, binnen Fontys.
Tijdens mijn promotieonderzoek ben ik op verschillende locaties werkzaam geweest. De 
ene helft van het werk heb ik uitgevoerd op de laboratoria voor Pathologie en Medische 
Microbiologie van Stichting PAMM, en de andere helft binnen het Jeroen Bosch Ziekenhuis 
(JBZ). Op alle locaties ben ik hartelijk ontvangen en ik ben dan ook altijd met veel plezier 
naar het lab gegaan. Bij Stichting PAMM heb ik vooral samengewerkt met arts-microbioloog 
Arjan Jansz, data-informatiemanager Gerrit Janssen en de laboratorium medewerkers 
Jitske, Christel, Mariëlle, Marion, en Elna. Ik heb veel van jullie mogen leren. Verder wil ik 
natuurlijk ook alle andere medewerkers bedanken voor de gezellige tijd. In het bijzonder 
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Mark, jij behoorde tenslotte bij de “harde kern” borrelaars. In december 2010 heb ik al 
mijn “labspullen” verhuist naar Den Bosch, om daar verder te klussen aan mijn onderzoek. 
Daar ben ik vooral samen gaan werken met moleculair bioloog Mirjam Hermans, arts-
microbioloog Peter Wever, intensive care arts Peter de Jager, klinisch epidemioloog Mirrian 
Hilbink, arts in opleiding Janna Tosserams en klinisch chemicus Ron Kusters. Dank voor al 
jullie wetenschappelijke input. Ronald, onze gesprekjes (vaak in de gang), waarin frustraties 
en blijdschap over artikelen, maar ook andere promotiezaken de revue passeerden, vond ik 
altijd erg waardevol. Jij hebt alles net achter de rug. Heel veel succes in je verdere carrière. 
Alle medewerkers van de afdelingen Medische Microbiologie, Moleculaire Diagnostiek en 
Klinische Chemie verdienen een woord van dank. Jullie hebben dit onderzoek op allerlei 
fronten ondersteund.
Ook het Catharina ziekenhuis in Eindhoven mag niet onvermeld blijven. Hier zijn belangrijke 
eerste discussies gevoerd over hoe de diagnostiek voor bloedbaaninfecties eruit zou moeten 
gaan zien. Herman Kreeftenberg en Arnoud Roos hebben hier een belangrijke rol in gespeeld 
en ik wil jullie daar dan ook hartelijk voor bedanken. Er is na 5 jaar werk echter nog steeds 
geen soort van “lakmoes test” beschikbaar. Op de afdeling klinische chemie ben ik ook heel 
veel geweest en daar hebben Paul van Kaathoven, Jan Michielse en Gitta Stienen altijd voor 
mij klaargestaan. Bedankt voor de fijne samenwerking.
Ik heb dit promotieonderzoek veelal alleen uitgevoerd. Ik was niet werkzaam in een grote 
onderzoeksgroep en heb dus veel gehad aan Judith en Wendy, twee collega promovendi van 
de afdeling Medische Microbiologie van het MUMC. Ik wil jullie graag bedanken voor de leuke 
samenwerking, jullie mening tijdens werkoverleggen en de gezelligheid op congressen. Dat 
geldt ook voor René en Suzanne van het Erasmus MC.
Tijdens mijn onderzoek heb ik ook veel samengewerkt met Philips Research en Biocartis. Ik 
wil Paul vd Wiel, Sigi, Irene, Bart, Roel en Geert hartelijk danken voor de samenwerking en 
steun. Ook Martine Bos en Paul Savelkoul van het VUMC wil ik bedanken voor de prettige 
samenwerking en de wetenschappelijke input.
Het vele werk beschreven in dit proefschrift was nooit verzet geweest dankzij de vele 
enthousiaste stagiaires die ik heb mogen begeleiden. Het begon allemaal met Jeandery, een 
Antilliaanse schone die bijna 1 jaar lang in dit onderzoek heeft meegedraaid. Jeandery, je 
hebt mega veel werk verzet en dat heeft ook geleidt tot mooie artikelen, bedankt. Desiree en 
Wouter konden tegelijk aan de slag op verschillende projecten binnen Stichting PAMM. Jullie 
hebben ervaren dat het niet altijd gemakkelijk is op meerdere plaatsen werkzaam te zijn. 
Eenmaal in het JBZ kwam Maurice de boel versterken. Een oude bekende van de PAMM. 
Maurice, je hebt een start gemaakt met het RNA project. Daarnaast hebben we genoten van 
je raps. Maikel kon een vliegende start maken binnen het RNA project en daarnaast hebben 
we veel (om je) gelachen. Ik hoop dat je nu al wat beter kunt koken. Mike was de laatste en 
heeft ook in 5 maanden veel werk verzet. Ik ben super trots op Jeandery, Maurice, Maikel 
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en Mike die hun werk hebben mogen presenteren op het BaMa symposium van de NvMM. 
Dankzij jullie allemaal is dit boekje zo compleet. Daarnaast ben ik ook blij dat de meeste 
van jullie een leuke baan hebben gevonden. Bedankt voor de tomeloze inzet en al het harde 
werken.
Ik heb de afgelopen 5 jaar veel kamergenootjes gehad. Te beginnen met Arantza. Arantza, 
jij was mijn collega docent/onderzoeker, die ook via Fontys een promotieonderzoek startte. 
Ondanks het feit, dat we totaal verschillende onderzoeken hadden, konden we elkaar wel 
steunen qua frustraties, die zijn bij alle promovendi toch veelal gelijk. Daarnaast natuurlijk 
bedankt voor de gezelligheid bij de etentjes en borrels. Wij vormden met Mark toch de “harde 
kern” bij de PAMM. Je bent een andere weg ingeslagen en nu bezig als patholoog in opleiding 
in Leiden. Weer een heel pittig traject en dat doe ik je dus niet na. Dan natuurlijk Lieke, 
mijn vaste kamergenootje op het JBZ. Ik rond mijn onderzoek iets eerder af dan jij, maar 
het gaat jou ook zeker lukken. Ik ben blij dat we elkaar zijn tegen gekomen, twee vreemde 
(een Brabantse en een Limburgse) eendjes in de bijt zeg maar. Bedankt voor al je input 
aangaande statistische analyses in SPSS, het luisterende oor, maar vooral de gezelligheid. 
We moeten denk ik wel concluderen dat het ons in het JBZ niet gelukt is een “borrelcultuur” 
te creëren. Dan wil ik ook de tijdelijke kamergenootjes, dus eigenlijk alle arts-assistenten in 
opleiding, waarmee ik in Eindhoven of Den Bosch een kamer heb mogen delen: Miranda, 
Saara, Wouter, An-Emmy, Bas, en Aletta bedanken voor de leuke tijd.
Alle vrienden en kennissen van sportschool BodyLine te Tilburg verdienen een woordje van 
dank. Ik wil daarbij Bart en Mieke in het bijzonder noemen. Jullie hebben gezorgd voor de 
broodnodige ontspanning en gezelligheid in de avonduren en weekenden. Natuurlijk moest 
ik zelf bewegen, maar de motiverende woorden tijdens een van jullie lessen zijn altijd welkom 
geweest. De aerobic lessen en de vele uren op de spinningfiets hebben me door de drukke 
tijden heen gesleept. Jan en Noud, bedankt voor de gezelligheid bij het hardlopen in de Oude 
Warande op zaterdagochtend. Frans, bij onze kennismaking een paar jaar geleden heb ik 
niet overzien, dat we nu zoveel tijd met elkaar zouden doorbrengen. Je hebt me overgehaald 
eens mee te gaan fietsen en moet je ons nu eens zien. Je hebt me besmet met het “Van 
Poppel fietsvirus”. Ik hoop dat Bart, ik en jij nog vele mooie tochten mogen maken op de 
racefiets. Jij staat daarnaast altijd voor ons klaar. Hiervoor ontzettend veel dank.
Mijn lieve vrienden en vriendinnen mogen natuurlijk ook niet ontbreken in dit hoofdstuk van 
mijn boekje. Enkele van jullie ken ik al zowat mijn hele leven. Ik ben blij dat sommige van 
jullie ook een promotieonderzoek hebben doorlopen, dan wel er zelf nog mee bezig zijn. Dat 
praat toch wat makkelijker en creëert begrip voor afwezigheid op feestjes i.v.m. “het werk”. 
Daarnaast hebben de vele feestjes, dinner-dates, en stapavondjes gezorgd voor de nodige 
ontspanning tijdens de weekenden. Bedankt hiervoor. Linda (dr. Loonen), ondertussen 
kennen we elkaar al een hele tijd. Samen begonnen aan de HLO in Etten-Leur en een leuke 
tijd in Vermont (Amerika) beleefd wat onze band alleen maar sterker heeft gemaakt. Geen 
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familie maar toch dezelfde achternaam. Ik ben blij dat je mijn paranimf wilt zijn. Steffen, jij 
nog bedankt voor de mooie foto van het doek welke mijn kaft siert. Het was een minder 
makkelijke opdracht dan ik dacht.
Lieve pap en mam, ik wil jullie bedanken voor de onvoorwaardelijke steun en jullie vertrouwen 
in mij. Jullie zijn nog altijd echt geïnteresseerd in mijn dagelijkse bezigheden, inclusief de vele 
frustraties (al hoop ik wel dat die nu in hoeveelheid gaan afnemen). Mam, ik ben blij dat je zo 
creatief bent. Dankzij jou heb ik nu een heel bijzondere kaft om mijn boekje zitten. Ik hoop 
dat je schilder-maatjes nu ook begrijpen wat je geschilderd hebt (ik blijf anders die dochter 
van dat rare schilderij). Mijn lieve broertje Paul, zusje Lieke, Marcella en Bennie mogen ook 
niet ontbreken in dit dankwoord. Ik ben blij dat we het altijd zo gezellig kunnen hebben met 
z’n allen. Lieke, als mijn paranimf heb je een belangrijke rol bij mijn promotie en ik ben blij dat 
je dit belangrijke moment in mijn leven op deze manier met me wil delen. De rest van mijn 
familie en schoonfamilie wil ik bedanken voor de interesse in mijn onderzoek. Ik hoop dat na 
het lezen van dit boekje het allemaal nog duidelijker is geworden.
Dan nog een laatste woord van dank aan de belangrijkste persoon in mijn leven, Bart. 
We zijn ondertussen al een hele tijd samen en ik heb met jou dus ook bijna alle “ups and 
downs” in mijn leven gedeeld. Deze bijzondere periode in mijn leven sluit ik nu af en ik 
ben blij dat jij gedurende dit promotietraject aan mijn zijde hebt gestaan. Je hebt me veel 
steun gegeven, gemotiveerd en gelukkig ook voor de broodnodige relativering gezorgd. Als 
registeraccountant sta je toch wat anders tegenover een promotieonderzoek. Nu hebben we 
hopelijk iets meer tijd om met onze Engelse Bulletjes Mike en Tygo erop uit te gaan in de 
avonden en weekenden.
Mocht ik toch nog iemand vergeten zijn persoonlijk te noemen, vul dan gerust je naam in op 
de stippellijn ………………………………, bedankt!
Anne
Loonen.indd   179 30-10-2013   8:15:58
180  |  Dankwoord, curriculum vitae and list of publications
Curriculum Vitae
Anne Loonen werd geboren op 18 januari 1983 in Goirle. Na het behalen van het VWO 
diploma aan het St. Odulphus Lyceum te Tilburg startte zij in 2001 aan de Avans Hogeschool 
(Etten-Leur en later Breda) met de studie Biologie en Medische Laboratoriumonderzoek. 
Zij heeft stage gelopen op de Universiteit van Vermont (Burlington, Vermont, USA) onder 
begeleiding van prof. dr. Nick Heintz en op het Josephine Nefkens Instituut (Rotterdam) 
onder begeleiding van dr. Ronald de Krijger en dr. Winand Dinjens. Na drie jaar behaalde 
zij haar diploma en startte ze in 2004 met de Master Medische Biologie aan de Radboud 
Universiteit te Nijmegen. Hiervoor heeft ze stage gelopen op de afdeling Moleculaire Biologie 
van het Nijmegen Centre for Molecular Life Sciences (NCMLS) onder begeleiding van dr. 
Marion Lohrum en op de afdeling Fertiliteit van Organon (Oss) onder begeleiding van Ruud 
Lagemaat en dr. Sietse Mosselman. In 2007 begon zij aan een promotieonderzoek in het 
NCMLS, afdeling (cel)fysiologie, onder begeleiding van prof. dr. Peter Deen. Hier deed zij 
onderzoek naar verstoorde waterhuishouding in het lichaam als gevolg van mutaties in de 
vasopressine V2 receptor. In 2008 startte zij als docent/onderzoeker bij Fontys Hogeschool 
Toegepaste Natuurwetenschappen (TNW) te Eindhoven. In samenwerking met het Maastricht 
Universitair Medische Centrum, Stichting PAMM, en het Jeroen Bosch Ziekenhuis (JBZ) is 
dit promotieonderzoek tot stand gekomen. Hierbij werd zij begeleid door dr. Adriaan van den 
Brule (PAMM en later JBZ), prof. dr. Cathrien Bruggeman (MUMC), en dr. ir. Petra Wolffs 
(MUMC). Naast het uitvoeren van haar promotieonderzoek is zij 2 dagen per week actief 
geweest als docent op Fontys Hogeschool TNW. In januari 2013 behaalde ze binnen Fontys 
de basis kwalificatie onderwijs (BKO) en sinds augustus 2013 is ze hier fulltime werkzaam.
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